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The discovery of ten-eleven translocation (TET) enzymes-mediated 5-methylcytosine 
(5mC) to 5-hydroxymethylcytosine (5hmC) gave rise to a new area of epigenetic study. 
Initially thought to be simply an intermediate in an active DNA demethylation pathway, 
5hmC was since demonstrated to play critical roles in mammalian development, cellular 
differentiation and cancer progression. The global 5hmC content is reduced in the vast 
majority of studied cancers and mutations in the three TET genes are present to a 
varying extent in some tumour types. The reactivation of the TET proteins was 
proposed as a therapeutic intervention in melanoma patients. However, the preliminary 
data from the Murrell lab suggests that 5hmC levels increase during colorectal cancer 
(CRC) metastasis to the liver and few TET mutations are reported in CRC patients. 
Given that 90% of cancer deaths occur due to metastasis, the role of TETs and 5hmC in 
CRC progression warrants closer investigation. 
The in-house ultrasensitive liquid chromatography-mass spectrometry method of global 
cytosine, 5mC and 5hmC levels detection in various DNA samples was successfully 
optimised and validated. It was found to robustly detect the 5hmC content in almost all 
DNA samples studied and offer a superior sensitivity to an external method. The 
primary SW480 and metastatic SW620 CRC cell lines were chosen to study the effects 
of 5hmC and TET levels manipulation. The SW480 cells were shown to have higher 
migration rate and TET2, 5mC and 5mhC content but lower TET1 expression and 
proliferation rate compared to the SW620 cells. The treatment of the two cell lines with 
vitamin C increased their 5hmC content, but its phenotypic effects were found to be 
5hmC-independent. The CRISPR/Cas9-based targeting of the three TET genes in these 
cell lines caused an incomplete ablation of TET and 5hmC levels and resulted in lower 
proliferation rate in the SW480 cells and reduced migration in the SW620 cells. The 
changes in TET expression and 5hmC levels are also described during the 
differentiation of human embryonic stem cells (hESCs) to hepatocyte-like cells (HLCs). 
Despite the initial attempt to knockdown TET1 levels in hESC to improve 
differentiation efficiency failing, future experiments utilising this approach could 
produce HLCs closer resembling human hepatocytes, which is critical for drug testing 
purposes. Taken together, these results contribute to the growing body of evidence for 
the critical role of 5hmC and TETs in cancer progression and hESC differentiation. 
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1.1 The times they are a-changin’ - going beyond the DNA 
sequence through the rise of epigenetics 
The idea of epigenetics has first been proposed by Conrad Waddington in his landmark 
1942 paper as a way to describe the mechanistic relationship between the phenotype and 
the genotype of an organism. The term “epigenetics” in that setting described a set of 
causal mechanisms linking the actions of genes to the phenotype (Waddington, 1942). 
From Waddington’s perspective, the study of epigenetics was mainly to be conducted 
with relation to the developmental processes and informed by the findings from the field 
of embryology. Indeed, this line of thinking has led him to create the idea of an 
“epigenetic landscape”, portrayed in Figure 1.1. This concept refers to a series of 
choices that a cell has to make on its way towards a terminally differentiated state and in 
the process acquiring characteristics specific to that differentiated cell type. It allows for 
easy conceptual visualisation of the epigenetic barriers that accumulate during the 
differentiation process and prevent a cell, under normal circumstances, from changing 
its identity by dedifferentiating or transdifferentiating. 
More recently, the concept of epigenetics has been transformed to refer to heritable 
changes in gene expression that are not dependent on alterations to the underlying DNA 
sequence. In other words, epigenetics is what allows cells with the same genotype to 
exhibit profound phenotypic differences. Since the original description of epigenetics, 
numerous components of the epigenetic machinery have been described. These include 
direct modifications of DNA bases such as N6-methyladenosine, 5-methylcytosine 
(5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), 5-carboxycytosine 
(5caC), 5-hydroxymethyluracil and 5-formyluracil (reviewed in detail by Bilyard et al., 
2020). The N-terminal tails of the histone proteins, around which the DNA is wrapped 
to form the nucleosome, can be modified by adding numerous chemical groups 
including phosphorylation, acetylation, methylation, sumoylation and ubiquitylation 
(reviewed by Bannister and Kouzarides, 2011). The addition and removal of these 
chemical groups in turn both change the structure of the surrounding chromatin (formed 
of the nucleosome subunits) and affect binding of proteins that contain domains 
responsible for recognising these modifications. Lastly, non-coding RNAs (ncRNAs) 
form the third main component of the epigenetic machinery (reviewed by Mongelli et 
al., 2019; Yang et al., 2020). The ncRNAs are transcribed but not translated to form a 
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protein. They hence act as an independent class of signalling molecules involved in 
numerous cellular processes such as regulating chromosomal architecture (reviewed by 
Creamer and Lawrence, 2017) and alternative splicing of RNAs (reviewed in detail by 
Romero-Barrios et al., 2018). They include, but are not limited to, circular RNAs, long 




Figure 1.1 A schematic representation of the Waddington’s epigenetic landscape 
concept 
The epigenetic landscape idea is visualised by a ball (representing a pluripotent cell) 
rolling down a slope and encountering multiple branches down which it can choose to 
travel (the lineage specification choices represented by the different ball colours). In this 
model, the cell cannot spontaneously move back up the slope (dedifferentiate) or move 
across to another path (transdifferentiate), as shown by the red arrows. This is due to 
certain epigenetic barriers being put in place in its DNA at every differentiation stage. 
 
Together, these factors can alter the chromatin between the permissive (euchromatin) 
and non-permissive (heterochromatin) states, thus affecting the ability of transcription 
factors to bind to target DNA sequences and hence regulating gene expression patters 
(reviewed by Klemm et al., 2019). 
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The work described in this thesis focuses specifically on the cytosine methylation and 
hydroxymethylation as well as the family of proteins responsible for generation of the 
latter chemical group. The role of these epigenetic DNA modifications is studied in the 
processes of cancer metastasis and cellular differentiation. 
 
 
1.2 The power of the methyl group - cytosine methylation in 
physiology and disease 
1.2.1 The discovery and mechanisms of DNA methylation 
The methylation of a cytosine base at carbon position 5, also termed the “fifth DNA 
base”, is the most well studied and understood epigenetic mark (Stricker and Götz, 
2018). Cytosine methylation in mammals was discovered only a few years after DNA 
was described as the source of cells’ genetic information (Avery et al., 1944; Hotchkiss, 
1948). Rollin Hotchkiss utilised paper chromatography to separate the DNA bases and 
observed a base migrating at rate slightly higher than that of cytosine, and which had a 
considerably lower abundance than cytosine. He termed this modification “epicytosine” 
and even suggested that it might be 5-methylcytosine based on the previous description 
of this base in Tubercle bacillus (Johnson and Coghill, 1925; Hotchkiss, 1948). Three 
decades after this discovery, 5mC was proposed to play a role in regulating gene 
expression, although the exact mechanism was still unclear (Holliday and Pugh, 1975). 
In the 1980s, it was already known that methylation patterns are both heritable and 
tissue-specific (Razin and Riggs, 1980). The 5mC mark was also observed to occur in 
the context of CpGs, which denote a cytosine followed immediately by a guanine, and 
CpG islands (CGIs) which is name given to a number of CpGs clustered in close 
proximity within the DNA sequence (Bird, 1980; Bird et al., 1985). The CpGs are now 
known to be between 70 to 80% methylated, although methylation can also exist in the 
non-CpG context (Jang et al., 2017). 
The enzymes responsible for methylating cytosines were discovered when the mouse 
DNA methyltransferase 1 (DNMT1) protein was described and sequenced by Timothy 
Bestor and colleagues (Bestor and Ingram, 1983; Bestor et al., 1988). DNMT1 was 
found by the authors to have a preference for hemimethylated DNA, which refers to 
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only one of the DNA strands being methylated. It is now known that this is because 
DNMT1 is predominantly a maintenance methyltransferase responsible for copying the 
methylation pattern of the template strand onto the newly synthesised DNA strand 
following the replication process (Edwards et al., 2017). DNMT1 was also found to be a 
self-inhibitory enzyme that requires interaction with the Ubiquitin-like with PHD and 
ring finger domains 1 (UHRF1) protein for DNA binding and subsequent cytosine 
methylation (Liu et al., 2013; Li et al., 2018). Subsequent to that, two de novo 
methyltransferases DNMT3A and DNMT3B were discovered by Okano and colleagues 
(Okano et al., 1998a; Okano et al., 1999). The two enzymes were shown by the authors 
to have no preference for hemimethylated DNA and to be essential for mammalian 
embryonic development. Additionally, DNMT2 and DNMT3L have also been 
identified. DNMT2 was shown to be non-essential in embryonic stem cells for neither 
de novo nor maintenance methylation (Okano et al., 1998b). However, the DNMT2 
protein is the most conserved member of the DNMT family in eukaryotes and more 
recently it has been identified as transfer RNA methyltransferase (Goll et al., 2006; 
Ashapkin et al., 2016). DNMT3L was identified later than the other two members of the 
DNMT3 family (Aapola et al., 2000), but did not display any de novo methyltransferase 
activity (Hata et al., 2002). It was instead found to regulate de novo methylation by 
interacting with DNMT3A and DNMT3B and enhancing their catalytic activity, 
especially during the embryogenesis process (Chédin et al., 2002; Suetake et al., 2004; 
Gowher et al., 2005; Van Emburgh and Robertson, 2011). The DNMT family 
establishes the methylation mark on the cytosine bases via a reaction involving a 
compound called S-adenosyl-L-methionine, also known as SAM, which provides the 
methyl group that is attached to the carbon position 5 of the unmodified cytosine by the 




1.2.2 The link between inactivation of gene expression and cytosine methylation 
The repressive effects of cytosine methylation on gene expression were first proposed in 
the 1980s (Razin and Riggs, 1980). The authors observed that “undermethylation” was 
correlated with activation of gene expression in a number of studies. Since then, 5mC 
was proposed to silence gene transcription by either physically preventing transcription 
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factors from interacting with DNA or by binding of repressor proteins to the methylated 
DNA sequences (Tate and Bird, 1993). More recent observations indicate that the direct 
mechanism of physical occlusion of transcription factor binding is likely to play a role 
in transcriptional repression caused by 5mC, but it is not the only mechanism 
responsible for it (Choy et al., 2010; Medvedeva et al., 2014). Methyl binding proteins, 
such as methyl-CpG binding protein 1 (MeCP1) (Meehan et al., 1989) and MeCP2 
(Lewis et al., 1992) have been shown to interact specifically with methylated cytosines 
and act as mediators of transcriptional silencing (Cross et al., 1997). An example of the 
mechanism of such gene expression repression involves a complex formed of MeCP2, 
SIN3A and histone deacetylase proteins: HDAC1 and HDAC2 (Nan et al., 1998). The 
deacetylation of histones utilises the nuceosomal assembly to subsequently change 
chromatin confirmation to a repressive state (Jones et al., 1998). More recently, it has 
also been proposed that the presence of 5mC may create new binding sites for 
transcription factors, which are not recognised by these proteins when DNA is 
unmethylated (reviewed by Zhu et al., 2016). The examples of these include KAP1 and 
ZFP57, which have specific recognition sequences that include methylated cytosines 
(Quenneville et al., 2011; Liu et al., 2012). Additionally, despite the consensus that 
5mC is predominantly associated with repression of transcription, it has been shown 
that gene body methylation is associated with transcriptional activation for a number of 
genes (Ball et al., 2009). Thus, the effects of DNA methylation are context dependent. 
 
 
1.2.3 The fifth DNA base during mammalian development  
The 5-methylcytosine base has been found to play critical roles at numerous stages 
during mammalian development due to its role in transcriptional regulation. The critical 
importance of DNA methylation in the developmental processes is highlighted by 
embryonic lethality of Dnmt1 and Dnmt3b knockout mice and the growth retardation 
and neonatal lethality of the Dnmt3a knockout mice (Li et al., 1992; Okano et al., 
1999). In general, mammalian development is characterised by two waves of DNA 
demethylation and subsequent re-methylation. In humans, following fertilisation both 
parental genomes are demethylated until the blastocyst stage, with the paternal genome 
showing a more rapid rate of demethylation than the maternal one (Guo et al., 2014). 
The majority of this genome-wide 5mC loss occurs between the fertilisation and the two 
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cell stage, which is contrast to the mouse embryonic development where most of 
demethylation occurs at the one cell stage (Guo et al., 2014; Okamoto et al., 2016). 
There are genomic regions, however, that resist this first wave of demethylation. Most 
notably, these include imprinting control regions (ICRs) responsible for regulating the 
expression of imprinted genes (Quenneville et al., 2011), although there are 
differentially methylated regions (DMRs) other than ICRs that resist demethylation 
until the blastocyst stage (Proudhon et al., 2012). Imprinted genes are expressed from 
either a paternal or maternal allele while being silenced by DNA and histone 
methylation on corresponding allele inherited from the other parent (reviewed by Reik, 
2007). The silencing is maintained through this first wave of global demethylation via 
recruitment of the KAP1 (KRAB-associated protein 1, also known as TRIM28) by 
Krüppel-associated box (KRAB) domain containing zinc-finger proteins (ZFPs) 
(Quenneville et al., 2011; Messerschmidt et al., 2012). KAP1 in turn acts as a scaffold 
for a number of proteins including HP1 and histone methyltransferases (HMTs) and 
HDACs to establish heterochromatin confirmation around the region that protects it 
from the loss of 5mC mark (Schultz et al., 2002; Alexander et al., 2015). Lastly, KAP1 
and KRAB-ZFPs are also thought to play a role in maintenance of cytosine methylation 
at transposable elements (Rowe et al., 2010; Coluccio et al., 2018; Stoll et al., 2019). 
These genomic regions contain the majority of 5mC persisting up to the blastocyst stage 
and in particular include the evolutionarily younger LINE-1 and SVA elements in 
human embryos (Guo et al., 2014) while in mice the IAP endogenous retrovirus 
sequences are particularly resistant to methylation loss (Rowe et al., 2010; Smith et al., 
2012). 
The second wave of demethylation during mammalian development occurs during the 
formation of primordial germ cells (PGCs). These are precursors to the sperm and the 
eggs and hence need to acquire the sex-specific imprints that will be passed on the next 
generation following fertilisation. This is achieved by removing methylation from the 
ICRs that were protected during the first demethylation wave (Hargan-Calvopina et al., 
2016). The mouse PGCs are first specified at embryonic day 6.5 (ED6.25) from epiblast 
cells, detected at approximately ED7.25 and migrate to the genital ridges by ED10.5 
where the female germ cell enter meiosis at ED13.5 while the male germ cells 
experience mitotic arrest (Lawson et al., 1999; Saitou and Yamaji, 2012). In humans 
this period is considerably longer and lasts between approximately week 3 and week 10 
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post fertilisation, although this has not been extensively studied due to ethical 
limitations (Leitch, et al., 2013). More recent evidence, however, suggest that human 
PGC specification occurs earlier than previously thought, at around day 12 post 
fertilisation (Chen et al., 2019). 
The demethylation of mammalian PGCs is thought to occur in two waves (Seisenberger 
et al., 2012; Kobayashi et al., 2013). The first wave of DNA demethylation occurs from 
approximately ED8 and involves passive loss of the 5mC mark through downregulation 
of de novo DNMT3A and DNMT3B methyltransferases as well as UHRF1 (Kagiwada 
et al., 2013). This results in cytosine methylation not being maintained and deposited in 
the genome through successive rounds of PGC replication. The second DNA 
demethylation wave begins around ED9.5 and involves active DNA demethylation by 
the ten-eleven translocation enzymes (TETs) resulting in the lowest levels of 5mC in 
PGCs of both sexes at ED13.5 (Seisenberger et al., 2012; Dawlaty et al., 2013; Hackett, 
et al., 2013). For a comprehensive description of the role of TETs in reducing the global 
methylation levels in PGCs, see section 1.4.1. The two gametes are subsequently 
remethylated, which establishes the correct, sex-specific genomic imprints. In sperm 
this occurs after ED13.5 while oocytes only complete the process after birth (reviewed 
by Kota and Feil, 2010; Hanna and Kelsey, 2014). 
 
 
1.2.4 The role of cytosine methylation in cellular differentiation - embryonic stem 
cells and the small intestine 
The process of cellular differentiation involves the progressive establishment of cellular 
identity from the pluripotent stem cell state. The unique characteristics of a terminally 
differentiated cell are maintained through epigenetic mechanisms, including cytosine 
methylation (reviewed by Khavari et al., 2010). The mouse embryonic stem cells 
(mESC) show low levels of CpG methylation (around 30%) compared to the somatic 
tissues (approximately 80%) thus enabling the plasticity of ESCs to differentiate into a 
chosen lineage upon an appropriate stimulus while retaining methylation at selected 
regions such as retrotransposons and imprinted genes (Hon et al., 2013; Lee et al., 
2014). This is thought to be established by reduced levels of DNMT3A, DNMT3B and 
DNMT3L as well as the activity of TET1 and TET2 (see section 1.4.2) (Ficz et al., 
2013; Hackett, et al., 2013). When ESCs begin to differentiate, the opposite pattern is 
 9 
observed with a drop in TET1 and TET2 levels coupled with an increased activity of the 
DNMT enzymes (Oda et al., 2013). This establishes methylation marks in the 
pluripotency-associated genes, such as Nanog or Lefty1, to silence them as the cells exit 
the pluripotent state (Farthing et al., 2008). The global gain in DNA methylation 
observed during differentiation is also involved in silencing the genes non-specific to 
the chosen lineage (Calvanese et al., 2012); however there are also genes which are 
specific to the differentiated progeny that loose methylation in order to be expressed 
(Liu et al., 2017; Cypris et al., 2019). This is achieved in part through the oxidising 
activity of the TET enzymes (see section 1.4.4). 
The mouse small intestine represents an excellent model for studying adult stem cell 
differentiation due to well-defined cellular subpopulations and rapid turnover of cells 
(Forn et al., 2015; Jorgensen and Ro, 2019). The structure of the small intestine has 
been extensively studied and a number of cell types were identified (Figure 1.2). The 
intestinal stem cells (ISCs) residing in the crypt are defined by their Lgr5 expression, 
self-renewal capabilities and the ability to differentiate into all the cell types making up 
the mouse small intestine (Barker et al., 2007). Within the intestinal crypt, the cells are 
numbered based on their position relative to the bottom of the crypt. The cells at 
position “+4” are thought to be a “reserve” stem cell, although this hypothesis and the 
true identity of these cells are still controversial (Barker et al., 2012). 
The other cell type residing in the intestinal crypt is the Paneth cell which provides the 
niche for the ISCs through factors and signals required for their maintenance (Meran et 
al., 2017). The ICSs give rise to the transit amplifying (TA) progenitors, which move 
through the TA zone to the villus to become one of the fully differentiated cell types 
residing there. These include the enterocytes, which represent the majority of the cells 
present in the intestinal villi, tuft cells, goblet cells and enteroendocrine cells with 
arterioles and venules responsible for blood supply and lacteals involved in fat 
absorption (Meran et al., 2017). In mice, the process of differentiation and migration of 
cells from the crypt niche to the tip of the villus is typically completed within 3-5 days 
thus providing a rapid turnover of cells that is advantageous for studying the 




Figure 1.2 The schematic structure of the epithelium lining the small intestine 
The schematic representation of the epithelium forming the crypt and the villi in the 
small intestine. The numbers represent the positions of the cells relative to the base of 
the intestinal crypt. Lgr5+ ISC = Lgr5-positive intestinal stem cell. 
 
The crypts are characterised by more rapid proliferation rate that the villi, as measured 
by the Ki67 marker expression while the global 5mC levels remain largely unchanged 
along the crypt-villus axis (Kaaij et al., 2013; Uribe-Lewis et al., 2020). This is in 
contrast to the global 5hmC levels, which are higher in the differentiated villus cells 
than in the crypt stem cell niche (see section 1.4.2) (Kim et al., 2016; Uribe-Lewis et al., 
2020). The analysis of the correlation between local DNA methylation changes by 
Sheaffer and colleagues revealed that 5mC plays an important role in regulation of the 
differentiation process (Sheaffer et al., 2014). Through combination of whole genome 
methylation and transcript analysis, the authors showed that gain in 5mC levels during 
differentiation is associated with silencing the genes required for stem cell function, 
such as Lgr5 and Olfm4, while enterocyte-specific genes such as AP or Lct showed 
reduced methylation. The vast majority of these changes were found to occur in the 
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introns of these genes. Additionally, numerous DMRs between the stem and 
differentiated cells are located in enhancers, whose demethylation contributes to 
activation of gene expression by facilitation of transcription factors binding (Sheaffer et 
al., 2014). 
There is some controversy regarding the extent of methylation changes occurring during 
the intestinal differentiation with Kaaij and colleagues reporting a modest 50 DMRs 
across the whole genome (Kaaij et al., 2013). However, this discrepancy is likely to 
have resulted from the strict DMR definition adopted by the authors, with DMRs 
specified by at least 40% difference in 5mC levels across at least 10 CpGs. Lastly, the 
importance of DNMT1 in the differentiation process was highlighted by Sheaffer and 
colleagues who used a conditional mouse Dnmt1 knockout to demonstrate an expansion 
of the intestinal crypt and reduction of differentiation markers in the villus epithelium 
(Sheaffer et al., 2014). Taken together, these results point towards a critical role of 5mC 
in both embryonic and adult stem cell differentiation. 
 
 
1.2.5 The disease states associated with 5-methylcytosine 
The evidence of critical role of the 5mC mark in numerous physiological processes 
described above makes it perhaps unsurprising that its deregulation is implicated in a 
number of human diseases. While the detailed description of all these conditions is 
beyond the scope of thesis, the examples discussed below give insight into the variety of 
diseases associated with perturbations in 5mC deposition and maintenance. For a 
detailed description of DNA methylation’s role in cancer, see section 1.2.6. 
A number of rare human diseases arise due to dysregulation of the imprinting process. 
Beckwith–Wiedemann syndrome occurs in approximately 1 in 13,000 births and is 
caused by pathological alterations to maternal chromosome region 11p15.5 which 
contains CDKN1C and IGF2 imprinted genes that play an important role in growth 
regulation of the foetus (Brioude et al., 2018). This disease is mainly diagnosed in 
children and is characterised by tongue and organ overgrowth and predisposition to 
embryonic tumours, most notably Wilms’ kidney tumour (Weksberg et al., 2001). 
Prader-Willi and Angelman syndromes are diagnosed in 1 in 20,000 and 1 in 15,000 
births, respectively, and both arise from imprinting defects in the 15q11-q13 
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chromosomal region (Nicholls and Knepper, 2001; Goldstone, 2004). Prader-Willi 
syndrome results from a deletion of the abovementioned chromosomal region on the 
paternal allele while the same deletion, but on the maternal allele, causes the Angelman 
syndrome (Kim et al., 2019). Both syndromes present with mental retardation and 
abnormal behavioural patterns, with the Prader-Willi sufferers also developing 
hyperphagia and obesity and Angelman syndrome patients displaying speech 
impairment and ataxia (Goldstone, 2004; Buiting et al., 2016). 
Beyond dysregulation of genomic imprinting, DNA methylation has also been 
implicated in autoimmune disorders, although the evidence is not as strong as for the 
imprinting disorders. These include rheumatoid arthritis (Liu et al., 2013; Ciechomska 
et al., 2019), systemic lupus erythematosus (Wu et al., 2016; Hedrich et al., 2017) and 
multiple sclerosis (Chomyk et al., 2017; Li et al., 2017; Maltby et al., 2018; Souren et 
al., 2019). Multiple X chromosome-linked disorders presenting with mental retardation 
were also shown to be associated with aberrant DNA methylation. These include Fragile 
X syndrome (Oberlé et al., 1991; Schenkel et al., 2016) and alpha-thalassemia mental 
retardation syndrome (Gibbons et al., 2000; Schenkel et al., 2017). Lastly, DNA 
methylation is known to be closely linked with the process of aging, which was recently 
proposed to be classified as a disease (Bulterijs et al., 2015; Zhavoronkov and Bhullar, 
2015; Lustgarten, 2016; Zhavoronkov and Moskalev, 2016; Khaltourina et al., 2020). 
This link was famously established by Steve Horvath’s research group, who proposed 
an epigenetic clock estimating the biological age of cells, tissues and individuals 
(Horvath, 2013; Horvath, 2015; Levine, et al., 2015; Marioni et al., 2015; Christiansen 
et al., 2016). This aging clock is based on the methylation status of 353 CpG sites across 
the genome (Horvath, 2013), and higher epigenetic age measured by Horvath’s method 
was found in, amongst others, Alzheimer’s and Parkinson’s disease sufferers (Horvath 
and Ritz, 2015; Levine et al., 2015).  
 
 
1.2.6 The dark side of the fifth DNA base - how cytosine methylation contributes to 
tumorigenesis 
The first indication of the role of DNA methylation in cancer pathophysiology came 
from Andrew Feinberg and Bert Vogelstein who demonstrated a reduction in 
methylation levels of a substantial number of CpGs in cancer cells (Feinberg and 
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Vogelstein, 1983a). The lower global 5mC levels in cancer cells compared to normal 
tissue were subsequently confirmed by Gama-Sosa and colleagues, with metastatic 
tumours showing a reduced DNA methylation content than benign ones (Gama-Sosa et 
al., 1983). This global DNA hypomethylation results in activation in numerous 
oncogenes, including RAS genes (Feinberg and Vogelstein, 1983b), metastasis-
associated S100A4 gene (Nakamura and Takenaga, 1998), HPV16 genome (Badal et al., 
2003) and CCND2 gene (Oshimo et al., 2003). Additionally, global loss of 5mC leads to 
increased genomic instability and genomic rearrangements which contribute to the 
tumorigenesis process (Qu et al., 1999; Sheaffer et al., 2016). Lastly, it was found that 
loss of genomic imprinting contributes to the tumorigenesis process, most notably in the 
embryonic Wilms’ tumours (Steenman et al., 1994; Mummert et al., 2005) and chronic 
myeloid leukaemia (Randhawa et al., 1998; Benetatos and Vartholomatos, 2015). A 
well-studied example of this is the first discovered imprinted genes, the IGF2 and H19 
locus, whose dysregulation of imprinting has been implicated in a variety of cancers 
(Hibi et al., 1996; Cui et al., 2002; Byun et al., 2007; Zhao et al., 2016; Gailhouste et 
al., 2019). 
The reduced global levels of 5mC in cancer cells do not correspond to the changes in 
DNA methylation content in numerous genomic loci, most notably within tumour 
suppressor genes. This was initially demonstrated through hypermethylation of the RB 
gene, the first tumour suppressor gene to be discovered, leading to the loss of its 
expression (Greger et al., 1989; Sakai et al., 1991; Ohtani-Fujita et al., 1993; Greger et 
al., 1994). Since then, hypermethylation of tumour suppressor genes was demonstrated 
in a plethora of cancer types, notably in the Tp53 tumour suppressor gene described as 
the “guardian of the genome” whose importance in prevention of tumorigenesis is 
highlighted by the fact that it is mutated in approximately 50% of human cancers 
(Aubrey et al., 2018). The Tp53 promoter was shown to be methylated in numerous 
cancers, including chronic lymphocytic leukaemia (Saeed et al., 2019), ovarian cancer 
(Chmelarova et al., 2013) and breast cancer (Kang et al., 2001). Novel examples of 
tumour suppressor gene hypermethylation continue to be identified, such as recent 
descriptions of promoter methylation of: TET1 in numerous cancer types (Li et al., 
2016), ECRG4 in breast cancer (Tang et al., 2019), CDH11 in colorectal cancer (Yuan 
et al., 2019) and CDO1 in lung cancer (Yin et al., 2020). In fact, a distinct term was 
proposed by Toyota and co-authors in 1999 for cancers characterised by promoter 
 14 
hypermethylation of a number of tumour suppressor genes simultaneously: CpG island 
methylator phenotype (CIMP) (Toyota et al., 1999). In particular, colorectal cancer is 
characterised by high incidence of this phenotype, with approximately 20% of 
colorectal tumours assigned CIMP, which was shown to be associated with 
microsatellite instability, older age and poor tumour differentiation (Jia et al., 2016; 
Advani et al., 2018; Advani et al., 2019). 
 
 
1.3 Passive and active DNA demethylation - the discovery of 
the TET enzymes and 5hmC 
1.3.1 Another brick in the epigenetic wall - the brief history of cytosine 
hydroxymethylation 
The existence of the 5hmC base in the DNA has been known for close to seventy years, 
when its presence was confirmed in bacteriophage DNA (Wyatt and Cohen, 1952; 
Hershey et al., 1953). Approximately twenty years later, it was also discovered in 
mammalian DNA, although the 15% of cytosine levels reported by Penn and colleagues 
in rat brain and liver are now known to be in fact fifteen-fold lower (Penn et al., 1972; 
Globisch et al., 2010). In 2009, two groups independently reported the presence of 
5hmC in murine Purkinje neurons (Kriaucionis and Heintz, 2009) and embryonic stem 
cells (Tahiliani et al., 2009) by thin layer chromatography and mass spectrometry. 
These two publications have subsequently created a new field within epigenetics with 
5hmC now known to play critical roles during mammalian development, cellular 
differentiation and tumorigenesis. 
 
 
1.3.2 TET1 and the discovery of the TET enzymes 
The laboratory group of Anjana Rao, responsible for the initial description of 5hmC in 
mouse ESCs, was the first one to identify the protein responsible for its deposition, Ten-
eleven translocation 1 (TET1), as a fusion partner of the MLL gene in acute myeloid 
leukaemia harbouring the t(10;11)(q22;q23) chromosomal translocation (Tahiliani et al., 
2009). The authors discovered this enzyme, along with TET2 and TET3, through a 
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homology search using the trypanosome J binding protein 1 and 2 as a reference. 
Through TET1 overexpression and the use of mass spectrometry, they confirmed that 
TET1 was indeed responsible for conversion of 5mC to 5hmC in an oxygen, iron (II) 
and α-ketoglutarate dependent manner (Tahiliani et al., 2009). Subsequently, the other 
two TET proteins, TET2 and TET3, were shown to be capable of generating 5hmC in 
the same way (Ito et al., 2010). The TET enzymes were demonstrated to all contain a 
conserved C-terminal region comprised of a cysteine-rich region and a double stranded 
beta-helix domain, where the iron (II) and α-ketoglutarate binding regions are located 
(Ito et al., 2010; Yin and Xu, 2016). While TET1 and TET3 contain a CXXC domain 
responsible for binding the DNA in both unmethylated and methylated CpG context, but 
the TET2 gene does not encode such a domain (reviewed by Yin and Xu, 2016). The 
CXXC domain of TET2 is in fact encoded by a separate gene called IDAX, which also 
regulates TET2 expression (Ko et al., 2013). Isoforms of TET1 and TET3 which do not 
contain the CXXC domain but are still recruited to DNA, albeit in TET1’s case to a 
reduced degree, by other proteins have also been described (Liu et al., 2013; Perera et 
al., 2015; Zhang et al., 2016; Good et al., 2017). In particular, the truncated TET1 
isoform was proposed to be overexpressed in glioblastoma, breast and uterine cancers 
with the latter two characterised by an association between high TET1 levels and lower 
overall survival (Good et al., 2017). 
 
 
1.3.3 Passive and active DNA demethylation 
The process of removal of methyl groups from cytosines can occur either passively or 
actively. The passive DNA demethylation occurs through a downregulation in the levels 
or activity of DNMT1 and its cofactor UHRF1, leading to a reduction in the 
maintenance of methyl marks during successive rounds of cell proliferation (Wang et 
al., 2009; He et al., 2017; Seo et al., 2017). The evidence from work done in ESCs also 
supports the role of reduced levels of de novo methyltransferases DNMT3A and 
DNMT3B, as well as DNMT3L, in the passive demethylation process (Ficz et al., 2013; 
Leitch et al., 2013; Yamaji et al., 2013). 
Active DNA demethylation involves a number of enzymatic reactions, the most 
prominent and widely accepted of which is the iterative oxidation of the 5mC base by 
the TET proteins followed by base excision repair (BER) through the thymine DNA 
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glycosylase (TDG) enzyme (Figure 1.3) (reviewed by Wu and Zhang, 2017). Both 5fC 
and 5caC, but not 5hmC, were shown to be recognised and excised by TDG (He et al., 
2011; Maiti and Drohat, 2011). The resulting abasic site is then incised by the APE1, 
NEIL1 or NEIL2 endonucleases removing the baseless sugar moiety, followed by the 
insertion of an unmodified cytosine by DNA polymerase β and DNA ligation trough the 
combined action of XRCC1 and LIG3 proteins thus completing the demethylation 




Figure 1.3 The active demethylation of cytosine mediated by the TET and TDG 
enzymes 
The schematic structural representation of the demethylation cycle of the cytosine base. 
The chemical group modified by the enzymatic reactions is highlighted in red. DNMT = 
DNA methyltransferase; TET = ten-eleven translocation; TDG = thymine DNA 
glycosylase; BER = base excision repair. 
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The removal of the methyl group from cytosine bases can also occur in a semi-passive 
manner. This process involves the oxidation of 5mC by the TET enzymes followed by 
passive removal of the resulting 5hmC, 5fC or 5caC bases through successive rounds of 
DNA replication. This is possible due to reduced preference of the DNMT1 enzyme for 
the oxidised forms of 5mC, which in turn can result in dilution of these bases from the 
DNA during cell proliferation (Hashimoto et al., 2012; Ji et al., 2014). Additionally, 
UHRF1 was suggested to have a reduced affinity towards 5hmC as compared to 5mC, 
which may therefore result in less efficient recruitment of DNMT1 to 5hmC-containing 
CpGs compared to 5mC-containing ones (Hashimoto et al., 2012; Otani et al., 2013).  
The activation-induced deaminase and apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide (AID/APOBEC) family of enzymes was also implicated in the 
active DNA demethylation process. This was based on evidence from in vitro and E.coli 
experiments (Morgan et al., 2004) and in vivo zebrafish work (Rai et al., 2008), with the 
zebrafish AID enzyme displaying a unique affinity amongst its mammalian orthologues 
towards deaminating 5mC to thymine (Abdouni et al., 2013). In the latter scenario, AID 
was proposed to cooperate with the MBD4 glycosylase and the GADD45A DNA repair 
protein to remove the thymine-guanine mismatch and complete the demethylation cycle 
(Rai et al., 2008). However, a contradictory report failed to observe a deamination 
activity of AID on 5mC in a double-stranded DNA context (Bransteitter et al., 2003). 
Additionally, the AID/APOBEC proteins were shown to have little in vitro activity on 
5mC, and no activity on 5hmC, as compared to an unmodified cytosine (Nabel et al., 
2012). Lastly, AID-knockout mice do not exhibit severe developmental defects aside 
from immune system issues and lymphoma formation (Muramatsu et al., 2000; Kotani 
et al., 2007) and APOBEC1-knockout mice appear healthy and fertile (Hirano et al., 
1996; Morrison et al., 1996), thus casting further doubt on the importance of these 
proteins in the DNA demethylation process. 
 
 
1.3.4 Are 5-hydroxymethylcytosine and 5-formylcytosine independent epigenetic 
marks? 
The initial description of the TET enzymes’ ability to convert 5mC to 5hmC (Ito et al., 
2010) as well as 5fC and 5caC (Ito et al., 2011) identified these bases as intermediates 
in the active DNA demethylation pathway. However, studies from the Murrell and 
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Balasubramanian groups provided evidence that 5hmC is a mostly stable DNA 
modification and 5fC can be stable, especially in the brain (Bachman et al., 2014; 
Bachman et al., 2015). A number of 5hmC and 5fC-binding proteins were identified 
including MeCP2 (Mellén et al., 2012), MBD3 (Yildirim et al., 2011) and UHRF1/2 
(Spruijt et al., 2013; Chen et al., 2017). Additionally, a screen of binding proteins of 
these two cytosine modifications found more proteins with specificity towards 5fC than 
5hmC, including TDG and a number of the FOX transcription factors (Iurlaro et al., 
2013). The 5fC base was found to alter the structure of the DNA double helix by 
causing its underwinding (Raiber et al., 2015). Taken together, this evidence suggests 
that both 5hmC and 5fC are epigenetic modifications in their own right. 
 
 
1.3.5 The wind of change - the emerging roles of cytosine hydroxymethylation and 
5-formylcytosine beyond active demethylation 
The distribution of the 5hmC base in the genome strongly suggests an association with 
active gene transcription (reviewed by Lio and Rao, 2019). Firstly, the presence of 
5hmC within gene bodies is positively correlated with gene expression with 5hmC 
found to be present in the gene bodies of highly transcribed genes in multiple tissues 
and cell types, including the brain (Wang et al., 2012; Lister et al., 2013), T-cells 
(Tsagaratou et al., 2014), ESCs (Pastor et al., 2011), liver (Ivanov et al., 2013) and 
small intestine (Uribe-Lewis et al., 2020). The ESC bivalent promoters, characterised by 
the presence of both the repressive H3K27me3 and activating H3K4me3 histone tail 
marks, mark genes whose transcription is only initiated during cellular differentiation 
(Blanco et al., 2020). These promoters are known to harbour 5hmC to protect them from 
hypermethylation which would otherwise stop their expression during differentiation 
(Pastor et al., 2011; Verma et al., 2018).  
The 5hmC base is also well documented to accumulate at the distal regulatory enhancer 
regions responsible for regulation of gene transcription levels (Mahé et al., 2017; Shi et 
al., 2017). The deposition 5hmC mark is associated with enhancer activation and this 
process was demonstrated to be mediated by the TET2 enzyme (Sérandour et al., 2012; 
Hon et al., 2014; Yang et al., 2016; Wang et al., 2018). The presence of 5hmC within 
exons and exon-intron boundaries was suggested to play a role in alternative splicing 
(Shi et al., 2017). It was found to promote the inclusion of the exon in the transcript in a 
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CTCF-mediated mechanisms in T-cells and MeCP2-dependent way in the brain, with 
no such function observed in the liver indicating the tissue specificity of this mechanism 
(Khare et al., 2012; Marina et al., 2016; Cheng et al., 2017). Lastly, 5hmC was shown to 
colocalize with DNA repair proteins to DNA damage loci in HeLa cells in a TET2-
dependent manner (Kafer et al., 2016). The authors also described evidence for the role 
of TET enzymes in genome integrity maintenance. A separate report confirmed the 
5hmC accumulation at DNA damage foci in numerous cell types and demonstrated the 
contribution of the TET3 enzyme to ATR-mediated DNA repair (Jiang et al., 2017). 
While the role of the TET enzymes and 5hmC in DNA repair is far from established and 
further work is required to elucidate it, it is tempting to speculate that the reduced levels 
of both in cancer cells could be contributing to the tumours’ genomic instability. 
The 5fC nucleotide is present in the genome at 0.00002 to 0.0011% of cytosine content 
with the base found to be enriched at active enhancers in a tissue-specific manner in the 
mouse embryo (Iurlaro et al., 2016). It was shown to induce a structural change in the 
DNA resulting in helical underwinding (Raiber et al., 2015), although conflicting results 
published by the Brown group mean that this effect is still debatable (Hardwick et al., 
2017). More recent report suggested that 5fC creates a localised change to the DNA 
structure which is recognised by the TDG enzyme prior to the base excision (Fu et al., 
2019). The presence of 5fC in the promoter region was demonstrated to repress gene 
expression (Kitsera et al., 2017) and it is also known to reduce the rate of transcription 
by the RNA polymerase II (Kellinger et al., 2012). Lastly, 5fC is known to induce 
DNA-protein crosslinks with the histone proteins (Li et al., 2017; Ji et al., 2019). 
Together, these findings suggest that the 5fC base may play a role in transcriptional 
control and nucleosomal regulation. 
 
 
1.3.6 The mysterious 5-carboxycytosine 
The 5caC base still remains poorly understood with its prevalence in mESCs recorded at 
0.00005% of cytosine levels (Hofer et al., 2019). In the same fashion as 5fC, it was 
demonstrated to both stall the RNA polymerase II during transcriptional elongation 
(Kellinger et al., 2012; Wang et al., 2015) and repress transcription when present within 
the promoter region (Kitsera et al., 2017). On the other hand, the evidence from mESCs 
studies suggests that 5caC marks active promoters and enhancer regions (Lu et al., 
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2015; Neri et al., 2015). The 5caC base was also found to be enriched in certain brain 
cancer cell lines (Ramsawhook et al., 2017) as well as breast cancer (Guo et al., 2017) 
and glioma samples (Eleftheriou et al., 2015), although the possible role of 5caC in 
tumorigenesis is yet to be elucidated. Lastly, a number of 5caC reader proteins were 
identified, including TDG (Zhang et al., 2012), the TCF4 transcription factor (Yang et 
al., 2019) and a specific domain within the TET3 enzyme (Jin et al., 2016). Overall, 
further work is required to confirm the potential functions of the 5caC base. 
 
 
1.3.7 The activity of TET enzymes is post-translationally regulated 
The TET proteins are known to have multiple sites and regions that can be post-
translationally modified (Liu et al., 2019). All three TET enzymes can be modified with 
O-linked N-Acetylglucosamine (O-GlcNAc) residues by the O-GlcNAc transferase 
(OGT) enzyme (Bauer et al., 2015). The TET1 enzyme was demonstrated to both 
interact with OGT and be O-GlcNAcylated in mESCs, which resulted in increased 
repression of the target genes (Shi et al., 2013; Vella et al., 2013). TET1 was also shown 
to be modified by OGT in vitro, which resulted in the increased activity of the former 
(Hrit et al., 2018). Conversely, two other reports found that OGT associates with both 
TET2 and TET3, but not TET1 and induces transcriptional activation (Chen et al., 2013; 
Deplus et al., 2013). TET3 was also independently shown to interact with OGT, be O-
GlcNAcylated and enhance OGT recruitment to DNA (Ito et al., 2014). This 
discrepancy in findings was suggested to stem from differing experimental approaches 
(Balasubramani and Rao, 2013), but this is unlikely to account for all the differences in 
results described above. It is therefore clear that further work is required to fully 
elucidate the nature of the relationship between the TET proteins and OGT as well as its 
functional importance. 
The TET1 enzyme was demonstrated to be polyADP-ribosylated by the polyADP-
ribose polymerase (PARP1) enzyme in both covalent and non-covalent manner which 
results in activation and suppression of TET1 activity, respectively (Ciccarone et al., 
2015). PARP1 is also known to promote TET1 expression through low promoter 
methylation and high H3K4 histone trimethylation levels (Ciccarone et al., 2014). The 
TET2 enzyme was shown to be acetylated by the p300 acetyltransferase which 
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stabilizes it and promotes its activity, and was suggested to protect cells from aberrant 
methylation due to oxidative stress (Zhang et al., 2017). The phosphorylation of TET2 
by the JAK2, AMPK and CDK5 kinases also results in its activation and increased 
stability (Wu et al., 2018; Jeong et al., 2019; Rao et al., 2020). The site of TET2 
phosphorylation by AMPK is bound by the 14-3-3 proteins which protects it from 
dephosphorylation; a process that was suggested to be deregulated in cancer via TET2 
mutations (Chen et al., 2019; Kundu et al., 2020). The DCAF1-containing E3 ubiquitin 
ligase complex monoubiquitylates the TET proteins promoting their binding to the 
DNA (Nakagawa et al., 2015). All three TET enzymes are also known to be degraded 
by the calpain proteases (Wang and Zhang, 2014). 
Different miRNAs have been demonstrated to regulate the TET enzymes (Fu et al., 
2013; Zhang et al., 2013). TET1 is regulated by miRNAs both during cellular 
differentiation and in cancer cells. The miRNA-191 was shown to play an oncogenic 
role in liver and endometrial cancers through downregulation of TET1 expression (Li et 
al., 2017; Yang et al., 2020). In hepatocellular carcinoma both miRNA-494 and 
miRNA-520b suppress tumour progression through reduction of TET1 level (Chuang et 
al., 2015; Zhang et al., 2015). Conversely, miRNA-21-mediated inhibition of TET1 
expression in colorectal cancer resulted in a higher cell proliferation rate (Ma et al., 
2018). The miRNA-29 family was shown to repress TET1 expression during 
differentiation of mESCs to embryonic bodies (Tu et al., 2015; Cui et al., 2016). 
TET2 transcript-targeting miRNAs including miRNA-101, miRNA-29b and c, miRNA-
7 and miRNA-125b were demonstrated to promote malignant haematopoiesis where 
TET2 plays a tumour suppressive role (Cheng et al., 2013). A different group reported a 
similar effect of miRNA-22, including induction of haematological malignancies in 
mice and defective differentiation of hematopoietic stem cells (Song et al., 2013). The 
miRNA-767-5p was found to promote thyroid cancer growth and invasion through 
TET2 inhibition (Jia et al., 2020). The TET3 mRNA was demonstrated to be regulated 
by miRNA-29b in the mouse hippocampus (Kremer et al., 2018). Additionally, TET3 is 
repressed during mouse cortical development and differentiation of neural progenitor 
cells (Lv et al., 2014). Lastly, all three TET transcripts were demonstrated to be 
downregulated by miRNA-29a in hepatocellular carcinoma cells which contributed to 
cancer progression (Chen et al., 2017). 
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In summary, the activity and functions of the TET proteins can be regulated by multiple 
mechanisms beyond the availability of oxygen, iron (II) and 2-oxoglutarate. However, 
more research is clearly needed to fully elucidate the functional importance of these 
mechanisms and resolve the controversies outlined above. 
 
 
1.4 The sixth DNA base and its roles in development and 
cellular differentiation 
1.4.1 The TET enzymes as novel regulators of the early mammalian development 
The TET enzymes play a critical role in the two major demethylation events occurring 
during mammalian development in the gametes and PGCs (see section 1.2.3 for details). 
The in vivo studies of the effects of Tet knockouts provide insight into the importance of 
these enzymes in the early mammalian development. While Tet1 and Tet2 knockout 
mice were reported to have no clear developmental impairments (Dawlaty et al., 2011; 
Li et al., 2011; Ito et al., 2019), homozygous knockout of the Tet3 gene leads to 
complete neonatal lethality (Gu et al., 2011). Intriguingly, two separate studies reported 
partial (Kang et al., 2015) and complete (Khoueiry et al., 2017) embryonic lethality of 
the Tet1 knockout mice. It is likely that this discrepancy is due to alternative exon 
targeting strategies and differences between mouse strains used (Khoueiry et al., 2017). 
The majority of Tet1 and Tet2 double knockout mice die perinatally and display 
developmental defects, but the viable animals are fertile, albeit with reduced female 
fertility (Dawlaty et al., 2013). This points to the fact that even the double knockout of 
Tet1 and Tet2 is partially conducive with embryonic development. A double Tet1 and 
Tet3 knockout leads to complete embryonic lethality (Kang et al., 2015). The triple Tet 
knockout mice display embryonic lethality with numerous severe defects observed 
during the gastrulation stage (Dai et al., 2016; Li et al., 2016). These experiments 
highlight the critical importance of the TET enzymes, and TET3 in particular, in the 
early mammalian development. The summary of the developmental effects of Tet 
deletions is presented in Table 1.1. 
The first wave of global DNA demethylation occurs in the two gametes following 
fertilisation (see section 1.2.3 for details). Initially, the maternal genome was shown to 
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be demethylated passively in a replication-dependent manner through the lack of 
DNMT1 activity (Rougier et al., 1998; Cardoso and Leonhardt, 1999). The TET3 
enzyme, which is highly expressed in the zygote, was thought to be responsible for 
actively demethylating the paternal genome prior to the onset of cell divisions (Oswald 
et al., 2000; Gu et al., 2011). The maternal genome is protected from the actions of 
TET3 via binding of the PGC7 protein to the H3K9me2 histone mark (Nakamura et al., 
2012). However, more recent studies indicate that both the maternal and paternal 
genomes are actively and passively demethylated (Guo et al., 2014; Wang et al., 2014). 
Lastly, the requirement of TET3 for paternal genome demethylation was recently 
questioned through demonstration of the formation of 5hmC following the loss of 5mC 
in the paternal genome (Amouroux et al., 2016). Instead, the authors suggested that an 
unidentified active DNA demethylation mechanism is responsible for 5mC loss while 
TET3 plays a role in preventing the gain of aberrant methylation patterns through the  
 
Table 1.1 The summary of the effects of in vivo Tet deletions on mammalian 
development 
Knockout type Phenotype References 
Single Tet1 
Strain dependent; no 
developmental defects or 
partial/complete embryonic 
lethality 
(Dawlaty et al., 2011) 
(Kang et al., 2015) 
(Khoueiry et al., 
2017) 
Single Tet2 
No developmental defects; 
myeloid malignancies in adult 
animals 
(Li et al., 2011) 
(Ito et al., 2019) 
Single Tet3 Complete embryonic lethality (Gu et al., 2011) 
Double Tet1 and 
Tet2 
Partial embryonic lethality; 
reduced fertility in surviving 
animals 
(Dawlaty et al., 2013) 
Double Tet1 and 
Tet3 
Complete embryonic lethality (Kang et al., 2015) 
Triple Tet1, Tet2 
and Tet3 
Severe gastrulation defects and 
complete embryonic lethality 
(Dai et al., 2016) 
(Li et al., 2016) 
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actions of DNMT1 and DNMT3a, which contrary to past findings, were demonstrated 
to be active in the zygote (Amouroux et al., 2016). 
The second wave of DNA demethylation involves imprint erasure in the PGCs. The 
active removal of cytosine methylation in PGCs occurs following the initial passive 
demethylation (see section 1.2.3) and focuses on a set of specific genomic regions 
including some imprinting genes and X-chromosome CGIs (Guibert et al., 2012; 
Seisenberger et al., 2012; Hackett, et al., 2013). This process was found to be mediated 
by the TET1 and TET2 enzymes with 5hmC reaching its peak at ED11.5 before being 
diluted out of the genome by ED13.5 (Hackett, et al., 2013; Vincent et al., 2013; 
Yamaguchi et al., 2013). At the same time the Tet3 expression was found to be 
undetectable (Hackett, et al., 2013). However, while Tet1 was found to be the highest 
expressed Tet gene during active PGC demethylation, its knockout did not prevent 
almost complete loss of the 5mC mark by ED13.5 (Hill et al., 2018). Additionally, 
TET1 was found to play a similar role to TET3 during zygotic demethylation by 
protecting genomic regions from acquiring aberrant DNA methylation patters (Hill et 
al., 2018). 
These results suggest that the TET enzymes play a role in both active removal of the 
5mC mark and protection from unwarranted DNA methylation. Further research is 
required to determine which of these functions is predominant. 
 
 
1.4.2 Acquisition of cellular identity and 5-hydroxymethylcytosine - stem cell 
differentiation and the small intestine 
In addition to their critical importance for early mammalian development described in 
the previous section, the TET enzymes are also known to be important regulators of the 
stem cell differentiation process. In mESCs, the Tet1 and Tet2 transcripts were found to 
be highly expressed while the Tet3 mRNA is present at very low levels (Ito et al., 2010; 
Koh et al., 2011). Upon differentiation to embryonic bodies, the Tet3 levels rise sharply, 
Tet1 levels exhibit a large drop and Tet2 levels remain largely unchanged following an 
initial drop (Szwagierczak et al., 2010). In terminally differentiated cells of various 
tissue types, Tet2 and Tet3 levels are high while Tet1 is barely detectable in most of 
them (Ito et al., 2010; Szwagierczak et al., 2010). 
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The distribution of the 5hmC mark in mESCs has been extensively studied and 
characterised. The total levels of 5hmC are estimated between 0.1% and 0.4% of all 
cytosines (Le et al., 2011; Münzel et al., 2011; Pfaffeneder et al., 2011; Pfaffeneder et 
al., 2014). The 5hmC base was found to be enriched in gene-rich areas of the genome, 
in particular in exons, and around their boundaries, of highly expressed genes and 
promoters of genes with low expression levels (Xu et al., 2011; Huang et al., 2014). 
Within the promoter regions, the 5hmC mark was found to specifically be enriched 
around the transcription start site (TSS) followed by a gradual increase towards the 
transcription termination site (Xu et al., 2011; Huang et al., 2014). In human ESCs 
(hESCs), 5hmC was also found to accumulate around the TSS and gene bodies of lowly 
expressed genes, as well as enhancers and DNA-protein interaction sites (Stroud et al., 
2011; Yu et al., 2012; Li et al., 2018). 
The experiments with Tet knockout mESCs shed further light on their roles in 
pluripotency maintenance and differentiation (summarised in Table 1.2). A single 
knockout of the Tet1 gene resulted in reduced 5hmC levels and a skewing towards the 
trophectoderm lineage during differentiation (Dawlaty et al., 2011). The Tet1 knockout 
also did not alter the pluripotency of the mESCs and it was compatible with embryonic 
development (Dawlaty et al., 2011). The single deletion of Tet2 in mESCs resulted in 
altered expression of genes involved in differentiation to neural progenitor cells which 
was associated with the hypermethylation and reduced activity of a subset of enhancer 
regions (Hon et al., 2014). The knockout of Tet2 resulted in a larger reduction of 5hmC 
levels (90%) than the Tet1 knockout (35-44%) (Dawlaty et al., 2011; Hon et al., 2014). 
The TET1 and TET2 proteins were found to play distinct roles in mESCs with TET1 
mainly responsible for 5hmC deposition in the promoter regions while TET2 drives the 
accumulation of the 5hmC marks within the genes bodies (Huang et al., 2014). This is 
thought to be driven by differential targeting of the two enzymes to genomic regions 
due to the lack of the DNA binding CXXC domain in the structure of the TET2 protein 
(Huang et al., 2014). Intriguingly, TET1 was found to both activate the expression of 
genes involved in mESC maintenance through safeguarding of a hypomethylated state 
and repress genes involved in differentiation through association with the PRC2 
complex (Wu et al., 2011). The binding to the PRC2 group of proteins by TET1 was 
also shown to play a role in maintaining the bivalency of certain promoters in mESCs 
which is thought to supress their expression (Neri et al., 2013). TET1 also binds to the 
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SIN3A protein which plays an important role in pluripotency maintenance and their 
interaction may explain the skewing of differentiation lineage choice in Tet1 knockout 
mESCs (Zhu et al., 2018). The single knockout of Tet3 resulted in skewing of mESC 
differentiation towards cardiac mesoderm, which was mediated by aberrant activation of 
the WNT pathway (Li et al., 2016).  
 
Table 1.2 The summary of the effects of Tet deletions on mouse embryonic stem 
cells 
Knockout type Phenotype References 
Single Tet1 
No effect on mESCs 
pluripotency and compatible 
with in vivo development 
(Dawlaty et al., 2011) 
Single Tet2 
Enhancer hypermethylation; 
loss of 90% of 5hmC marks and 
delayed induction of genes 
involved in differentiation  
(Hon et al., 2014) 
Single Tet3 
Aberrant activation of WNT 
signalling and skewed 
differentiation towards cardiac 
mesoderm 
(Li et al., 2016) 
Double Tet1 and 
Tet2 
Complete loss of 5hmC; no 
effect on mESCs pluripotency; 
skewed differentiation towards 
trophoblast cells 
(Dawlaty et al., 2013) 
Triple Tet1, Tet2 
and Tet3 
Complete loss of 5hmC in both 
mESCs and embryonic bodies; 
severely impaired differentiation 
with a skew towards cardiac 
mesoderm, telomere 
homeostasis and enhancer 
demethylation 
(Dawlaty et al., 2014) 
(Lu et al., 2014) 




The double knockout of Tet1 and Tet2 resulted in complete loss of global 5hmC levels 
despite elevated expression of Tet3 (Dawlaty et al., 2013). The authors also 
demonstrated that the double knockout mESCs are pluripotent and capable of 
differentiation, albeit defective, into the three germ layers with an aberrant preference 
towards the trophoblast lineage (Dawlaty et al., 2013). The triple knockout of the Tets 
resulted in complete loss of 5hmC levels but the mESCs retained their normal 
morphology, pluripotency marker expression and proliferation rate, although the more 
recent publication by Li et al found a significantly reduced proliferation rate in Tet triple 
knockout mESCs (Dawlaty et al., 2014; Lu et al., 2014; Li et al., 2016). However, the 
triple knockout mESCs displayed a severe skew towards cardiac mesodermal lineage 
during the differentiation process due to aberrant activation of the WNT pathway 
(Dawlaty et al., 2014; Li et al., 2016). Additionally, through studying these cells, the 
TET proteins were demonstrated to demethylate promoters, enhancers and distal 
regulatory elements in mESCs and their deletion resulted in increased telomere length 
(Lu et al., 2014). The crucial role of the TET enzymes in regulation of cellular 
differentiation was recently confirmed by studying triple TET knockout hESCs. The 
TET enzymes were shown to maintain promoter bivalency through hypomethylation 
and their loss resulted in aberrant differentiation of embryoid bodies (Verma et al., 
2018). In particular, the authors demonstrated impaired neuroectoderm differentiation in 
hESCs due to PAX6 promoter hypermethylation caused by the triple TET knockout 
(Verma et al., 2018). 
The mouse small intestine is an easily accessible model to study adult stem cell 
differentiation with a well-defined role of the 5mC mark in this process (see section 
1.2.4). Cytosine hydroxymethylation, together with the TET proteins, was demonstrated 
to regulate this process, although the exact role of the latter remains controversial (see 
section 6.2.1 for more details on the TET enzymes) (Haffner et al., 2011; Kim et al., 
2016; Uribe-Lewis et al., 2020). The global 5hmC levels are depleted in the ISCs 
compared to the differentiated villus progeny in both mouse and human intestine 
(Uribe-Lewis et al., 2015; Kim et al., 2016; Uribe-Lewis et al., 2020). Kim and co-
authors found that 5hmC presence within the gene bodies was positively correlated with 
gene expression in the two cell types (Kim et al., 2016). In ISCs, 5hmC was associated 
with genes involved in cellular differentiation and development while in differentiated 
cells it was enriched in genes responsible for nutrient transport and metabolism (Kim et 
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al., 2016). Uribe-Lewis and colleagues further confirmed the importance of 5hmC in 
controlling gene expression during the differentiation process and highlighted its 
association with both active and bivalent enhancer regions (Uribe-Lewis et al., 2020). 
Lastly, both research groups found that while the majority of genes show a positive 
correlation between the change in expression and 5hmC content during differentiation, 
in a small proportion of genes the presence of 5hmC is associated with transcriptional 
repression (Kim et al., 2016; Uribe-Lewis et al., 2020). 
Taken together, these results indicate the critical role of the TET proteins and the 5hmC 
mark during the cellular differentiation process and highlight their functions beyond the 
originally described ones during stem cell pluripotency maintenance and differentiation. 
 
 
1.4.3 Forever young - the promise of induced pluripotent stem cells and 
methylation barriers in cellular reprogramming 
In 2006 a ground-breaking study published by Takahashi and Yamanaka demonstrated 
that the use of a cocktail of four transcription factors: OCT4, SOX2, KLF4 and C-MYC 
allowed a conversion of differentiated cells to a pluripotent, ESC-like state termed 
induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006). This 
discovery was rewarded with a Nobel prize for Physiology and Medicine in 2012 and 
the so-called “Yamanaka factors” have demonstrated great promise in tackling aging, 
aiding drug discovery and testing and the field of regenerative medicine (Johnson and 
Cohen, 2012; Doss and Sachinidis, 2019; Kane and Sinclair, 2019; Haridhasapavalan et 
al., 2020; Lee et al., 2020). Intriguingly, the TET1 protein can replace OCT4 in the 
Yamanaka factor cocktail as it demethylates the Oct4 promoter and enhancer resulting 
in its reactivation (Gao et al., 2013). The TET1 and TET2 proteins were demonstrated 
to enhance the efficiency of reprogramming through demethylation of key genomic 
regions associated with pluripotency such as Essrb, Oct4 and Nanog (Costa et al., 2013; 
Sardina et al., 2018). The critical role of the TET enzymes in the reprogramming 
process was further highlighted by the fact that the deletion of all three genes in mouse 
embryonic fibroblasts prevents iPCSs generation (Hu et al., 2014). The authors also 
suggested that the TETs are critical for the mesenchymal to epithelial transition step of 
reprogramming rather than the reactivation of the pluripotency genes, which is in direct 
contradiction to the studies mentioned above (Hu et al., 2014). Vitamin C was shown to 
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improve the efficiency of mouse and human iPSCs generation (Esteban et al., 2010), 
although its presence in the media was suggested to prevent TET1 from promoting the 
reprogramming process (Chen et al., 2013). 
 
 
1.4.4 The link between cellular differentiation and cancer 
The processes of cellular differentiation and tumorigenesis share multiple common 
characteristics. In clinical pathology, grading of tumour differentiation status has been 
used for decades as a prognostic marker (Jögi et al., 2012). In general terms, higher 
degree of differentiation of tumour cells is positively correlated with patient prognosis, 
while a poorly differentiated tumour that does not resemble the tissue of origin tends to 
be more malignant and hence difficult to treat (Jögi et al., 2012). One of the four 
Yamanaka factors involved in generation of iPSCs, C-MYC, is a known oncogene 
(Takahashi and Yamanaka, 2006). Indeed, teratoma formation, along with tumours 
arising from cells which differentiated into an unintended tissue types, still represents a 
major risk for therapies based on pluripotent stem cells (Kumazaki et al., 2013; Itakura 
et al., 2017; Kimura et al., 2019; Martin et al., 2020). Additionally, the concept of 
“cancer stem cells” (CSCs) is becoming more widely accepted, with these cells forming 
a subpopulation within the tumour that is more resistant to conventional treatments such 
as chemotherapy and radiotherapy which can be responsible for patient relapse (Gupta 
et al., 2009; Kurrey et al., 2009). These CSCs have now been identified in multiple 
cancer types including colorectal (Dalerba et al., 2007; Ricci-Vitiani et al., 2007), liver 
(Ma et al., 2007), breast (Al-Hajj et al., 2003) and brain (Singh et al., 2004) cancers. 
Lastly, the ISCs are known to give rise to tumours in mice thus providing a further link 
between the differentiation status and oncogenic transformation potential of the small 






1.5 5hmC and the TETs as important pieces of the 
tumorigenesis puzzle 
1.5.1 The epigenetic hallmarks of cancer cells 
In their landmark 2000 review paper published in Cell, Douglas Hanahan and Robert 
Weinberg directed a shift in thinking about the common characteristics of the 
heterogenous disease of cancer (Hanahan and Weinberg, 2000). The six acquired 
capabilities, or hallmarks, they described are evasion of apoptosis, self-sufficiency in 
growth signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless 
replicative potential and tissue invasion and metastasis (Hanahan and Weinberg, 2000). 
In an update to the original publication, the authors presented two emerging hallmarks: 
deregulation of cellular energetics and avoidance of immune destruction as well as two 
enabling characteristics: genome instability and mutation and tumour-promoting 
inflammation (Hanahan and Weinberg, 2011). The role of epigenetics and its 
contribution to establishment of each of the hallmarks in cancer cells is increasingly 
being recognised (Macaluso et al., 2003; Schnekenburger et al., 2015; Flavahan et al., 
2017). It was proposed that dysregulation of epigenetic mechanisms, in particular 
aberrant DNA methylation, should in fact be considered as a hallmark of cancer 
development and progression (Stahl et al., 2016; Cheng et al., 2019; Darwiche, 2020). 
In particular, global loss of 5hmC and promoter hypermethylation of tumour suppressor 
genes were suggested as epigenetic hallmarks of melanoma (Lian et al., 2012; 
Mannavola et al., 2020). It is still debatable whether these epigenetic changes should be 
conceptualised as one of the cancer hallmarks. One could argue that epigenetic changes, 
as well as DNA mutations, are mechanisms by which the cancer hallmarks are acquired. 
However, the well-established role of cytosine methylation and accumulating evidence 
of the importance of the TET enzymes and 5hmC suggest that they should be 
considered as part of the hallmark framework in the future. 
 
 
1.5.2 The landscape of 5-hydroxymethylcytosine in the tumour genome 
The global loss of 5hmC is a characteristic feature of a number of both solid and 
haematological cancers (Table 1.3). This has been reported to be in part due to the TET 
mutations present in numerous cancer types (see section 1.5.3) (Pfeifer et al., 2013). 
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Additionally, the mutations in the isocitrate dehydrogenase genes (IDH1 and IDH2) 
result in production of an oncometabolite 2-hydroxyglutarate instead of the TET co-
factor and Krebs cycle intermediate 2-oxoglutarate (also known as α-ketoglutarate). 
This results in competitive inhibition of the activity of the TET proteins thus lowering 
global 5hmC levels (Xu et al., 2011).  
 
Table 1.3 The examples of human cancer types with globally reduced 5hmC levels 
Cancer type References 
Bladder (Peng et al., 2018) 
Breast (Tsai et al., 2015) 
Cervical (Zhang et al., 2016; Bhat et al., 2017) 
Colorectal 
(Uribe-Lewis et al., 2015; Huang et al., 2016; 
Hu et al., 2017) 
Gastric (Yang et al., 2013; Park et al., 2015) 
Glioma/Glioblastoma (Johnson et al., 2016; Fernandez et al., 2018) 
Head and neck (Misawa et al., 2019) 
Kidney (Chen et al., 2016) 
Leukaemia (Marçais et al., 2017; Wernig-Zorc et al., 2019) 
Liver (Thomson et al., 2016) 
Lung (Li et al., 2016; Liao et al., 2016) 
Lymphoma (De Souza et al., 2014; Lemonnier et al., 2018) 
Melanoma (Lian et al., 2012) 
Myeloma (Alberge et al., 2019) 
Oesophageal (Murata et al., 2015) 
Oral (Jäwert et al., 2013; Wang et al., 2017) 
Ovarian (Zhang et al., 2015; Tucker et al., 2018) 
Pancreatic (Bhattacharyya et al., 2013) 
Prostate (Feng et al., 2015; Storebjerg et al., 2018) 
Testicular (Munari et al., 2016) 
Thyroid (Tong et al., 2019; Iancu et al., 2020) 
Uterine (Ibrahim et al., 2019) 
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Tumour hypoxia is also known to lead to reduced hydroxymethylation across the 
genome and hypermethylation of tumour suppressor gene promoters by reducing the 
availability of oxygen to the TET enzymes (Thienpont et al., 2016). Interestingly, it is 
known that the 5hmC loss does not correlate with TET and IDH mutations in certain 
cancer types (Jin et al., 2011; Uribe-Lewis et al., 2015). Instead, it was suggested that 
the reduction in global 5hmC content is due to the increased proliferation rate of cancer 
cells as the DNMT1 enzyme does not recognise and maintain 5hmC marks and there is 
a delay in their re-establishment following DNA replication (Valinluck and Sowers, 
2007; Otani et al., 2013; Bachman et al., 2014; Uribe-Lewis et al., 2015). 
Changes in the 5hmC distribution were also observed in tumours’ genomes isolated 
from patients as compared to matched normal cells. In melanoma the loss of 5hmC was 
found to occur across all genomic sites, including promoter, intragenic and intergenic 
regions, compared to nevi cells (Lian et al., 2012). In gastric adenocarcinoma, the 
biggest loss of 5hmC was observed in exons and CGIs (Liu et al., 2019). Bladder cancer 
is characterised by a loss of 5hmC content mainly in the promoters and intragenic 
regions (Peng et al., 2018). In kidney tumours, sites with 5hmC loss were enriched 
within the gene bodies of genes associated with renal cell carcinoma progression (Chen 
et al., 2016). Glioblastomas were found to have reduced 5hmC levels within the 
promoter regions and elevated 5hmC content at enhancer regions (Johnson et al., 2016). 
The 5hmC enrichment at genomic enhancers was further confirmed in IDH1 wild-type 
and mutant gliomas (Glowacka et al., 2018). The hyperhydroxymethylation of enhancer 
elements was also reported in hepatocellular carcinoma patient samples (Hlady et al., 
2019). Intriguingly, two studies found 5hmC enrichment in promoters and gene bodies 
of cancer-associated genes in pancreatic cancer patient-derived xenografts and samples 
(Bhattacharyya et al., 2013; Bhattacharyya et al., 2017). The increased 5hmC content 
within these genes was positively correlated with their expression levels (Bhattacharyya 
et al., 2013; Bhattacharyya et al., 2017). 
These results suggest that global 5hmC loss is a hallmark of most cancer types and it 
predominantly occurs in promoter and intragenic regions during cancer progression. 
However, in certain cancer types aberrant increase in 5hmC levels is observed at 
selected genomic loci, most prominently the enhancer elements. It is hence likely that 
the heterogeneity of pathological genetic and signalling changes between tumour types 
extends to epigenetic alterations that contribute to their progression and development. 
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1.5.3 The prevalence of TET and IDH enzyme mutations in human cancers 
The fusion of the TET1 and the HMT MLL genes was initially described in acute 
myeloid leukaemia biopsies harbouring the t(10;11)(q22;23) translocation (Ono et al., 
2002; Lorsback et al., 2003). Subsequently, mutations in the TET genes were identified 
in numerous haematological and solid cancers. 
In haematological malignancies, loss-of-function TET2 mutations are the most prevalent 
mutation type among the three TET genes, with TET1 and TET3 mutations rarely 
observed in these cancers (Abdel-Wahab et al., 2009; Huang and Rao, 2014; Lasho et 
al., 2018). This is despite the latter two genes being expressed in these malignancies, 
albeit at reduced levels compared to the TET2 transcript (Scourzic et al., 2015; Lio et 
al., 2019). The TET2 gene is mutated particularly often (as high as 70-80% of cases) in 
angioimmunoblastic (AIML) and peripheral T-cell lymphomas (Lemonnier et al., 2012; 
Odejide et al., 2014; Palomero et al., 2014), chronic myelomonocytic leukaemia 
(Kosmider et al., 2009; Tefferi et al., 2009; Haferlach et al., 2014; Xie et al., 2014), 
blastic plasmacytoid dendritic cell neoplasm (Alayed et al., 2013; Menezes et al., 2014) 
and acute myeloid leukaemia (AML) (Abdel-Wahab et al., 2009; Shen et al., 2011; 
Weissmann et al., 2012; Ley et al., 2013). 
The mutations in the TET genes are rarely observed in solid cancers, up to 
approximately 10% of cases assessed in most solid tumour types (Scourzic et al., 2015). 
TET1 was observed to be mutated in 18.4% of prostate cancer cases (Spans et al., 2016). 
The analysis of the COSMIC database revealed a lower TET1 mutation frequency 
(0.12%) in prostate cancer, likely due to larger sample size compared to the study 
referenced above (Li et al., 2016; Spans et al., 2016). The latter study also found low 
TET1 mutation burden in ovarian (0.57%), lung (0.12%), breast (0.07%) and upper 
respiratory and digestive system (0.25%) cancers. TET2 was mutated in 18.2% of 
neuroendocrine (Pivovarcikova et al., 2019) and 5.7% of clear-cell (Sato et al., 2013) 
kidney tumours. Its mutations were identified in 10% of endometrial cancers (Chang et 
al., 2016) with copy number losses reported in the vast majority (73%) of clear cell 
ovarian cancers (Kim et al., 2018). TET2 was found to be mutated in 100% of 
metastatic and 0% of primary breast cancer cases (Nickerson et al., 2013). In gastric 
cancer, only 2.9% of cases were positive for TET3 mutations (Mo et al., 2020). TET3 
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was also reported to have a low mutation frequency (<1%) in ovarian cancer (Cao et al., 
2019). 
The genes encoding the two main IDH enzymes, IDH1 (cytoplasmic) and IDH2 
(mitochondrial), were described to be mutated in numerous haematological 
malignancies (Lio et al., 2019). These include AML (15-30%) (Figueroa et al., 2010), 
AIML (30.4%) (Sakata-Yanagimoto et al., 2014), blast crisis chronic myeloid 
leukaemia (3.5%) (Soverini et al., 2011) and myelodysplastic syndrome (MDS) (12%) 
(Patnaik et al., 2012). Intriguingly, TET2 and IDH1/2 mutations were found to be 
mutually exclusive in AML patients, but not in AIML (Figueroa et al., 2010; Sakata-
Yanagimoto et al., 2014).  
The mutations of IDH1/2 are more prominent in the more aggressive AML while TET2 
mutations occur with greater frequency in the more benign MDS and myeloproliferative 
neoplasms (Shih et al., 2012; Xie et al., 2014). This indicates that alterations in IDH1/2 
genes likely have a higher oncogenic potential than TET2 mutations (Shih et al., 2012; 
Xie et al., 2014; Inoue et al., 2016). This could be in part due to the inhibition of a wider 
range of enzymes by IDH1/2 mutations; indeed, enzymes such as TET1, TET3 (Xu et 
al., 2011), histone lysine demethylases (Chowdhury et al., 2011; Xu et al., 2011; Janke 
et al., 2017), transaminases (McBrayer et al., 2018) and prolyl hydroxylases (Xu et al., 
2011; Sasaki et al., 2012) were found to be inhibited by 2-hydroxyglutarate.  
IDH1/2 mutations were also identified in solid cancers such as glioma, where the 
mutation burden of these genes in very high (70-90%) (Yan et al., 2009; Dang et al., 
2010). Approximately 10% of melanoma cases were found to harbour an IDH1/2 
mutation (Shibata et al., 2011). In chondrosarcomas, alterations in IDH1/2 genes were 
reported in between 46.1 and 56% of cases depending on their origin and grade (Amary 
et al., 2011; Arai et al., 2012). The incidence of IDH1/2 mutations is lower in 
malignancies such as thyroid (7.9%) (Murugan et al., 2010) and lung (0.5%) (Rodriguez 
et al., 2020) cancers. 
These results highlight the considerable variation in TET and IDH mutation prevalence 
in human cancers. Furthermore, they point to the fact that these genetic alterations on 




1.5.4 The TET enzymes in cancer progression and metastasis 
Since the discovery of TET1 and its ability to convert 5mC to 5hmC in 2009, the levels 
and activity of the TET enzymes have been studied in numerous cancer types (Tahiliani 
et al., 2009; Ko et al., 2010; Lian et al., 2012; Carella et al., 2020; Yu et al., 2020). In 
melanoma patients, the expression of all three TET genes was found to be reduced in the 
melanoma lesions compared to benign nevi, with TET2 levels showing the greatest 
reduction (Lian et al., 2012). In glioblastoma patients, the expression of TET3 was 
shown to be reduced (Carella et al., 2020) while TET1 and TET2 expression was lower 
compared to normal tissue in papillary thyroid carcinoma sufferers (Yu et al., 2020). 
Similarly, the expression of TET1 was found to be lower in pancreatic tumour tissue 
compared to normal tissue (Wu et al., 2019). There is evidence, however, that in certain 
cancer types, such as lung cancer and leukaemia, TET1 can also play an oncogenic role 
(Huang et al., 2013; Filipczak et al., 2019) Additionally, TET3 expression was shown to 
be elevated and predict poor patient outcome in renal cell carcinoma (Chen et al., 2017) 
and ovarian cancer (Cao et al., 2019). These results indicate that while the TET 
enzymes broadly have a tumour suppressive function, this pattern may not be true in all 
cancer types and their role should be investigated in each tumour type separately. 
The mostly tumour suppressive function of the TET enzymes is further supported by 
studies assessing the effects of altering the levels of these proteins both in vitro and in 
vivo in multiple cancer types. TET1 transcript overexpression was found to reduce cell 
growth and promote apoptosis in an osteosarcoma cell line (Teng et al., 2019). 
Similarly, overexpression of TET1 led to reduced cell proliferation in hepatocellular 
carcinoma cell lines (Lin et al., 2015). Overexpression of the TET2 enzyme in a 
melanoma cell line resulted in reduced invasion in vitro and reduced tumour growth in 
vivo (Lian et al., 2012). Furthermore, overexpression of the TET2 protein resulted in 
reduced growth in gastric cancer (Deng et al., 2016) and glioblastoma (García et al., 
2018) cell lines. Similarly, the overexpression of the TET3 enzyme was shown to have 
tumour suppressive properties in ovarian cancer (Ye et al., 2016) and glioblastoma 
(Carella et al., 2020) cell lines.  
The genetic knockouts of the TET enzymes provide further insights into their role in 
different cancer types. The deletion of Tet1 gene in mice was shown to predispose the 
animals to development of B cell lymphoma (Cimmino et al., 2015). The TET1 
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knockout in a pancreatic cancer cell line resulted in increased cell proliferation and 
migration, thus further supporting the tumour suppressive properties of TET1 (Wu et 
al., 2019). However, a deletion of TET1 in a triple negative breast adenocarcinoma cell 
line led to significant reduction in cell proliferation and migration, indicating a potential 
oncogenic role of TET1 in some cancer types (Good et al., 2018). A genetic knockout of 
Tet2 in a mouse model resulted in development of myeloid lineage cancers in line with 
the evidence from cancer patients supporting the tumour suppressive role of TET2 in 
haematopoietic cancers (Li et al., 2011). The knockout of Tet2 in a murine melanoma 
cell line did not result in significant changes in tumour growth in vitro or in vivo but it 
led to resistance to PD-L1-based immunotherapy (Xu et al., 2019). Additionally, genetic 
knockout of TET2 resulted in increased parathyroid cancer cell growth and metastasis in 
vitro (Barazeghi et al., 2017). Mice with a double Tet2 and Tet3 knockout were shown 
to develop aggressive myeloid leukaemia which was not observed in a single knockout 
in ether of the genes, indicating synergistic tumour suppressive effects of TET2 and 
TET3 in mice (An et al., 2015). This result was further supported by genetic knockouts 
of three out of four Tet2 and Tet3 alleles which also resulted in development of acute 
myeloid leukaemia (Shrestha et al., 2020). Additionally, TET3 knockdown in tumour-
initiating cell subpopulations of two breast cancer cell lines reduced tumour growth in 
vitro and in vivo (Wu et al., 2015). The shRNA-mediated TET3 knockdown in a 
glioblastoma cell line, on the other hand, was found to increase tumour growth both in 
vivo and in vitro (Cui et al., 2016). 
Taken together, the findings described in the above sections present a highly complex 
story of the role of the TET proteins and 5hmC in cancer progression and metastasis. 
Despite the progress made in the field, numerous questions remain. These include, but 
are not limited to, the following. Is the global loss of 5hmC levels observed in most 
cancer types mostly due to their increased proliferation rate? If not, what are the exact 
mechanisms responsible for global hypohydroxymethylation in cancers without a large 
burden of TET and IDH mutations? Are reduced 5hmC levels a by-product of cellular 
transformation or do they drive cancer progression? How do the metabolic changes 
characteristic of cancer cells affect and regulate the catalytic and non-catalytic functions 
of the TET proteins? What do the dual context-dependent roles, both as tumour 
suppressors and oncogenes, of the TET enzymes reported so far mean for their viability 
as drug targets? Do 5fC and 5ca also have potential roles in cancer progression? 
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1.6 Colorectal cancer as a disease of modernity and its 
epigenetics 
1.6.1 Colorectal cancer in the contemporary world 
Colorectal cancer (CRC) is described as “disease of modernity” due to its association 
with improved standard of living and the fact that it mainly occurs in developed 
countries (reviewed in Brody, 2015; Holmes, 2015). In the USA alone, the projections 
estimate 147,950 cases and 53,200 death will be recorded in 2020 (Siegel et al., 2020). 
In 2018, approximately 1.8 million new cases were diagnosed worldwide and 881,000 
deaths were attributed to the disease which account for just over 10% of all cancer cases 
and deaths that year (Bray et al., 2018). The incidence of CRC in developed countries 
such as the USA, UK, Australia, Denmark, New Zealand and Canada is either 
stabilising or declining, although the opposite trend is observed in adults below 50 years 
of age in these nations (Araghi et al., 2019; Siegel et al., 2020). The decline of CRC 
incidence in those countries is mainly attributed to improved uptake and availability of 
screening programmes, higher standard of healthcare as well as dietary and lifestyle 
changes (Ouakrim et al., 2015; Mármol et al., 2017). Despite this, the yearly global 
burden of cases and deaths due to CRC is predicted to rise to 2.2 million and 1.1 
million, respectively, in 2030 (Arnold et al., 2017) and 2.5 million cases by 2035 
(Dekker et al., 2019; Xie et al., 2020). These models stress the importance of 
improvements in prevention, access to healthcare and screening programmes and 
development of novel therapeutic agents to combat the disease. 
 
 
1.6.2 Colorectal cancer as a model for stepwise tumour progression and its 
metastasis 
The aetiology of CRC has clear and well-studied familial and genetic components: 
approximately 70% of cases are sporadic, 25% are of familial origin without a known 
germline mutation and 5% are due to clearly defined, inherited genetic changes 
associated with hereditary syndromes (Mármol et al., 2017; Jansen et al., 2020; 
Schubert et al., 2020). The latter include the Lynch Syndrome, Familial Adenomatous 
Polyposis (FAP) and a group of Hamartomatous Polyposis Syndromes (Stoffel and 
Kastrinos, 2014). Recently, a number of previously unidentified candidate genes have 
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been suggested to contribute to the familial cases of CRC, including POLD1, NOTCH2, 
RAB25, GALTN12 and RPS20 (Jansen et al., 2020; Schubert et al., 2020).  
In the sporadic cases, the development of CRC is proposed to arise through a defined 
series of genetic mutations which result in progression from a normal colonic 
epithelium through adenoma to an invasive carcinoma. This hypothesis was first put 
forward in 1990 and centred around KRAS and TP53 mutations (Fearon and Vogelstein, 
1990). It is now generally accepted that the initial mutation in the progressive sequence 
is observed in the adenomatous polyposis coli (APC) gene (Vogelstein et al., 2013). 
APC is a known tumour suppressor gene which plays a role in ß-catenin degradation 
and its mutation is responsible for the FAP inherited syndrome (Leoz et al., 2015). Its 
initial mutation results in an increase in cell proliferation rate and formation of small 
adenomas which progress to larger ones through mutations in KRAS or BRAF 
oncogenes (Huang et al., 2018). The mutations in TP53, DCC, SMAD4 and PIK3CA 
genes occur at a later stage in the malignant progression sequence, leading to 
development of carcinomas (Fearon and Vogelstein, 1990; Vogelstein et al., 2013; 
Huang et al., 2018). The APC, KRAS and TP53 genes are mutated in 81%, 43% and 
60% of sporadic CRC cases which highlights their importance in CRC progression 
(Lichtenstern et al., 2020). 
The most common site of CRC metastasis is the liver which occurs due to the direct 
drainage of blood containing nutrients from the intestines through the hepatic portal 
vein (Zarour et al., 2017). The second common site of CRC metastases are the lungs, 
with the peritoneum, the brain, bones, adrenal glands and the spleen representing less 
commonly observed targets for CRC metastases (Vatandoust et al., 2015). 
Approximately 15-20% and over 50% of CRC patients develop lung and liver 
metastases, respectively, at some stage of their life (Misiakos et al., 2011; Valderrama-
Treviño et al., 2017). Only 20-25% of CRC patients presenting with liver metastases 
qualify for their resection (Vatandoust et al., 2015; Engstrand et al., 2018). Following 
hepatic resection, the 5-year survival is estimated at approximately 45% (Wang et al., 
2017) The prognosis is much worse for patients with non-resectable liver metastases 
who have a 5-year survival of below 10% (Gorgen et al., 2018; Dueland et al., 2020). 
The genes implicated in CRC progression and described in the previous paragraph are 
also closely linked to the metastatic process - a significant association was found 
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between KRAS, SMAD4 and TP53 mutations and CRC metastasis (Huang et al., 2018). 
The exact details of the role of these genes in the metastatic cascade remains, however, 
unclear. Interestingly, the role of CRC CSCs in the metastatic process is gaining 
increasing support (Zhou et al., 2018). The CRC CSCs subpopulations have previously 
been reported to express cell surface markers such as CD26, CD44, CD133, CD166, 
ALDH1, EpCAM and LGR5, which allow for their isolation and study (Dalerba et al., 
2007; Pang et al., 2010; De Sousa E Melo et al., 2017; Zhou et al., 2018). The CD26-
positive cells were found present in liver metastases of CRC patients and were capable 
of forming metastases in mice (Pang et al., 2010). Similarly, CSCs expressing variant 6 
of CD44 membrane protein were the drivers of CRC metastasis (Todaro et al., 2014). 
The LGR5-positive CSCs were shown to be necessary for CRC metastasis formation 
(De Sousa E Melo et al., 2017). A recent study further demonstrated that the CRC 
metastasis is driven by LGR5-negative cells, but the growth at the secondary site 
requires them to convert to the CSC LGR5-positive phenotype (Fumagalli et al., 2020). 
This indicates that the presence of CSCs and a degree of plasticity in the differentiation 
phenotype of CRC cells is required for a successful distant metastasis. 
 
 
1.6.3 The epigenetics of colorectal cancer 
The role of cytosine methylation in CRC development and progression has been 
extensively studied to date (Lam et al., 2016; Vymetalkova et al., 2019; Cervena et al., 
2020). Both hypo- and hypermethylation is observed in CRC. The potential role of 
hypomethylation of CRC was demonstrated as early as 1983 through description of 
hypomethylation of the RAS oncogenes which can lead to their aberrant activation 
(Feinberg and Vogelstein, 1983b). Hypomethylation of the C-MYC oncogene was also 
reported in CRC (Luo et al., 2010). Another example involves hypomethylation of the 
LINE-1 transposable elements in CRC, which comprise just under 20% of the genome 
and whose hypomethylation is thought to result in chromosomal rearrangements and 
genomic instability (Ogino et al., 2008; Jung et al., 2020). Conversely, 
hypermethylation of numerous tumour suppressor genes including APC, CDKN2A, 
MGMT and MLH1 was reported in CRC (Vymetalkova et al., 2019; Jung et al., 2020). 
This gain in cytosine methylation in tumour suppressor gene promoters is associated 
with the CIMP phenotype, briefly described in section 1.2.6. Inhibitors of DNMT 
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enzymes are being currently evaluated in early clinical trials for use in CRC patients 
with higher, aberrant DNA methylation levels (Cervena et al., 2020). Beyond cytosine 
methylation, the function of TET enzymes and 5hmC in CRC is also increasingly better 
understood (Chapman et al., 2015; Rawłuszko-Wieczorek et al., 2015; Tian et al., 2017; 
Gao et al., 2019). In particular, the use of 5hmC as a CRC biomarker is an exciting new 
avenue in CRC diagnosis. A number of assays have been demonstrated to be capable of 
distinguishing heathy and cancerous colonic tissue based on global 5hmC levels and 
distribution (Gilat et al., 2017; Gao et al., 2019; Margalit et al., 2020). Intriguingly, the 
same could be achieved using cell-free DNA which represents a much less invasive, and 
hence preferable, form of diagnosis (Li et al., 2017; Gao et al., 2019; Berger et al., 
2020). However further validations of the specificity and sensitivity of these methods 
will be required before they are translated into clinical use. For a detailed discussion of 
the role of TET proteins in CRC, see section 5.2. 
Other components of the epigenetic machinery, such as HDACs, histone demethylases 
(HDMs), miRNAs and long non-coding RNAs (lncRNAs) have also been demonstrated 
to play a role in CRC progression (reviewed by Jung et al., 2020). A number of HDAC 
genes, including HDAC1, HDAC2 and HDAC8 were found to have elevated expression 
in CRC and contribute to silencing of tumour suppressor genes (Mariadason, 2008; 
Chou et al., 2011). HDAC inhibitors have shown promising results in clinical trials with 
CRC patients and are being investigated further (Azad et al., 2018; Advani and Kopetz, 
2019). The LSD1 HDM was demonstrated to be overexpressed in CRC patients and its 
inhibition reduces CRC cell line migration in vitro (Li et al., 2019; Peng et al., 2020). 
The miRNAs, such as miRNA-21 and miRNA-92a which are upregulated in CRC, have 
mainly shown promise as diagnostic biomarkers, although their specificity remains 
controversial (Ren et al., 2015; Fu et al., 2018; Choi et al., 2019; Igder et al., 2019; 
Sabry et al., 2019). The antisense oligonucleotides targeting these miRNAs, despite 
showing early promise, are unlikely to be used in clinical setting anytime soon (Ding et 
al., 2018; Jung et al., 2020). The lncRNAs can function both as tumour suppressors, 
such as the GAS5 lncRNA (Liu et al., 2019; Ni et al., 2019), and oncogenes such as the 
CCAT1 lncRNA (Abedini et al., 2019; Chen et al., 2019). While certain lncRNAs, such 
as CCAT1 and CCAT2 show early promise as CRC biomarkers, the current evidence of 
their sensitivity and specificity is too sparse to justify clinical implementation in the 
near future (Zhao et al., 2015; Ozawa et al., 2017). 
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In recent years the research of epigenetic influences on CRC development and 
progression provided an understanding of this process that goes beyond the genetic 
model of colon epithelium-to-adenoma-to-carcinoma sequence. Further research in this 




1.7 The main hypothesis and key aims of the project 
The main hypothesis: 
The TET enzymes and 5hmC contribute to the process of colorectal cancer metastasis to 
the liver. 
Key aims of the project: 
1. To develop a cost-effective sensitive method of detection for global 5mC and 
5hmC levels using the mass spectrometry facilities available at the University of 
Bath. 
2. To characterise the in vitro properties of the two colorectal cancer cell lines, 
SW480 and SW620, selected as a metastasis model and the effects of 
compound-based 5hmC levels modulation on the in vitro migration and 
proliferation rates of these cells. 
3. To examine the effects of CRISPR/Cas9-induced mutations in genes encoding 
all three TET enzymes on in vitro proliferation, colony formation and migration 
of the SW480 and SW620 colorectal cancer cell lines. 
4. To examine the changes in 5hmC and TET levels during adult and embryonic 
stem cell differentiation of the small intestine and the liver to further the 
understanding of their role in untransformed tissue and to complement the 













The reagents and chemicals used in this project were purchased from Sigma-Aldrich, 
Thermo Fisher Scientific or VWR unless otherwise specified. The primers were 
purchased from Eurofins Genomics and Primerdesign. 
 
 
2.1.1 Cell lines 
The HCT116 cell line was obtained from American Type Culture Collection. 
The SW480 and SW620 cell lines were obtained from Professor Ann Williams (School 
of Cellular and Molecular Medicine, University of Bristol).  
The SW480 2I7, SW480 6B12 and SW620 2H13 TET triple knockout cell lines were 
obtained from Horizon Discovery. 
The H9 human embryonic stem cell line was obtained from Professor David Tosh 
(Department of Biology and Biochemistry, University of Bath) 
 
 
2.1.2 Murine samples 
The mouse brain tissue was obtained from Dr Kim Moorwood (Department of Biology 
and Biochemistry, University of Bath).  
The FACS-sorted CD24a_Mid (stem progenitor cells) and CD24a_Neg (differentiated 
progeny cells) cell aliquots isolated from mouse small intestines were obtained from Dr 







2.2 Cell culture 




2.2.1 Cell lines passaging 
The HCT116 cells were cultured in the Roswell Park Memorial Institute-1640 (Sigma-
Aldrich) supplemented with 5% (v/v) Fetal Bovine Serum (FBS) (Thermo Fisher 
Scientific) and 1% (v/v) Penicillin-Streptomycin solution (Gibco). 
The SW480, SW620, SW480 2I7, SW480 6B12 and SW620 2H13 cell lines were 
grown in Dulbecco's Modified Eagle Medium containing high glucose concentration of 
4500 mg/L (Sigma-Aldrich) supplemented with 5% (v/v) FBS and 1% (v/v) Penicillin-
Streptomycin solution. 
All cell lines were passaged every three or four days upon reaching 70-85% confluency. 
This was performed by aspirating the growth media from the culture dish, washing the 
cell monolayer once with pre-warmed 1X phosphate buffered saline (PBS) (Gibco) and 
incubating the cells with 0.05% trypsin solution (Gibco) for 8-12 minutes at 37°C. The 
trypsin solution was then inactivated by adding an appropriate amount of growth media 
and the desired proportion of the cells were added to the new cell culture dish. 
The H9 hESC line was cultured in feeder-free conditions as separate colonies in 6-well 
cell culture plates. The H9 cells were maintained in either mTeSR1 or mTeSR+ growth 
media (STEMCELL Technologies) with media changed either daily or every two days, 
respectively. The extracellular matrix coating for stem cell growth was prepared using 
human recombinant Laminin-521 (BioLamina) according to the manufacturer’s 
instructions. Briefly, 1 mL/well of the 5 µg/mL Laminin-521 solution prepared in DPBS 
(Sigma-Aldrich) was added to each plate followed by a 2 hour incubation at 37°C or 
storage at 4°C overnight before use. 
The colonies formed by the H9 cells were passaged upon reaching 70-80% confluency 
approximately every 3-4 days. The colonies were dissociated using the ReLeSR reagent 
(STEMCELL Technologies) by washing each well with DPBS and adding 0.5 mL/well 
of ReLeSR reagent for approximately 30 seconds. Following this short incubation, the 
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dissociation reagent was removed from each well and the plates were incubated for 5 
minutes at 37°C. Following that, 1.5 mL/well of either mTeSR media was added and the 
sides of the plates were tapped to aid the dissociation of the colonies. The resulting cell 
suspension was split approximately 1:6 into wells of a new Laminin-521 coated cell 
culture plate for propagation. 
The passaging and maintenance of the H9 hESC cell line was performed by Dr Stephen 
Weston and Dr Zoë Burke.  
 
 
2.2.2 Cell lines freezing and thawing 
The cell lines used in this project were cryopreserved by detaching the cells from the 
cell culture dish as described in section 2.2.1. The cell suspension was centrifuged at 
400 x g for 5 minutes at RT. The resulting supernatant was aspirated off and the cell 
pellets were resuspended in freezing media consisting of 50% (v/v) cell culture medium, 
40% (v/v) FBS and 10% (v/v) dimethyl sulphoxide (DMSO) (Sigma-Aldrich). The 
cryovials containing the cells were then tightly wrapped in thick tissue paper and kept at 
-80°C for 24 hours before transferring them to the liquid nitrogen tank for long term 
storage. 
The cells were thawed by warming the cryovial up in a 37°C water bath until half of its 
contents reached a liquid state. And equal volume of pre-warmed growth media was 
added to the cell suspension and gently mixed. The whole mixture was then transferred 
to a cell culture dish containing 5-10 mL of pre-warmed growth medium. The cells were 
then allowed to attach to the surface of the culture dish for at least 8 hours, following 
which the media was changed to remove the trace quantities of DMSO. 
 
 
2.2.3 Cell treatments with 5hmC levels modifying compounds and assessment of 
cell morphology 
The SW480 and SW620 cell lines were treated with the following compounds known to 
modify 5hmC levels: vitamin C (L-ascorbic acid) (Sigma-Aldrich), vitamin C and 
catalase (Sigma), dimethyl 2-oxoglutarate (Sigma-Aldrich) and nickel (II) chloride 
(Sigma-Aldrich). The doses of the compounds used in these treatments are listed in 
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Table 2.1. Cell images were taken using the EVOS FL microscope (Invitrogen) at the 
following 24 hour intervals after the start of the treatment: 0 hours, 24 hours and 48 
hours. 
 
Table 2.1 The doses of the 5hmC modifying compounds used in the in vitro assays 
Compound Manufacturer Catalogue number Concentrations used 
L-Ascorbic acid Sigma-Aldrich A4403 
0.1 mM, 0.5 mM, 
1 mM 
L-Ascorbic acid 


















2.2.4 Cell counting 
The cell lines were detached from the cell culture dish and dissociated into a single cell 
suspension using trypsin solution followed by its inactivation with the growth media. 
The cells were counted using a Neubauer counting chamber following a 1:2 dilution 
with a trypan blue solution (Sigma-Aldrich). The cell count was obtained by counting 
the cells in each of the four corner squares out of the nine large squares present in the 
haemocytometer ruled chamber area. The following equation was used to derive the 
number of cells per 1 mL:  




2.2.5 Cell size measurements 
The cell images at 20X magnification were taken using the EVOS FL microscope 
(Invitrogen) 48 hours after seeding. Between 100 and 200 cells per condition and cell 
line were randomly selected. The size measurement was taken of each cell by measuring 
the longest possible diameter of each cell using the ImageJ software. 
 
 
2.2.6 Cell viability assessment - the MTT assay 
The cell viability of the cell lines treated with the 5hmC levels modifying compounds 
and the TET triple knockout cell lines was assessed by the 3-[4,5-dimethylthiazole-2-
yl]-2,5-diphenyltetrazolium bromide (MTT) assay.  
The cells were seeded in a 96-well cell culture plate at the density of 10,000 cells/ well 
for all assays. In the case of treatments, the media was changed 24 hours after seeding 
and this was deemed the “0 hour” time point. The cell viability was assessed 48 hours 
following the start of the treatment or seeding. In the vitamin C and vitamin C in the 
presence of catalase experiments the media was changed every 24 hours in all wells. 
The media was removed from each well and 1 mg/mL of Thiazolyl Blue tetrazolium 
bromide (Alfa Aesar) dissolved in 1X PBS was added to all wells. The plates were 
incubated for 30 minutes at 37°C. The contents of the wells were decanted and 
isopropanol was added to dissolve the blue formazan crystals. Control wells containing 
isopropanol-only were included in all experiments to assess the background absorbance. 
The plates were gently shaken until all crystals were dissolved. The absorbance (A560 
nm) was measured using a plate reader (Turner Biosystems).  
 
 
2.2.7 Cellular transfection 
The transfection of of hESCs and cancer cell lines with plasmid constructs was carried 
out using the FuGENE HD transfection reagent (Promega Corporation) according to 
manufacturer’s instructions. The transfection conditions were obtained from the online 
FuGENE HD Protocol Database. The details of plasmids used for cellular transfections 
are shown in Table 2.2. 
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2.3 In vitro cancer hallmark assays 
2.3.1 Cell proliferation assays 
The cells were seeded in a 12-well cell culture plate at the density of 50,000 cells/ well 
for the assessment of the effects of the 5hmC levels modifying compounds on cell 
proliferation and 100,000 cells/well for all other assays. In the case of treatments, the 
media was changed 24 hours after seeding and this was deemed the “0 hour” time point 
for the cell counting purposes. The cells were counted at following 24 hour intervals 
after the start of the treatment or seeding: 24 hours, 48 hours, 72 hours and 96 hours. In 
the vitamin C and vitamin C in the presence of catalase experiments the media was 
changed every 24 hours in all wells. 
 
 
2.3.2 Cell migration assays 
The cells were seeded at a sufficiently high number to allow them to reach confluency 
within 48 hours in a 6 cm cell culture dish. Upon reaching confluency, the media in the 
6 cm dishes was changed to one containing 4 µg/mL Mitomycin C (Sigma-Aldrich) in 
order to arrest cell proliferation. Following a 2 hour incubation at 37°C, the cells were 
scratched with a P200 pipette tip as demonstrated in Figure 2.1. Each plate was washed 
three times with the growth media to remove the dead cells and traces of Mitomycin C. 
The 0 hour images were then taken using the EVOS FL microscope as described in 
Figure 2.1. Pictures of the same areas of the plate were also taken 24 hours and 48 hours 
after the scratch was performed. In the vitamin C and vitamin C in the presence of 
catalase experiments the media was changed every 24 hours in all cell culture dishes. 
The size of the gap at each time point was measured using the ImageJ software for all 
images by taking an average of three measurements for each image taken, yielding a 




Figure 2.1 The schematic representation of the migration assay set up in a 6 cm 
cell culture dish 
The letters “T” and “B” denote top and bottom of the plate respectively. The red line 
passing through the red dots represents the scratch made with the pipette tip while the 
dots themselves mark the areas where images of the gap between the two sides of the 
scratch were taken. In the schematic the 6 cm dish is depicted upside down. 
 
 
2.3.3 Colony formation assays 
The cells were seeded at the density of 200 cells/well in a 6-well cell culture plate for all 
assays. After the period of 24 hours, media was changed to one containing the correct 
concentration of the compound under investigation for the 5hmC levels modifying 
compounds. In the vitamin C and vitamin C in the presence of catalase experiments the 
media was changed every 24 hours in all cell culture dishes. For all other assays, the 
media was changed every 48-72 hours. The growth of the colonies was closely 
monitored to avoid separate colonies merging together while allowing sufficient time 
for the colonies to reach quantifiable size. 
The plates were fixed by carefully removing all of the growth media from each well and 
adding the fixing solution (1% v/v methanol and 1% w/v formaldehyde in 1X PBS) for 
30 minutes at RT. The colonies were then stained with 0.01% (w/v) crystal violet 
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solution for 1 hour at RT. Images of each plate were taken using the ChemiDoc-It2 UV 
Imager (Ultra-Violet Products). The GIMP software was used to remove any 
background staining from the images and the ImageJ software was utilized for the 
purpose of both counting colonies and measuring their surface area in square pixels 
through the “Analyse particles” macro. 
 
 
2.4 Epigenetic modulation of human embryonic stem cell 
differentiation 
2.4.1 Human embryonic stem cell differentiation to hepatocyte-like cells 
The H9 hESCs were differentiated into hepatocyte-like cells (HLCs) using a modified 
version of previously published protocols (Hay et al., 2008; Cameron et al., 2014; Wang 
et al., 2017). Colonies formed by the H9 cells were washed with DPBS and dissociated 
for 5-10 minutes at 37°C with the Accutase solution (STEMCELL Technologies) added 
at 0.5 mL/well. An equal volume of the mTeSR+ medium was added to the resulting 
cell suspension which was then centrifuged for 3 minutes at 1000 rpm. The supernatant 
was carefully aspirated off and the cell pellet was resuspended in the mTeSR+ medium 
with the 1X RevitaCell supplement added. The cells were counted as described in 
section 2.2.4. and seeded at the density of 7 x 104 cells/cm2 in pre-made Laminin-521 
coated 6-well cell culture plates. 
Approximately 24 hours after seeding, the first stage of the protocol was initiated - 
namely differentiation into definitive endoderm (DE) cells. The mTeSR+ medium was 
changed to RPMI-1640 supplemented with the 1X B27 supplement without vitamin A 
(Thermo Fisher Scientific), 2 µM of the 1m glycogen synthase kinase 3 (GSK3) 
inhibitor and 100 ng/mL of Activin A (PeproTech). Both 24 and 48 hours after that, the 
media was changed to RPMI-1640 supplemented with the 1X B27 supplement without 
vitamin A and 100 ng/mL of Activin A. 
Upon reaching the DE stage, the cells were further differentiated into hepatoblast (HB) 
cells by replacing the media with KnockOut-DMEM (Gibco) supplemented with 20% 
(v/v) KnockOut Serum Replacement (Gibco), 1% (v/v) Penicillin/Streptomycin 
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solution, 1 % (v/v) DMSO, 1X MEM Non-Essential Amino Acids Solution (Gibco), 
0.5X GlutaMAX supplement (Gibco) and 0.1 mM β-mercaptoethanol solution (Gibco). 
Subsequently, the same media was used for media changes every 24 hours for the next 
three days. 
The final stage of the protocol involved differentiation of HB cells to HLCs. The media 
was changed to HepatoZYME-SFM (Gibco) serum-free media supplemented with 1% 
(v/v) Penicillin/Streptomycin, 1X GlutaMAX supplement, 0.1 mM β-mercaptoethanol 
solution, 10 ng/mL Recombinant Human Hepatocyte Growth Factor (PeproTech), 20 
ng/mL Recombinant Human Oncostatin M (PeproTech), 10 µM hydrocortisone 21-
hemisuccinate sodium salt (Sigma-Aldrich), 10 µg/mL human insulin (Sigma-Aldrich), 
6.7 ng/mL sodium selenite (Sigma-Aldrich) and 5.5 µg/mL human holo-transferrin 
(Sigma-Aldrich). Subsequently, the same media was changed every 24 hours for the 
next 9 days. On the last day (day 18) the cells were pelleted as described in section 
2.2.2. and snap frozen at -80°C prior to DNA and RNA extraction. 




2.4.2 Human embryonic stem cell transfection 
The H9 hESCs were seeded as described in section 2.4.1. and allowed to proliferate for 
24 hours. Following the incubation period, the cells were transfected with 3µg/well of 
the appropriate shRNA vector using the FuGENE HD transfection reagent according to 
manufacturer’s instructions. A transfection reagent-only control was included in all 
experiments. After 24 hours, the transfection efficiency was assessed using the EVOS 
FL microscope and the differentiation to DE stage was initiated and carried out as 
described in section 2.4.1. 
 
 
2.4.3 Antibody staining of the definitive endoderm markers 
Upon reaching the DE stage, the media was aspirated from wells of the 6-well cell 
culture dishes and the cells were detached using the Accutase solution added at 
1mL/well for 5 minutes at 37°C. Following the incubation, 5 mL/well of 2% (v/v) FBS 
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in DPBS was added and the cell suspension was centrifuged at 1000 rpm for 3 minutes. 
The cells were then resuspended in 2% (v/v) FBS in DPBS and split into four tubes for 
antibody staining.  
The anti-c-Kit (anti-CD117) and anti-CXCR4 (anti-CD184) antibodies were added to 
the appropriate tubes and incubated at 4°C for 30 minutes. The cells were span down at 
4°C and 1000 rpm for 3 minutes, washed once in 300 µL of 2% (v/v) FBS in DPBS and 
centrifuged in the same way again. The cell pellet was resuspended in 500 µL of 2% 
(v/v) FBS in DPBS and the staining results were analysed using fluorescence-activated 
cell sorting (FACS). The details of the anti-c-Kit and anti CXCR4 antibodies are listed 
in Table 2.3. 
 

















MHCXCR404 Invitrogen Mouse 1:100 
 
 
2.4.4 Fluorescence-activated cell sorting 
The FACS analysis was performed on the BD FACSAria III instrument (Becton, 
Dickinson and Company) according to manufacturer’s instructions with the assistance 
of Dr Michael Zachariadis. The data was interpreted using the BD FACSDiva software 
(Becton, Dickinson and Company). 
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2.5 Assessment of global 5mC and 5hmC levels in genomic 
DNA 
2.5.1 DNA extraction 
The DNA was extracted from cell lines and tissues using the following protocol unless 
otherwise specified. The harvested cells or shredded tissue were incubated in 1X PCR 
buffer (10 mM Tris, 50 mM KCl, 2 mM MgCl2 and pH 8.3) diluted from a 10X stock 
solution and supplemented with Proteinase K (Sigma-Aldrich) at 65°C for 1 hour. This 
was followed by heat inactivation of the Proteinase K enzyme for 15 minutes at 95°C. 
An equal volume of Phenol:Chloroform:Isoamyl alcohol mixture (Sigma-Aldrich) was 
added to the resulting solution and the organic and aqueous phases were separated 
during a centrifugation step using Phase Lock Gels (5 Prime). The DNA present in the 
aqueous phase was next precipitated using ethanol absolute and sodium acetate by 
incubating the sample at -80°C for at least an hour. The ethanol was added at a 3:1 
volume ratio to the aqueous phase and sodium acetate at 0.1:1 ratio. The DNA was then 
spun down for 30 minutes at maximum speed in a 4°C centrifuge and the pellet was 
washed and spun down for 10 minutes at maximum speed twice in cold 70% ethanol. 
All pellets were resuspended and stored in nuclease-free water at -20°C. DNA 




2.5.2 Dual DNA and RNA extraction 
DNA and RNA were extracted simultaneously form the same sample using the ZR-Duet 
DNA/RNA MiniPrep kit (Zymo Research) according to manufacturer’s instructions. 
Both DNA and RNA were eluted from the spin column in nuclease-free water. The 
resulting DNA was stored at -20°C and RNA at -80°C. 
 
 
2.5.3 DNA degradation 
The DNA samples were digested into singe nucleotides using the DNA Degradase Plus 
enzyme (Zymo Research). Unless otherwise specified, 1 µg of DNA was incubated with 
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5 U of the enzyme for 4 hours at 37°C followed by inactivation of the Degradase 
enzyme at 70°C for 20 minutes. The samples were diluted 1:8 in LC/MS-grade water 
following the addition of equimolar internal standard mix to a final concentration of 250 
nM and analysed on the mass spectrometer. The internal standard mix consisted of the 
following isotopically labelled nucleosides: 2’-deoxycytidine (15N3) (Cambridge 
Isotope Laboratories), 5-methyl-2’-deoxycytidine-d3 (Toronto Research Chemicals) and 
5-hydroxymethyl-2’-deoxycytidine-d3 (Toronto Research Chemicals). 
 
 
2.5.4 Liquid chromatography and mass spectrometry analysis on the MaXis QTOF 
mass spectrometer 
The QTOF-UHPLC analysis was conducted using a MaXis HD quadrupole electrospray 
time-of-flight (ESI-QTOF) mass spectrometer (Bruker Daltonik GmbH), which was 
coupled to an Ultimate 3000 UHPLC (Thermo Fisher Scientific). Analyses were 
performed using ESI positive-ion mode. The capillary voltage was set to 4500 V, 
nebulizing gas at 4 bars, drying gas at 12 L/min at 220°C. The TOF scan range was 
from 50 – 600 mass-to-charge ratios (m/z). Liquid chromatography was performed 
using a Waters Acquity UPLC HSS T3, 1.8 µM, 2.1 x 50 mm reverse phase column 
(Waters) with a flow rate of 0.3 mL/min, and an injection volume of 15 µL. Mobile 
phases A and B consisted MS-grade water (Merck), and 0.1% formic acid in acetonitrile 
(Merck), respectively. Gradient elution was performed as follows; 0.0 – 2.0 min, 1.0% 
B; 2.0 - 5.0 min, 20% B; 5.0 – 6.0 min, 95% B; 6.0 – 8.0 min, 95% B; 8.0 – 8.1 min, 1% 
B; 8.1 – 10.0 min, 1% B. 
The MS instrument was calibrated using a range of sodium formate clusters introduced 
by 10 µL loop-injection prior to the chromatographic run. The mass calibrant solution 
consisted of 3 parts of 1 M NaOH to 97 parts of 50:50 water:isopropanol with 2% 
formic acid. The observed mass and isotope pattern matched the corresponding 
theoretical values as calculated from the expected elemental formula within 2 ppm mass 
accuracy. 2’-deoxycytidine, 5’-methyl-2’-deoxycytidine and 5’-hydroxymethyl-2’-
deoxycytidine were detected as [M + H]+, [M + Na]+ and [2M + H]+ ions with within 
0.01 Da. Data processing was performed using the Compass Data Analysis software 
version 4.3 (Bruker Daltonik GmbH). The work involving the MaXis HD ESI-QTOF 
mass spectrometer was performed with the assistance of Dr Shaun Reeksting from the 
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Material and Chemical Characterisation Facility at the University of Bath. 
 
 
2.5.5 Liquid chromatography and mass spectrometry analysis on the Xevo triple 
quadrupole mass spectrometer and the validation of the in-house protocol against 
a previously published external method 
The mass spectrometry analysis was conducted using a Xevo TqD triple quadrupole 
mass spectrometer (Waters), which was coupled to a Waters Acquity H-class UPLC 
(Waters). The capillary voltage was set to 2750 V and the pressure limits at between 4 
bar and 600 bar. The source temperature was set at 150°C and the desolvation 
temperature at 500°C. The source gas flow was set at 1000 L/h for desolvation and at 
100 L/h for the cone. The points-per-peak frequency was set at 30.5 with the run time 
set at 12 minutes. Argon was used as the collision gas. The instrument was tuned using 
an equimolar mixture of synthetic standards 2′-deoxycytidine (Sigma-Aldrich), 5-
methyl-2′-deoxycytidine (Cambridge Bioscience) and 5-hydroxymethyl-2′-
deoxycytidine (Cambridge Bioscience). All samples and calibration curves were spiked 
with an equimolar 250 nM mixture of isotopically labelled internal standards: 2’-
Deoxycytidine (15N3) (Cambridge Isotope Laboratories), 5-Methyl-2’-deoxycytidine-d3 
(Toronto Research Chemicals) and -(Hydroxymethyl)-2’-deoxycytidine-d3 (Toronto 
Research Chemicals). The mass spectrometer was operated in multiple reaction 
monitoring (MRM) mode with the dwell time set to 0.038 seconds for all the MRM 
transitions.  
Liquid chromatography was performed using a Waters Acquity UPLC HSS T3, 1.8 µM, 
2.1 x 50 mm reverse phase column (Waters) or using a Kinetex 1.7µM, 2.1 x 100 mm 
HILIC column (Phenomenex) with flow rates between 0.1 and 0.3 mL/min, and an 
injection volume of 20 µL. Mobile phases A and B consisted MS-grade water (Merck), 
and 0.1% formic acid in acetonitrile (Merck), respectively. Gradient elution was 
performed as follows; 0.0 - 5.0 min, 100% A; 5.0 - 7.0 min, 100% B; 7.1 - 12.0 min, 
100% A. Data processing was performed using the TargetLynx software (Waters). The 
work involving the Xevo TqD triple quadrupole mass spectrometer was performed with 
the assistance from Dr Jack Rice and Andrew Kannan, under the supervision of 
Professor Barbara Kasprzyk-Hordern from the Department of Chemistry at the 
University of Bath. 
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The limits of detection (LOD) and limits of quantification (LOQ) for both mass 
spectrometers are defined here as a lowest analyte concentration that gives a signal to 
noise ratio above 3 and 10, respectively. The results were obtained from three 
independent synthetic standard calibration curves prepared on the QTOF instrument and 
six synthetic standard calibration curves prepared on the triple quadrupole mass 
spectrometer. The LOD and LOQ values given for both mass spectrometers represent 
the lowest values experimentally obtained to date on each mass spectrometer. The 
linearity of calibration curves was determined by plotting the concentrations of the 
standards used in the dilution curves against the relative response obtained on the mass 
spectrometer. The Excel software (Microsoft) was used to calculate the R2 values of the 
lines of best fit, which denote the linearity across the range of the concentrations tested. 
The ranges of concentrations used to prepare the calibration curves were pre-determined 
experimentally based on the range of responses observed in CRC cell lines DNA 
samples. 
The intraday instrument validation was conducted by calculating the mean relative 
response obtained from three injections of the same technical triplicate of each quality 
control (QC) standard injected at three different times during the same day. The 
percentage deviation, which measures the reproducibility, between the three injections 
was calculated by dividing the standard deviation by the mean relative response value 
and converting the resulting number into percentage. 
The interday instrument validation was conducted by calculating the mean relative 
response obtained from analysis of the freshly prepared technical triplicate of each QC 
standard injected on six different days. The percentage deviation, which measures the 
reproducibility, between the six injections was calculated by dividing the standard 
deviation by the mean relative response value and converting the resulting number into 
percentage. 
The validation of the in-house protocol against a previously published external method 
was conducted through a collaboration with Dr Anna Caldwell and Dr Alison Brewer 
from King’s College London (KCL). The samples were analysed on the mass 
spectrometer by Dr Anna Caldwell as detailed in their previously published method 
(Burr et al., 2018). 
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It should be noted that in all the figures depicting mass spectrometry results in Chapter 
3, the compounds analysed are denoted as “dC” (2’-deoxycytidine), “5mdC” (5-methyl-
2’-deoxycytidine) and “5hmdC” (5-hydroxymethyl-2’-deoxycytidine). This is due to the 
mass spectrometer analysing these compounds as nucleosides, rather than nucleotides. 
To avoid confusion, however, they are referred to in the main text and subsequent 
Chapters as “cytosine”, “5mC” and “5hmC”. 
 
 
2.5.6 Dot blots 
The DNA, either 4 µg/sample or 2 µg/sample, was diluted in nuclease-free water and 
sodium hydroxide to give a 0.1 mM final NaOH concentration in a total volume of 50 
µL. These reactions were placed at 95°C for 5 minutes in order to denature the DNA. 
Following this incubation, an equal volume of cold 2 M ammonium acetate solution 
was added to each sample. For each experiment a set of short double-stranded DNA 
standards consisting entirely of cytosine,5- methylcytosine or 5-hydroxymethylcytosine 
(Zymo Research) was included. These were used to confirm the specificity of the 
antibodies utilized and the following amounts of each standards were used for every 
DNA denaturation reaction: 10 ng of the cytosine standard, 5 ng of the 5-
methylcytosine standard and 0.125 ng of the 5-hydroxymethylcytosine standard. The 
quantities used of all three DNA sequences have been determined experimentally to 
give the optimal staining strength. 
Each DNA reaction was then serially diluted to yield three separate technical replicates. 
In the case of 4 µg/sample the following amounts of DNA for each sample were spotted 
onto the membrane: 2 µg, 1 µg and 0.5 µg; while in the case of 2 µg/sample 1 µg, 0.5 
µg and 0.25 µg were added. Following that, a rectangular piece of the Amersham 
Hybond-N+ nitrocellulose membrane (GE Healthcare) was incubated for 10 minutes at 
RT on the rocker in 6X saline sodium citrate (SSC) solution. 
The pre-wet membrane was placed on top of a filter paper of the same size and inserted 
into the Minifold Dot Blot System (GE Healthcare). Samples were carefully spotted 
onto the membrane using the well system provided by the Minifold apparatus. All the 
empty wells were filled with an equal volume of 6X SCC solution to ensure that the 
subsequent vacuum suction was applied evenly throughout the membrane. Following 
 59 
the solution from all the wells passing through the membrane under the applied vacuum, 
the membrane was allowed to air dry for 15 minutes before UV fixing it at 700 mJ/cm2 
using the CL-10000 Series UV Crosslinker (Ultra-Violet Products). 
The membrane was incubated in the blocking buffer consisting of 5% (w/v) milk 
(Marvel) and 0.1% (v/v) Tween-20 (Sigma-Aldrich) dissolved in PBS for 1.5 hours at 
RT before an overnight incubation with the anti-5hmC primary antibody (Active Motif) 
diluted in blocking buffer. Following that, the membrane was washed three times in 
PBS-Tween buffer before an incubation for 1 hour at RT with an anti-rabbit secondary 
antibody (Abcam) diluted in blocking buffer. After three more washes of the membrane, 
the Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) was used 
according to manufacturer’s instructions to allow chemiluminescence-based detection of 
horseradish peroxidase signal. The signal was visualised using the Fusion SL imaging 
system (Vilber Lourmat). 
Following the visualisation, the membrane was washed three times in PBS-Tween 
buffer. It was then incubated twice in the Restore PLUS stripping buffer (Thermo Fisher 
Scientific) for 20 minutes at 37°C to remove the antibodies before being washed three 
times in PBS-Tween buffer again. The membrane was then blocked and probed with the 
antibodies again in the same way as described above; this time with an anti-5mC 
primary antibody (Merck Millipore) and an anti-mouse secondary antibody (Sigma-
Aldrich). The details of the antibodies used for all dot blot experiments are given in 
Table 2.4. 
The total DNA quantity spotted in each well was assessed by methylene blue staining. 
The membrane was stained in 0.05% (w/v) methylene blue solution prepared in 0.3 M 
sodium acetate for 1 hour at RT. The staining was visualised using ChemiDoc-It2 UV 


























Primary Mouse 1:2,000 
Anti-Mouse IgG 
(Fab specific)  
A2304 Sigma-Aldrich Secondary Goat 1:2,000 
Anti-Rabbit IgG  ab205718 Abcam Secondary Goat 1:2,000 
 
 
2.6 Assessment of transcript levels 
2.6.1 RNA extraction 
The RNA was extracted from harvested cells using the GeneJet RNA Purification Kit 
(Thermo Fisher Scientific) according to manufacturer’s instructions except for an 
additional on-column DNase I digestion step using the RNase-free DNase Set (Qiagen). 
Briefly, 350 µL of Wash Buffer 1 was added to the purification column and centrifuged 
for 1 min at 12,000 x g. The 10 µL of DNase I stock solution was added to 70 µL of 
Buffer RDD and gently mixed. This mixture was pipetted onto the membrane of the 
column and incubated for 15 minutes at RT. Lastly, 350 µL of Wash Buffer 1 was 
added to the column and centrifuged for 15 sec at 12,000 x g. 
Alternatively, RNA was extracted using the TRI reagent (Sigma-Aldrich) according to 
manufacturer’s instructions with an additional wash of the RNA pellet in 75% (v/v) 
ethanol. All RNA samples were eluted or dissolved in nuclease-free water and stored at 
-80°C. The RNA concentration and purity were assessed using a NanoPhotometer 




2.6.2 Reverse transcription 
The reverse transcription reactions were performed using the QuantiTect Reverse 
Transcription Kit (Qiagen) according to manufacturer’s instructions using 1 µg of RNA 
unless otherwise stated. For each set of RNA samples being reverse transcribed at the 
same time at least one “no reverse transcriptase” (no RT) was included where the RT 
enzyme was replaced with nuclease-free water. All reactions were diluted to a final 2.5 
ng/µL cDNA concentration in nuclease free water and stored at -20°C.  
 
 
2.6.3 Quantitative real-time polymerase chain reaction 
The qRT-PCR reactions were set up in MicroAmp Fast 96-well Reaction Plate (Applied 
Biosystems) using the Fast SYBR Green Master Mix (Applied Biosystems) according 
to manufacturer’s instructions. For each reaction, 5 ng of cDNA was used in a 10 µL 
final volume with 200 nM final primer concentration unless otherwise specified. All the 
reactions were performed on the StepOne Real-Time PCR machine (Applied 
Biosystems). All primer pairs were tested in silico for off target amplification using the 
NCBI primer design tool (National Center for Biotechnology Information). The 
excessive hairpin and primer dimer formation was assessed in silico through the 
OligoAnalyzer Tool (Integrated DNA Technologies). A “no RT” and “water-only” 
control was included for each set of samples reverse transcribed at the same time and 
each primer pair used, respectively. Unless otherwise specified, all of the results were 
analysed using the “Delta-delta Ct” method (Livak and Schmittgen, 2001). 
The assessment of TET transcript levels in a panel of CRC cell lines was performed by 
Tracey Collard (University of Bristol) using primers designed by the author. 
 
 
2.6.4 Selection of the most stably expressed reference genes - the GeNorm method 
The stability of reference genes in the SW480 and SW620 cell lines was assessed using 
the geNorm 12 gene kit (Primerdesign). The kit’s protocol was modified to include the 
qRT-PCR running conditions specified in section 2.6.3. with the exception of primer 
concentration, which was the same as in the manufacturer’s instructions. The results of 
this experiment were analysed using the qBASE+ software (Biogazelle). 
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Table 2.5 Details of human and mouse primers used in the qRT-PCR experiments 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.6 Details of all human reference gene primers from geNorm 12 gene kit 
used in the qRT-PCR experiments 
The nucleotide sequences of these primers are a property of Primerdesign and are hence 
not provided 
Target Accession number Anchor nucleotide 
18S M10098 235 
ACTB NM_001101 1194 
GAPDH NM_002046 1089 
RPL13A NM_001135 727 
UBC NM_021009 271 
B2M NM_004048 302 
YWHAZ NM_003406 2534 
CYC1 NM_001916 890 
EIF4A2 NM_001967 876 
SDHA NM_004168 1032 
TOP1 NM_003286 2362 
ATP5B NM_001686 1200 
 
 
2.6.5. Primer efficiency analysis 
To assess the qRT-PCR primer efficiency, selected primers were ran with decreasing 
amounts of the same cDNA. The cDNA was serially diluted 1:2 with the starting 
amount per well set at 10 ng and final amount per well equal to 0.625 ng. All the 
reactions were performed exactly as detailed in section 2.6.3. The Pfaffl equation was 




2.7 Absolute transcript quantification 
2.7.1 cDNA amplification 
The same primers targeting the three TET transcripts in qRT-PCR reactions were used 
in a regular PCR reaction using cDNA previously prepared from HCT116 RNA. The 
OneTaq DNA polymerase (New England Biolabs) was utilized for this amplification 
and the reactions were performed according to manufacturer’s instructions. The same 
primer concentration and the amount of cDNA per reaction as in all qRT-PCR 
experiments was used (see section 2.6.3). 
 
 
2.7.2 Agarose gel electrophoresis 
The 1.2% - 2% agarose (Sigma-Aldrich) gels were stained using the GelRed Nucleic 
Acid Gel Stain (Cambridge Bioscience). The samples were loaded using the BlueJuice 
loading buffer (Thermo Fisher Scientific). The 100 bp DNA ladder (Invitrogen) or 1 
kbp DNA ladder (New England Biolabs) were used to assess the size of the DNA 




2.7.3 PCR product clean up from agarose gels 
The agarose gels were illuminated with UV light with care being taken to minimize the 
duration of exposure. The bands containing the PCR products were cut out of the gel 
using a scalpel blade. The DNA was then extracted from the agarose gel fragments 
using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare) 
according to manufacturer’s instructions. 
 
 
2.7.4 Ligation of PCR products into a plasmid vector 
The purified PCR products were ligated into a pGEM-T Easy Vector System (Promega 
Corporation) according to manufacturer’s instructions. An overnight ligation at 4°C was 
utilized to maximise the number of transformants. 
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2.7.5 Bacterial transformation 
The plasmid vectors were transformed into in-house made supercompetent E. coli using 
the following protocol. The E.coli were thawed on ice and 1 - 2 µL of the ligation 
reaction was added to the bacteria. The mixture was incubated on ice for 12 minutes 
before heat shocking them at 42°C for 45 seconds. Following that the mixture was 
incubated for 2 minutes on ice and pre-warmed Super Optimal broth with Catabolite 
repression (SOC) media was added at a 3:1 volume ratio of SOC media to bacteria and 
plasmid mixture. The tubes were placed in a shaking incubator at 225 rpm and 37°C for 
1 hour. The liquid was then streaked on Luria-Bertani (LB) agar plates supplemented 
with 100 µg/mL carbenicillin, 50 µg/mL 5-bromo-4-chloro-3-indolyl-β-d-
galactopyranoside (X-Gal) and 100 µM isopropyl-β-D-thiogalactoside (IPTG) and 
incubated at 37°C overnight. 
 
 
2.7.6 Bacterial miniprep 
The white colonies from plates for each plasmid construct were picked using a pipette 
tip for plasmid extraction. The miniprep was performed using the Zyppy Plasmid 
Miniprep Kit (Zymo Research) according to manufacturer’s instructions. The plasmid 
DNA was eluted in nuclease-free water and stored at -20°C. 
 
 
2.7.7 Restriction digest confirmation of insert ligation 
The purified plasmid DNA was digested with the EcoRI enzyme (New England 
BioLabs) according to manufacturer’s instructions. To confirm the presence of the 
insert, the digestion reactions were run on an agarose gel as described in section 2.7.2. 
 
 
2.7.8 Preparation of standard curves using the ligated plasmid constructs 
The concentration of the purified DNA constructs was assessed by taking ten 
independent readings using a NanoPhotometer (Implen) according to manufacturer’s 
instructions. The average of the ten readings for each of the three plasmids was taken as 
the plasmid concentration. A series of six five-fold dilutions of pre-assessed 
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concentrations of each of the three constructs was ran alongside the regular qRT-PCR 
reactions, as described in section 2.6.3. The absolute levels of each of the TET 
transcripts were calculated by using the equations of the three standard dilution curves 
to convert the average Ct values obtained for each TET transcript in the three cell line 
samples to picograms of vector used in the reactions. 
 
 
2.8 Protein levels and activity analysis 
2.8.1 Protein extraction 
The harvested and pelleted cells were re-suspended in radioimmunoprecipitation assay 
(RIPA) buffer supplemented with cOmplete, EDTA-free Protease Inhibitor (PI) 
Cocktail (Roche) to a final 1X concentration. The RIPA buffer was prepared fresh 
before each experiment and consisted of 150 nM sodium chloride, 1% (v/v) IGEPAL 
CA-630 (Sigma-Aldrich), 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) sodium 
dodecyl sulphate (SDS) and 50 mM Tris pH 8.0. The extraction reactions were then 




2.8.2 Nuclear and cytoplasmic protein extraction 
The nuclear and cytoplasmic fractions of cells were isolated using the NE-PER Nuclear 
and Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific) according to 
manufacturer’s instructions. The cOmplete, EDTA-free Protease Inhibitor Cocktail 
(Roche) was added to CER I and NER reagents to a final 1X concentration immediately 
before use. The cytoplasmic and nuclear extracts were subsequently stored at -80°C. 
 
 
2.8.3 Protein quantification 
The protein concentration in the extracts was assessed using the Pierce BCA Protein 
Assay Kit (Thermo Fisher Scientific) according to manufacturer’s instructions. The 
absorbance (A562 nm) was measured using the plate reader (Turner Biosystems). The 
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protein quantification experiments were designed by the author and the experimental 
procedures were performed and analysed by Dr Jennifer Pinnell. 
 
 
2.8.4 Western blotting 
The protein samples were diluted in the RIPA + PI buffer to a final volume between 15 
and 25 µL containing 30 µg of protein in total. An equal amount of Laemmli sample 
buffer (Sigma-Aldrich) was added to the diluted samples and the resulting mixture was 
incubated at 95°C for 5 minutes. The samples were loaded into the wells of Novex 
WedgeWell 4-12% Tris-Glycine Mini Gels (Thermo Fisher Scientific) placed inside the 
XCell SureLock Mini-Cell (Invitrogen) according to manufacturer’s instructions. The 
Spectra Multicolour Broad Range Protein Ladder (Thermo Fisher Scientific) was used 
to provide a size reference for the protein bands. The gels were ran for 90 minutes at 
125 V in running buffer consisting of 0.3% (w/v) Tris base, 1.5% (w/v) glycine and 
0.1% (w/v) SDS solution. 
The transfer of proteins from the gel to the PVDF membrane (GE Healthcare) was 
carried out inside the XCell II Blot Vertical Module (Invitrogen) according to 
manufacturer’s instructions. The transfer was carried out for 90 minutes at 25 V in 
transfer buffer consisting of 0.3% (w/v) Tris base, 1.5% (w/v) glycine and 20% (v/v) 
methanol. The membrane was blocked overnight at 4°C in blocking buffer consisting of 
5% (w/v) milk (Marvel) and 0.1% (v/v) Tween-20 (Sigma-Aldrich) dissolved in PBS. 
The following day the membrane was incubated with the primary antibodies diluted in 
blocking buffer for 2 hours at RT. The membrane was then washed three times in PBS-
Tween buffer before a 1 hour incubation at RT with the secondary antibodies diluted in 
blocking buffer. The details of all antibodies used for Western blotting experiments are 
given in Table 2.7. 
After three more washes of the membrane in PBS-Tween, the Pierce ECL Western 
Blotting Substrate (Thermo Fisher Scientific) was used according to manufacturer’s 
instructions to allow chemiluminescence-based detection of horseradish peroxidase 
signal. The signal was visualised using the Fusion SL imaging system (Vilber Lourmat). 
Following the visualisation, the membrane was washed three times in PBS-Tween 
buffer. It was then incubated twice in the Restore PLUS stripping buffer (Thermo Fisher 
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Scientific) for 20 minutes at 37°C to remove the antibodies before being washed three 
times in PBS-Tween buffer again. The membrane was then blocked and probed with 
antibodies again in the same way as described above. The intensity of the bands was 
measured using the ImageJ software and the results were normalized to the β-tubulin 
signal. The Western blotting assays were designed by the author and the experiments 
were performed and analysed by Dr Jennifer Pinnell. 
 













MA5-16312 Invitrogen Primary Mouse 1:1,000 
Monoclonal 
anti-TET2 
(hT2H 21F11)  




GTX121453 GeneTex Primary Rabbit 1:1,000 
Monoclonal 
anti-β-Tubulin  
T0198 Sigma-Aldrich Primary Mouse 1:1,000 
Anti-Mouse IgG 
(Fab-specific)  
A2304 Sigma-Aldrich Secondary Goat 1:10,000 
Anti-Rabbit IgG ab205718 Abcam Secondary Goat 1:10,000 
 
 
2.8.5 TET enzymes activity assay 
The activity of the TET enzymes in cell line samples was assessed using the TET 
Hydroxylase Activity Quantification Kit (Abcam) according to manufacturer’s 
instructions. The absorbance (A450 nm and A655 nM) was measured using the plate 
reader (Turner Biosystems). The TET activity assay was designed by the author and the 
experiments were performed and analysed by Dr Jennifer Pinnell. 
 70 
2.9 Statistical analysis and figure preparation 
The statistical significance of the difference observed between two experimental groups 
was determined by two-tailed, unpaired student’s t-test unless otherwise specified. 
The statistical significance of the difference observed between three or more 
experimental groups was determined by a one-way ANOVA followed by the Tukey’s 
single-step multiple comparison unless otherwise specified. 
Unless otherwise specified, all figures were prepared using the Excel software 
(Microsoft) and all tables were made using the Word software (Microsoft). 
Figure 1.1, Figure 2.1, Figure 3.1, Figure 3.2, were prepared using the PowerPoint 
software (Microsoft). 
Figure 1.2 was modified from Servier Medical Art, licensed under a Creative Common 
Attribution 3.0 Unported License using the PowerPoint software (Microsoft). 

















Establishing an in-house mass 
spectrometry detection method 






3.1 Chapter summary 
The aim of the work described in this chapter was to develop and optimise an in-house 
mass spectrometry method for detection of global 5mC and 5hmC levels. The rationale 
behind this project was that having the ability to analyse DNA samples at University of 
Bath would be both time- and cost-effective. 
The MaXis HD ESI-QTOF and Xevo TqD triple quadrupole mass spectrometers were 
assessed for their sensitivity of 5mC and 5hmC detection. This was followed by the 
optimisation of the sample preparation process, improvement of the liquid 
chromatography performance, assessment of the inter- and intraday variability of the 
method validation against a previously published mass spectrometry protocol at an 
external institution. In summary, a robust in-house mass spectrometry-based method of 
cytosine modifications was developed with limits of detection as low as 30 attomoles of 
the analyte. 
Lastly, the results are presented in the context of the wider literature and are discussed 
in relation to the objectives set out prior to the start of the experiment series with the 














The rise of the field of epigenetics was made possible by the various methods of 
detection and quantification of DNA and histone modifications. For the cytosine 
modifications 5mC and 5hmC, these can be categorised as assessing either their global 
or locus-specific levels (comprehensively reviewed by Qing et al., 2017). Briefly, the 
latter category includes methods such as bisulfite and oxidative bisulfite conversion, 
DNA immunoprecipitation with 5mC- and 5hmC-specific antibodies and T4 
bacteriophage b-glucosyltransferase based glucosylation of 5hmC. The methods used to 
investigate the global levels of 5mC and its oxidative derivatives include, among others, 
high performance liquid chromatography, thin layer chromatography, dot blots as well 
as immunohistochemistry and immunofluorescence. The locus-specific changes in 5mC 
and 5hmC levels affect the gene and enhancer activity. The techniques used to measure 
them are hence often coupled with gene expression measurements such as RNA-seq. 
This allows one to better understand how these epigenetic alterations affect the 
expression of a particular gene or multiple loci at the same time. The measurement of 
global 5mC and 5hmC levels enables one to gain insight into whole-genome changes of 
these cytosine modifications. This is particularly useful for understanding the dynamics 
of cytosine modifications turnover and their role during biological processes such as 
vertebrate development, cellular differentiation and cancer progression. A prominent 
example of this is the finding that global 5hmC levels are reduced in numerous cancer 
types as compared to healthy tissues of the same origin and have hence been proposed 
as a potential diagnostic tool (Chen et al., 2017; Gilat et al., 2017). 
Since the discovery of the TET enzymes and confirmation of the presence of 5hmC in 
human tissues, liquid chromatography coupled to mass spectrometry (LC-MS) has 
emerged as a gold standard for quantifying the global levels of 5mC and 5hmC levels 
initially, followed by global levels of 5fC and 5caC shortly after (Münzel et al., 2010; 
Ito et al., 2011; Bachman et al., 2014; Bachman et al., 2015). This method was initially 
pioneered by Thomas Carell’s group and subsequently became widely used in the 
epigenetic field with a wide variety of sample preparation methods and LC-MS running 
conditions published to date (Bachman et al., 2014; Amouroux et al., 2016; Thienpont 
et al., 2016; Burr et al., 2018). This is due to its established superior sensitivity and the 
recent advancements allowing the use of very low quantities of DNA for the analysis 
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(Le et al., 2011; Yuan et al., 2020). The method is also more time efficient and allows 
processing of considerably more samples in one run as compared to antibody-based 
detection of 5hmC levels such as dot blots. From studying these protocols, it becomes 
clear that there are a number of steps that have to be optimised in order to create a 
procedure that is best suited for the in-house mass spectrometry instruments available at 
the University of Bath. This is particularly important because of the requirement for 
high sensitivity to reliably detect 5hmC in biological samples due to its low abundance 
in genomic DNA. These steps include the selection of the appropriate mass 
spectrometer for this type of analysis, optimisation of the DNA extraction and digestion 
steps, selection of the correct liquid chromatography column and running conditions as 
well as fine-tuning the running parameters on the mass spectrometer. 
 
 
3.2.1 Liquid chromatography 
Liquid chromatography coupled to mass spectrometry is an analytical technique 
characterised by very high sensitivity and specificity that is widely used in, amongst 
others, proteomic and metabolomic analysis experiments. It allows one to identify 
unknown compounds in a mixture and predict their structure based on the mass and 
charge of the fragment ions. While historically LC instruments relied on the force of 
gravity to achieve separation of compounds in a mixture, the development of high-
performance liquid chromatography (HPLC) led to considerably improved resolution as 
well as reduced sample processing time. HPLC relies on pumps to generate a highly 
pressurised liquid stream that passes through the HPLC column where the separation of 
a compound mixture takes place. This occurs because different molecules exhibit 
varying affinities for the solid phase that makes up the inside of the column due to 
various degrees of their polarity (Figure 3.1). 
In this particular method, reverse phase chromatographic separation of analytes has 
been utilised. It is the most commonly used chromatography type in HPLC analysis, and 
it relies on the interaction of the hydrophobic nucleosides with the hydrophobic 
moieties that make up the stationary phase of the HPLC column (Claessens, 2001). In 
that scenario, the more hydrophilic compounds will elute from the column at an earlier 
time point following the initiation of the organic mobile phase gradient. The most 
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commonly used stationary phases in reverse phase HPLC are octadecyl carbon chain 
(C18) and octyl carbon chain (C8). These long carbon molecules are attached to, most 
commonly, silica particles that form the stationary phase. The C18 chains are more 
hydrophobic that the C8 chains and hence will lead to a longer retention of less polar 
analytes. Both of these molecules mainly interact with the analytes via the hydrophobic 




Figure 3.1 A schematic representation of passage of compounds through a HPLC 
column 
The compounds passing through the HPLC column bind to the stationary phase and are 
eluted depending on their polarity and the mobile phase composition. In the case of the 
reverse phase HPLC, hydrophobic compounds (green, full circle) will be retained on the 
stationary phase longer. In normal phase HPLC, the hydrophilic molecules (red, empty 
circle) will stay bound to the stationary phase longer. 
 
Normal phase HPLC operates on opposite principle to reverse phase; namely it relies on 
stationary phase being polar which leads to longer retention of hydrophilic compounds 
on the column. In this case, the mobile phase flowing through the column in non-polar - 
examples include hexane, chloroform and 2-propanol. This is in stark contrast to reverse 
phase where the mobile phase is polar and most commonly includes a mix of water and 
either methanol or acetonitrile. Regardless of the type of chromatography used, the 
mobile phase can be applied to the column using either isocratic or gradient elution. 
Isocratic HPLC refers to a constant composition of the mobile phase throughout the run. 
On the other hand, gradient elution involves gradually changing the proportions of the 
mobile phase constituents over the run period. This allows for increased sensitivity of 
the downstream detection as well as improved separation of peaks corresponding to 
compounds with similar retention times due to structural similarities, such as cytosine 
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and its modifications. All the mass spectrometry experiments performed in this chapter 
have hence utilised gradient elution. 
An interesting case of normal phase HPLC is the hydrophilic interaction liquid 
chromatography (HILIC) method. It involves an improvement of retention on the 
column, as well as the overall response, of polar analytes while running a mobile phase 
that is normally used in reverse phase chromatography. It provides a viable alternative 
to normal and reverse phase HPLC when a mixture of polar and non-polar molecules is 
analysed. In particular, it is likely to improve the retention time and chromatographic 
peak shape of polar compounds as compared to reverse phase HPLC. 
 
 
3.2.2 Mass spectrometry 
Following the chromatographic separation on the HPLC column, the analytes are 
required to arrive at the mass spectrometer detector in a gaseous ionised state. Multiple 
ionisation methods have been described to date, including electrospray ionisation (ESI), 
atmospheric pressure chemical ionisation (APCI) and matrix-assisted laser 
desorption/ionization (MALDI) (Siuzdak, 2004). APCI involves desolvation of the 
sample droplets via a heating mechanism followed by passing next to the corona 
discharge needle and analyte-solvent collisions resulting in the ion formation. Corona 
discharge refers to an ionisation process where a fluid such as air or vaporised mixture 
of analytes is ionised in an electrical field created by a strongly charged electrode. 
MALDI on the other hand utilizes a combination of a pulsing laser beam and a 
protective matrix compound to ionise the analyte molecules without their destruction by 
the laser (Clark et al., 2013). In the experiments described in this thesis, ESI was 
exclusively used as an ionisation method and formic acid was added to the components 
of the mobile phase to aid with the process of positive ion formation. 
The initial stage of ESI involves the passage of the liquid containing the analytes 
through a fine capillary whose tip is charged with a strong electric current (Siuzdak, 
2004). This allows the formation of a droplet stream through the nebulisation process 
which is then subjected to both dry gas and heat in the desolvation unit to facilitate the 
desolvation of the droplets (Figure 3.2). The ever-decreasing size of these droplets leads 
to an increasing charge on their surface which is subjected to forces of repulsion 
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between ions of the same charge, known as the Coulomb forces. Once those forces 
reach a point where the surface tension of the droplets is lower than the repulsion 
between ions (called the Rayleigh limit), the droplets are fragmented into smaller ones, 
also releasing some of the ions (Banerjee and Mazumdar, 2012) It has also been 
suggested that the ions are expelled from the droplet via the formation of what is known 
as a Taylor cone (Wilm, 2011). Taylor cone is also thought to form at the end of the 
charged capillary and lead to the nebulisation process described above. Ionisation can 
be performed both in a positive or negative mode. This refers to formation of either 
cations or anions of the analyte molecules, respectively. All the mass spectrometry 




Figure 3.2 A graphical representation of the ESI process 
The green, full circles represent a hydrophobic compound and the red, empty circles 
represent hydrophilic molecules. 
 
Once the ions are formed by the ESI process, they are transferred into the vacuum of the 
mass spectrometer through the electrically charged sampling apertures. How the ions 
are subsequently processed and detected depends on the type of mass spectrometer 
being used. The two instruments used in this project are the MaXis HD quadrupole ESI-
QTOF and Xevo TqD triple quadrupole mass spectrometers. They represent two 
different approaches to mass spectrometry: time-of-flight and triple quadrupole analysis. 
Triple quadrupole mass spectrometry utilizes, as the name suggests, three quadrupoles 
to process the ion gas formed by the ionisation process. The quadrupoles consist of four 
metal cylinders arranged together and subjected to an electric field. This allows for the 
selection of the ions with particular mass to charge ratio at each quadrupole by varying 
the voltage applied to them. In a triple quadrupole system, the first and third 
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quadrupoles act as such “mass to charge ratio gates” for ions while the middle 
quadrupole forms a collision cell. The collision cell is filled with a neutral gas (argon in 
the case of the Xevo TqD model) which the analyte ions collide with resulting in their 
fragmentation.  
The triple quadrupole system can be used for a number of analysis types (Pitt, 2009). 
These rely on utilising either the first or the third quadrupole, or indeed both 
(summarised in Table 3.1). In a product scan mode, the first quadrupole selects for an 
ion of a certain mass that is then fragmented and all the resulting daughter ions are 
scanned based on their mass to charge ratio in the third quadrupole and are hence all 
analysed on the mass spectrometer. This allows for confirmation of a structure of an 
unknown compound based on its structural fragmentation spectrum. In an opposite 
scenario, called the precursor scan mode, all ions are scanned using the first quadrupole 
and allowed to fragment. The third quadrupole then selects only fragments of a 
particular mass. This allows for identification of all the precursor ions that produce a 
common fragment ion. In a neural ion loss scan, both the first and the third quadrupole 
are used to scan for ions with a difference in mass selected for corresponding to an 
uncharged ion being lost in a collision cell. This allows for identification of the parent 
ions that loose the same neutral ion in the fragmentation process (Hoffman et al., 2006). 
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The mode that is directly relevant to this project and used in all the experiments 
subsequently described is referred to as multiple reaction monitoring (MRM). MRM 
utilizes both the first and third quadrupoles to select for ions of a known mass to charge 
ratio. This allows one to detect only the compounds of interest thus greatly increasing 
the sensitivity. The main requirement of this method is that the exact mass of each 
precursor and daughter ion has to be known in advance or experimentally determined 
first. 
Time-of-flight mass spectrometry refers to a method of spectrometric analysis that 
utilizes the measurement of the time it takes an analyte ion to reach the detector. The 
path of the ions is of a known distance and they are accelerated by an electric field of a 
known strength. The time required for the signal to be detected hence depends on the 
mass to charge ratio of each ion. An improvement on the regular time of flight mass 
spectrometers is a QTOF instrument where a quadrupole and a collision cell are 
introduced. The MaXis HD quadrupole ESI-QTOF is an example of such instrument. In 
a similar fashion to the triple quadrupole mass spectrometer, the first quadrupole is 
followed by a collision cell (equivalent to second quadrupole in a triple quadrupole 
instrument). The difference between the instruments is that the last quadrupole in the 
triple quadrupole mass spectrometer is replaced by the time of flight sensor in the 
QTOF. As such, the QTOF is more suited to studying a larger number of compounds in 
a mixture simultaneously. An excellent example of that is a metabolomic analysis. It is 
however less suited to a more targeted analysis of a few selected low-abundance 
compounds where sensitivity is paramount. 
For the analysis of mass spectrometer data to be quantitative, a set of standards of 
known concentrations must be included in every sample. These are referred to as 
internal standards and they should be structurally closely related to the analytes of 
interest, so that they ionise and fragment in the same way. In the in-house method 
described in this chapter, a set of three such compounds was hence included in the 
analysis. These have an identical structure to the synthetic standards used, except for 
isotopically labelled moieties (see Figure 3.3 for details). A known concentration 
mixture of those was included in every calibration curve point and sample subsequently 
prepared to allow for quantitative analysis. In this way, they act in a manner similar to 





Figure 3.3 The structures of all compounds analysed on the mass spectrometer 
The synthetic standards are shown on the left-hand side while the corresponding 
internal isotopically labelled standards are displayed on the right-hand side. The 
isotopically labelled moieties are shown in red. 
 
 
3.2.3 The rationale behind the development of an in-house mass spectrometry 
method 
The reduction in global levels of 5mC and 5hmC is an established characteristic of a 
multitude of human cancers. Importantly, the lower abundance of 5hmC in cancers’ 
genome was proposed as a sensitive diagnostic biomarker for, amongst others, gastric, 
liver and colorectal tumours (Chen et al., 2013; Li et al., 2017). Mass spectrometry has 
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emerged as a gold standard for quantification of global levels of cytosine modifications 
in the DNA. It provides a superior sensitivity as compared to the methods described in 
the introduction to this chapter, many of which are only semi-quantitative. This 
analytical technique is hence crucial for this PhD project as it focuses on investigating 
the changes in global 5hmC levels in colorectal cancer and its metastasis as well as 
cellular differentiation. There are multiple advantages to setting up an in-house mass 
spectrometry method rather than sending the samples for analysis to an institution 
already performing such experiments. Firstly, by performing all the experiments in-
house, one has the complete control over the whole experimental process. The necessary 
changes and adjustments to the protocol can be made with relative ease and the 
possibility of an error being made is reduced. Additionally, it is considerably more time- 
and cost-efficient as there are no delays and costs associated with transportation of 
samples. Having the infrastructure to analyse the global levels of 5mC and 5hmC in the 
DNA in-house allows one to run samples on the same day as they are prepared and 
reduce the risk associated with transport. Given the attomole sensitivity levels of the 
mass spectrometer, one risks skewing the results considerably if the samples or 
standards are subjected to degradation because of variation in storage temperatures. 
Lastly, it allows one to gain a deeper understanding of the mass spectrometry technique 
itself. By optimising all the components of the workflow to provide the required 
sensitivity, one gains the insight into every part of the process and experience in 
experiment troubleshooting. As such, the method optimisation approach outlined in this 
chapter could be used as a guide to establishing a network of mass spectrometry 
instruments at academic institutions that would allow hospitals access to quick and 
reliable cancer diagnosis in cases where routinely used methods, such as histological 
analysis, give inconclusive results. This expertise can be used to expand the method to 
include other compounds of interest. These might include the further oxidative 
derivatives of 5mC: 5-formylcytosine and 5-carboxylcytosine as well as the DNA 
damage marker 8-oxoguanine. The latter would be of particular interest given the fact 
that 5hmC colocalizes to the sites of DNA damage and 8-oxoguanine may play a role in 





3.3 Experimental objectives  
Aim: to develop a cost-effective sensitive method of detection for global levels 5mC 
and 5hmC levels using the mass spectrometry facilities available at the University of 
Bath.  
Objectives: 
1. Determine whether the mass spectrometry facilities at the University of Bath possess 
the required sensitivity for robust detection of the low abundance 5hmC in tissues 
and cell lines 
2. Optimise parameters of the sample preparation and liquid chromatography process in 
order to maximise the sensitivity of this method 



















3.4 Results  
3.4.1 The assessment of the mass spectrometry facilities at the University of Bath 
for sensitivity and robust detection of the low abundance 5hmC in tissues and cell 
lines 
The initial parameters for testing of the method were set up following the protocol 
previously used by Adele Murrell’s group at the University of Cambridge (Bachman et 
al., 2014). These included the C18 liquid chromatography column, DNA digestion 
protocol and the mass spectrometer running parameters. The first mass spectrometer 
tested for its suitability for this type of analysis was the MaXis HD ESI-QTOF mass 
spectrometer. While in general TOF instruments are more widely used for an analysis of 
a panel of compounds simultaneously, the inclusion of the quadrupole in the MaXis 
instrument offers increased sensitivity that could potentially be sufficient for reliable 
and reproducible 5hmC levels detection. 
To assess the sensitivity of this mass spectrometer, calibration curves made up of serial 
synthetic standard dilutions were prepared (Figure 3.4 A). The calibration curves 
displayed a high degree of linearity, although the R2 values should ideally be higher 
than 0.999 (the generally accepted value denoting a high degree of linearity). 
Additionally, the high R2 values were obtained across a narrow concentration range for 
both 5mC and 5hmC. The DNA extracted from whole mouse brain (known to have high 
5hmC levels) and HCT116 colorectal cancer cell line (known to have low 5hmC levels) 
was also analysed (Figure 3.4 B). While both 5mC and 5hmC were detectable in both 
the mouse brain and HCT116 DNA, a large amount of digested DNA was required to 
do so (approximately 8 µg for the mouse brain and 30 µg for the HCT116 cell line).  
Additionally, the signal obtained for 5hmC in the HCT116 DNA was close to the 
detection limit. The same pattern was observed across a number of experiments with 
different cell line samples (data not shown). In the light of these results, it became clear 
that the MaXis HD ESI-QTOF mass spectrometer will be unlikely to provide sufficient 
sensitivity for reproducible detection of global 5hmC levels in the DNA samples 




Figure 3.4 The MaXis HD ESI-QTOF mass spectrometer is capable of detecting 
5hmC in DNA samples but lacks the required sensitivity 
(A) Calibration curves display a high degree of linearity for all three compounds across 
the following ranges: dC 12 - 6250 nM: 5mdC 78 - 1250 nM; 5hmdC 4 - 63 nM. The 
serial dilutions were prepared using a synthetic standard mix of dC, 5mdC and 5hmdC. 
The R2 values denote the degree of linearity across the concentrations analysed. The 
dotted line represents the line of the best fit. 
(B) 5mdC and 5hmdC are detectable in DNA from mouse whole brain and HCT116 cell 
line. The results are expressed as percentage of total (dC+5mdC+5hmdC) cytosines 





To allow a direct comparison between the two mass spectrometers (Table 3.2), a similar 
set of calibration curves was prepared and analysed on the Xevo TqD instrument 
(Figure 3.5). The calibration curves showed a higher degree of linearity across a larger 
range of dilutions as compared to the ones prepared on the QTOF machine - the R2 
value for all three compounds was above 0.999. When directly compared, the limits of 
detection for all three compounds were considerably lower, almost 1000-fold for all 
compounds, than those obtained on the QTOF mass spectrometer (Table 3.2). The Xevo 
TqD triple quadrupole instrument was hence selected for subsequent method 
optimisation and sample analysis. 
 
Table 3.2 The direct limits of detection comparison between the two mass 
spectrometers 
Compound QTOF mass spectrometer 
Triple quadrupole mass 
spectrometer 
dC 12.2 nM 22.5 pM 
5mdC 0.61 nM <1.4 pM 






Figure 3.5 The Xevo TqD triple quadrupole mass spectrometer has a high degree 
of linearity across a broad 5mdC and 5hmdC concentration range 
A representative example of a set of calibration curves prepared on the Xevo TqD triple 
quadrupole mass spectrometer. The linearity for the three compounds was obtained 
across the following ranges: dC 0.24 - 5940 nM (top graph); 5mdC 0.0015 - 990 nM 
(middle graph); 5hmdC 0.0015 - 792 nM (bottom graph). The calibration curves were 
prepared using a synthetic standard mix of dC, 5mdC and 5hmdC. The R2 values denote 
the degree of linearity across the concentrations analysed. The dotted line represents the 
line of the best fit. 
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3.4.2 The optimisation of mass spectrometry, sample preparation and liquid 
chromatography parameters in order to maximise the sensitivity of the in-house 
protocol 
The selection of the correct mass spectrometer for the in-house method development 
was followed by optimisation of the mass spectrometry parameters, the sample 
preparation and liquid chromatography set-up. This was done to maximise the analyte 
signal obtained and to minimise the possible effects of ion suppression. The term ion 
suppression refers to a reduction in the efficiency of the ionisation process. This can be 
caused by the presence of, for example, salts, intracellular metabolites or proteins that 
interfere with the nebulisation and droplet evaporation (Annesley, 2003). Presence of 
such contaminants can also negatively affect the lifespan of the HPLC column. It is 
therefore paramount to assess whether certain steps in the method workflow contribute 
to the suppression of the ionisation process. Additionally, given the low abundance of 
5hmC in genomic DNA, the sensitivity of the in-house method described here is critical 
as alluded to earlier. 
 
 
3.4.2.1 The optimisation of mass spectrometry parameters 
The mass spectrometry conditions were optimised through tuning the mass spectrometer 
using a high concentration solution of each individual standard (Table 3.3). The MRM 
transition values for each ion, namely the mass to charge ratio of the precursor and 
product ions obtained from the literature (Bachman et al., 2014) were experimentally 
confirmed. The retention time is provided as an average of the retention times of all 
calibration curve points shown in Figure 3.5. The structural similarity and little 
difference in retention time between 5mC and 5hmC led to an addition of a 5hmC 
“qualifier” ion to the method. The role of the qualifier ion is to provide identity 
confirmation of the analyte being detected and it plays no part in the quantification 
process, for which the “quantifier” ion is used. Additionally, the cone voltage and 
collision energy were optimised for each compound. The former refers to the voltage 
applied to the guide cones that direct the ion beam from the ESI source to the mass 
spectrometer vacuum. The latter describes the electric potential applied the second 
quadrupole of the mass spectrometer instrument that leads to fragmentation of the 
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precursor ions. The example chromatograms obtained for all compounds analysed are 
shown in Supplementary Figure 1. 
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3.4.2.2 Assessment of the potential sources of ion suppression in the sample 
preparation and liquid chromatography workflow 
The main sources of possible ion suppression in the method were identified as DNA 
extraction, DNA degradation and HPLC conditions, including the column type, mobile 
phase flow rate and analyte dimerization. The DNA extraction process involves 
numerous incubation steps with buffers and enzymes that can potentially lead to 
contamination of the DNA with various salts and proteins. Commercially available 
DNA extraction and clean up kits were briefly considered, however a trial of a selected 
few of them failed to improve either the signal-to-noise ratio or the overall signal of the 
analysed compounds as compared to the traditional phenol:chloroform:isoamyl alcohol 
(PCI) protocol followed by the ethanol and sodium acetate precipitation (data not 
shown). These kits included the Quick-DNA Miniprep Plus Kit (Zymo Research) and 
KAPA Express extract kit (Kapa Biosystems) as well as the Genomic DNA Clean & 
Concentrator (Zymo Research) and Monarch PCR & DNA Cleanup Kit (New England 
Biolabs). The latter two kits were used in an attempt to clean up the DNA following the 
regular PCI extraction protocol. The DNA extraction method selected was hence the 
traditional PCI extraction.  
It was still, however, entirely possible that the PCI method of DNA extraction 
contributed to ion suppression and hence caused an increase in the limit of detection for 
the analytes of interest. In order to test this hypothesis, 10 kDa Amicon filters (Sigma) 
used for desalting and protein removal were utilised. They were included to clean up the 
DNA samples isolated from the HCT116 colorectal cancer cell line or the breast cancer 
cell line MCF7 either post DNA extraction, post DNA digestion or both (Figure 3.6). 
Surprisingly, the signal-to-noise ratio was not significantly improved in any of the 
Amicon filter combinations in neither of the cell lines tested. This result, combined with 
the high cost of the columns, led to their exclusion from all future experiments. 
Next, the DNA degradation process was optimised. The manufacturer of the DNA 
degradase enzyme suggests 2 hours as the optimal digestion time for obtaining single 
nucleotides from DNA molecules. It is, however, possible that this might not be a 
sufficient amount of time to allow for complete DNA degradation. In order to test this, a 
24-hour DNA digestion time course was performed (Figure 3.7). The overall signal 
obtained for all three analytes was assessed with the expectation of a bell-shaped 
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response. Initially, an increased response would be observed as the digestion time was 
extended. This would be followed by a decrease in the signal due to the prolonged 
exposure of nucleotides to the high digestion temperature (37ºC). Indeed, the results 
indicate that approximately 8 hours of digestion appears to maximise the signal 
obtained on the mass spectrometer for the analytes of interest. In order to compromise 
between digestion efficiency and digestion time, however, 4 hours was chosen as the 
optimal digestion time for all future experiments. 
The last stage of the optimisation process involved the manipulation of HPLC 
parameters in order to increase the overall signal obtained on the mass spectrometer, 
reduce the signal-to-noise ratio and improve the peak shape and resolution for the 
analytes. In order to achieve that, a HPLC column utilising a different chromatography 
method was compared to the C18 column used so far - namely the HILIC column (see 
section 3.2.1 for background on this method). It is also known that chemical additives 
can improve the chromatographic peak shape and resolution. Additionally, they can 
help with dissociating analyte dimers, which have been observed for all three 
nucleosides during instrument tuning (data not shown). In order to test this, 10 mM 
ammonium acetate was added to both mobile phase buffers while using the original C18 
column. Neither the HILIC column nor the ammonium acetate managed to improve the 
peak shape or resolution and were hence not included in the future experiments (see 
Supplementary Figure 2 for comparison of chromatograms). 
The flow rate of mobile phase through a HPLC column can affect the chromatographic 
peak shape and hence the signal obtained on the mass spectrometer. If the flow rate is 
set too high or too low, it can lead to peak broadening, peak splitting or shift to an 
earlier retention time. This can lead to less analyte binding to the column and a more 
gradual elution resulting in a reduced overall signal and lower sensitivity of the method. 
In order to establish the optimal flow rate for this method, a range of flow rates were 
tested - between 150 and 300 µL/min in increments of 50 µL/min (Supplementary 
Figure 3). By assessing the chromatograms obtained from this experiment, it is clear 




Figure 3.6 DNA clean up with Amicon filters has no effect on the signal-to-noise 
ratio in cell line samples 
The following samples were analysed: NN - no Amicon filters were used; NA - Amicon 
filters were only used post DNA degradation; AN - Amicon filters were only used post 
DNA extraction; AA - Amicon filters were used both after the DNA extraction and 
DNA degradation. Three independent replicates were analysed for each sample. The 
error bars represent the standard deviation. The significance was established using a 




Figure 3.7 The highest signal for dC, 5mdC and 5hmdC is obtained after 8 hours 
of DNA digestion 
The solid line represents a direct trend between the time points and the dotted line 
displays the line of best fit. The error bars represent the standard deviation of three 
independent replicates. The x-axis lists all the time points assessed in this experiment. 
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3.4.2.3 The method and instrument validation 
The completion of this in-house mass spectrometry method optimisation was followed 
by assessment of the analyte losses during sample preparation (method validation) as 
well as the assessment of both intra-and interday variability of the mass spectrometer 
(instrument validation). The method validation experiment was carried out by 
introducing three known concentrations of synthetic standard mix into the samples 
either pre- or post-digestion to assess the analyte losses during the enzymatic reaction. 
The three concentrations are referred to as “High”, “Middle” and “Low”, as a 
commonly used system of quality control standards (QCs) in mass spectrometry to 
assess instrument performance. The exact values of these concentrations are based on 
the calibration curves prepared for each standard. These QCs are commonly used with 
each sample run to allow comparison of the signal it produces on different days and 
sample runs.  
All three compounds showed a high degree of recovery during the digestion process 
(Figure 3.8). Only 5mC showed a significantly reduced recovery for medium and low 
QCs, however none of the relative signals obtained were lower than 80% of the post-
degradation spikes. It was particularly encouraging to see no significant losses of 5hmC 
signal as it is the lowest abundance molecule of the three. This results also validates the 
previously chosen 4-hour digestion time as one that does not cause sufficient analyte 
degradation to cause issues with their detection. 
The intraday instrument validation was performed using a similar set of QCs comprised 
of pure synthetic standards. The aim of the experiment was to inject the same 
concentration of the analytes three times in one day to assess the measurement 
variability inherent to the mass spectrometer. All samples were injected on the mass 
spectrometer in a technical triplicate and at different times of the day relative to each 
other, and hence it is critical to know what inherent variation between those injections 




Figure 3.8 The three analytes show minimal losses during DNA digestion reaction 
The SW620 cell line DNA was spiked with the High, Middle and Low QCs either pre- 
or post-digestion. The QCs used were as follows: 2300 nM (High, blue bar), 35.9 nM 
(Middle, yellow bar) and 8.98 nM (Low, red bar) for cytosine; 230 nM (High, blue bar), 
3.59 nM (Middle, yellow bar) and 0.90 nM (Low, red bar) for 5mC and 5hmC. The 
results are shown as the percentage of the signal obtained for the pre-digestion spike 
samples divided by the signal produced by the post-digestion spike samples. The error 
bars represent the standard deviation of three independent replicates. The significance 
was established using a one-way ANOVA followed by the Tukey’s single-step multiple 
comparison (** p<0.01). 
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The results outlined in Table 3.4 demonstrate that there is a degree of variation in the 
reproducibility of the mass spectrometry analysis that one can expect from the 
experimental set up itself. The percentage variation (a direct measure of the 
reproducibility) is below or around 10% for most of the synthetic standard samples 
tested. The only outlier is the Low QC cytosine sample. This is not of a particular 
practical concern, however, as one would never observe a cytosine concentration this 
low in the DNA samples. Interestingly, 5mC displays a considerably lower percentage 
deviation for all its QC samples compared to the other two molecules. This is in line 
with the general observation that 5mC has the lowest detection limit, the best shape of 
the HPLC peak and the highest degree of linearity of response across multiple 
calibration curves (data not shown). 
 
Table 3.4 The summary of intraday instrument validation results 
dC 





High QC (2760 nM) 0.3930 0.0322 8.20 
Middle QC (690.0 nM) 0.0819 0.0090 11.0 
Low QC (14.38 nM) 0.0011 0.0002 21.4 
5mdC 





High QC (552 nM) 1.9708 0.0193 0.98 
Middle QC (69.0 nM) 0.2315 0.0050 2.14 
Low QC (1.43 nM) 0.0048 0.0001 1.15 
5hmdC 





High QC (92.0 nM) 0.0261 0.00152 5.84 
Middle QC (5.75 nM) 0.0016 0.00019 12.1 
Low QC (0.36 nM) 0.0003 0.00003 11.1 
 
 
The interday instrument validation was performed in a similar way to the intraday 
validation described above. The selected High, Middle and Low QC samples were 
injected on six different days to assess the reproducibility in the signal obtained on the 
mass spectrometer across independent experimental runs (Table 3.5). Prior to the 
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experiment, the hypothesis was that the variation observed will be considerably greater 
than the intraday one described above. While all the dilutions were prepared from the 
same aliquoted stock, the pipetting errors in a serial dilution series can compound to 
affect the signal obtained on the mass spectrometer on different days. In addition to that, 
the HPLC column performance can contribute to the variability. 
 
Table 3.5 The summary of interday instrument validation results 
dC 






High QC (3960 nM) 1.3003 0.5185 39.9 
Middle QC (247.5 nM) 0.1122 0.0879 78.3 
Low QC (3.867 nM) 0.0068 0.0066 97.5 
5mdC 





High QC (396 nM) 1.7083 0.5725 33.5 
Middle QC (24.8 nM) 0.1570 0.1118 71.2 
Low QC (0.39 nM) 0.0077 0.0094 122 
5hmdC 





High QC (396 nM) 0.1516 0.0535 35.3 
Middle QC (24.8 nM) 0.0112 0.0041 36.6 
Low QC (0.39 nM) 0.0005 0.0002 41.7 
 
 
As predicted, the interday variability was indeed considerably higher for all compounds 
and samples as compared to the intraday values, ranging from 3-fold to as high as 106-
fold increase in the percentage deviation values. Interestingly, the lowest variability was 
seen in the 5hmC samples, especially at the lowest concentration. This is indeed in stark 
contrast to the pattern described for the intraday variation results. In the light of these 
findings, it was decided to run all the samples that will be directly compared to each 





3.4.3 The validation of the in-house protocol against a previously published 
external method 
The last step of optimising the in-house mass spectrometry method was to compare its 
performance directly with an already established mass spectrometry method at an 
external facility. Alison Brewer’s group at King’s College London (KCL) previously 
successfully used their in-house mass spectrometry method to demonstrate the effect of 
oxygen gradient on 5hmC levels during hESC differentiation (Burr et al., 2018). The 
same method described in the paper was utilised in this case and was indeed capable of 
detecting 5mC and 5hmC in the hESC differentiation samples (Figure 3.9 A). It should 
be noted that the two mass spectrometry methods provided different absolute values for 
both 5mC and 5hmC levels in the same samples. The 5mC levels detected by the 
external method were between 8 and 9% of all cytosines compared to between 2.5 and 
4% obtained with the in-house protocol. Similarly, there was also discrepancy in 5hmC 
levels measured: between 0.015 and 0.08% of all cytosines according to the external 
mass spectrometer as compared to between 0.1 and 0.4% seen with the in-house 
method. This is likely due to different calibration curves being used to normalise the 
results obtained on the two instruments and the inclusion of internal standards in the in-
house analysis. Additionally, the results of the in-house experiment had a greater degree 
of variability in both the 5mC and 5hmC levels as shown by the larger error bars in 
Figure 3.9 B. This is likely an indication of lower intraday variability of the external 
method. 
However, the external mass spectrometer failed to detect 5hmC in any of the colorectal 
cancer cell lines including the SW480 and SW620 cell lines characterised in the 
subsequent Chapter (Supplementary Figure 4). In contrast, the in-house mass 
spectrometry method described here was capable of robustly detecting 5hmC levels in 
all the cell line samples analysed indicating a higher sensitivity of the in-house protocol 




Figure 3.9 The similar pattern of changes of 5mC and 5hmC levels in the human 
embryonic stem cell differentiation samples using the in-house and external mass 
spectrometry methods 
The 5mC and 5hmC levels measured in human embryonic stem cell differentiation 
samples by (A) the external KCL method; (B) the in-house mass spectrometry method. 
The following samples were analysed: H9 ESCs - human embryonic stem cell line (blue 
bars); DE stage - definitive endoderm stage of differentiation (yellow bars); HB stage - 
hepatoblast stage of differentiation (red bars); HLC stage - hepatocyte-like cell stage of 
differentiation (green bars). The error bars represent the standard deviation of two 










In order to study the epigenetic changes in cancer progression and cellular 
differentiation, a sensitive quantification method of these processes must be employed. 
There are numerous methods of 5mC and 5hmC levels quantification on a global DNA 
scale. Dot blots offer a simple and inexpensive method of antibody-based 5mC and 
5hmC detection (Jia et al., 2017). They are, however, only semi quantitative in nature 
and their limited sensitivity prevents them from being able to accurately show small 
changes in the levels of these nucleotides. They also require a considerable amount of 
starting DNA (usually a few micrograms) and are prone to errors due to uneven DNA 
loading or unspecific antibody binding.  
Immunofluorescence and immunohistochemistry are also antibody-based and frequently 
used to visualise changes in levels of cytosine modifications across a tissue section 
(Kim et al., 2016; Chapel et al., 2019). They are a critical tool to show changes in 5mC 
and 5hmC between tissue types or during a process such as cellular differentiation of 
adult stem cells in the mouse small intestine (Uribe-Lewis et al., 2020). These methods 
are also only semi-quantitative and affected by the non-specific binding of antibodies. 
They cannot hence be used to accurately determine the changes in global 5mC and 
5hmC levels. There are commercially available ELISA kits for 5hmC detection, such as 
the Quest 5-hmC DNA ELISA Kit (Zymo Research). They were found, however, to 
suffer from poor reproducibility and low sensitivity (Gilat et al., 2017). Lastly, thin 
layer chromatography was utilised prior to the widespread use of mass spectrometry in 
the field. While it was successfully used to detect 5mC, 5hmC and even the low 
abundance 5fC and 5caC, it is not itself quantitative and requires the use of radioactive 
isotopes (Kriaucionis and Heintz, 2009; Tahiliani et al., 2009). It is therefore clear why 
mass spectrometry became the gold standard in the field and why it was chosen as the 
preferred quantification method for this PhD project. 
When developing a mass spectrometry-based method of detection of low-abundance 
analytes, it is critical to remove all potential sources of contamination. The most 
prominent of those are compounds and molecules that interfere with the process of ion 
formation following the chromatographic separation (the phenomenon known as ion 
suppression). There are numerous possible sources of ion suppression that can 
contribute to increased limit of detection and limit of quantification values. It was hence 
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critical to address these effects in a comprehensive way as part of the in-house method 
development given the low abundance of 5hmC in the genome. The choice of the 
correct mass spectrometer type for the analysis represents the logical first step of such 
development. To date, numerous mass spectrometer types have been used to assess the 
global 5hmC levels in DNA samples. These include triple quadrupole, QTOF and an 
orbitrap triple quadrupole instruments (Bachman et al., 2014; Thienpont et al., 2016; 
Guo et al., 2017). The triple quadrupole mass spectrometer was found to be the most 
suitable for this in-house analysis method with superior sensitivity over the QTOF 
instrument. Regrettably, the University of Bath does not own an orbitrap triple 
quadrupole instrument similar to the one used by Bachman and colleagues to allow 
comparison to the other two instrument types. 
The Agilent 6490 triple quadrupole instrument has emerged as the gold standard 
instrument for detection of low-abundance cytosine modifications such as 5mC, 5fC 
and 5caC (Thienpont et al., 2016). The same instrument was also used by Petra 
Hajkova’s group at Imperial College London to detect 5hmC levels in low quantities of 
DNA extracted from a small (as little as 100) number of cells (Amouroux et al., 2016; 
Hill et al., 2018). It is nearly impossible to directly compare the performance of this 
cutting-edge mass spectrometer to the Xevo TqD instrument used in the in-house 
method without running the same set of standards and samples on both machines. 
According to both manufacturers data, the Agilent instrument appears to be roughly 
1000-fold more sensitive (Agilent, n.d.; Waters, 2019). It should be noted that different 
compounds were used for these measurements and hence this is just an approximation. 
The proprietary iFunnel Agilent technology likely contributes to the superior sensitivity 
of the instrument by providing an improved ESI and ion focusing that results in up to 
zeptomole detection limits (Agilent, n.d.).  
A direct comparison can also be made between the in-house protocol and an external 
method. Bachman and colleagues have reported that the linearity of response in their 
orbitrap-based method extends to analyte quantities below 10 amol as compared to the 
in-house method which had linearity of response limit at 30 amol for 5mC and 120 amol 
for 5hmC (Bachman et al., 2014). Petra Hajkova’s group published 5 amol as their 
limits of quantification (defined as signal to noise ratio above 10) for both 5mC and 
5hmC (Amouroux et al., 2016). This is almost 400-fold lower than the in-house limits 
of quantification which were 1.9 fmol for both 5mC and 5hmC. These lower 
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quantification limits obtained by Hajkova’s group reflect their need for superior 
sensitivity given the previously mentioned scarce amount of starting material. 
Nevertheless, it is important to recognise that low detection levels were obtained for the 
analytes in the in-house protocol while using a considerably less sensitive mass 
spectrometry instrument. 
The DNA extraction and digestion processes have been identified as another potential 
source of ion suppression. In particular, the cell lysis and DNA digestion buffers contain 
multiple salts that may reduce ionisation efficiency. Numerous methods of sample 
clean-up have been used in the literature, including filtration plates or spin columns 
(Shen and Zhang, 2012; Thienpont et al., 2016; Mulholland et al., 2018; Ambati et al., 
2019). In particular, the use of Amicon filters was previously published as a way of 
removing contaminants that could affect the ionisation process (Bachman et al., 2014). 
However, when tested, the extra filtration step failed to improve the signal-to-noise ratio 
that directly measures the level of sample contamination relative to the signal produced. 
This could potentially be due to the samples already having low level of contamination. 
Extensive ethanol precipitation, careful washes and substantial dilution of the sample 
following digestion could all be contributing to that. Similarly, various approaches to 
DNA digestion have been described previously. These ranged from a simple DNA 
degradase-based digestion to more complicated procedures involving Nuclease S1 and 
antarctic phosphatase or benzonase and alkaline phosphatase (Bachman et al., 2014; 
Amouroux et al., 2016; Thienpont et al., 2016). While the method described here relied 
on the DNA degradase enzyme, it was found that an increased digestion time improved 
the signal obtained on the mass spectrometer. Instead of the 2 hours suggested by the 
manufacturer, between 4 and 8 hours was found to give a higher signal for all three 
compounds analysed. The most likely explanation is that the longer digestion time 
provides the enzyme with an opportunity to complete the DNA digestion. This is 
despite using the Degradase enzyme in excess, as per manufacturer’s instructions. 
The method validation experiment provided an insight into the analyte losses during the 
digestion process. Prior to the analysis, it was hypothesised that the exposure of analytes 
to the digestion temperature of 37ºC and the buffer matrix of the digestion reaction 
could result in losses of said analytes. In particular, the added moieties on 5mC and 
5hmC were thought to be prone to degradation, possibly through hydrolysis. It was 
indeed found that a few of the QC-spiked samples did lose a part of the analyte signal; 
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however, the majority of the samples had no significant losses. This finding provided 
additional evidence for the method being well optimised already for maximising the 
signal obtained on the mass spectrometer. 
The investigation of intra- and interday variability offered an insight into the degree of 
reproducibility of the future experimental results. The intraday values were found to be 
relatively low - below or around 10% deviation for most QC samples. These values 
reflect the reproducibility of performance of the mass spectrometer and possible analyte 
degradation over time. Cytosine stood out as the analyte with the highest percentage 
deviation across the range of QC concentrations. This is in line with the compound 
having the broadest peaks during liquid chromatography, the highest detection limit and 
generally the lowest linearity across multiple calibration curves (data not shown). The 
high QC concentration, however, showed the lowest variability which is encouraging 
given that it is the concentration of cytosine most closely resembling the one observed 
in DNA samples. The very high reproducibility of the 5mC signal across all QCs was in 
line with its aforementioned high linearity and low detection limit in numerous 
calibration curves. Lastly, 5hmC signal showed a slightly higher degree of deviation 
from the mean. It should be noted, however, that all 5hmC QC concentrations are 
considerably lower than the equivalent QCs for the other two compounds which could 
be contributing to the variation.  
The interday variability was predicted to be considerably higher than the intraday 
counterpart prior to the experiment. This is due to a drastically increased number of 
factors that can contribute to the changes in results obtained on different days. These 
include, among others, liquid chromatography column and mass spectrometer 
performance, pipetting error during calibration curve dilutions, time taken before the 
QC preparation and running as well as inherent variation in the analyte concentration in 
the frozen master stocks from which the dilutions are prepared. Indeed, the interday 
reproducibility was found to be considerably lower than the intraday one for all analytes 
and QC concentrations assayed. In particular, the values were surprisingly high for 
5mC, with the low QC concentration showing over 100% deviation from the mean. This 
high variation, while concerning, was not deemed particularly problematic for future 
analysis as it was decided to run all samples that will be directly compared to each other 
on the same day. This de facto bypasses the issue of poor interday reproducibility. 
Additionally, for the vast majority of samples they are compared to one another in terms 
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of their 5mC and 5hmC levels rather than having the absolute levels of these molecules 
established in them independently. As such, as long as each independent replicate set of 
samples is ran on the same day, even when the three independent replicates are ran on 
different days, the interday variation will not affect the results. 
When developing a mass spectrometry method in-house, it is critical to compare its 
performance to a previously established one in order to gain a better understanding of 
its performance and limitations. In this case, the in-house method was compared to a 
previously published protocol from Dr Brewer’s group at KCL. Both methods displayed 
similar performance when assessing the 5mC and 5hmC levels in samples from a 
protocol of human embryonic stem cell differentiation to hepatocyte-like cells (see 
Chapter 6 for a detailed description of the process). This was to be expected given high 
levels of these modifications previously found in the H9 ESCs and a similar hESC 
differentiation experiment to a pancreatic lineage (Li et al., 2018; Koutsouraki et al., 
2019). The external mass spectrometer was not, however, able to detect 5hmC in a 
number of colorectal cancer cell lines. These cell lines are known to have low 5hmC 
levels, possibly due to their high proliferation rate (Li and Liu, 2011; Bachman et al., 
2014; Uribe-Lewis et al., 2015; Huang et al., 2016). In stark contrasts, however, 5hmC 
was readily detectable in the same cell line samples on the in-house triple quadrupole 
mass spectrometer. This is of particular importance given that the subsequent Chapters 
mostly describe work done in cell line models. This finding hence validated the in-
house method as one that is more sensitive than a previously published external method 
used by Dr Brewer’s group at KCL. 
There are still, however, a number of steps that could be taken to further improve the 
method described here. The first clear limitation of this protocol is the inferior detection 
compared to the previously published methods described above. As alluded to earlier, 
this might be caused by the lower sensitivity of the mass spectrometer instrument itself. 
One could, however, make further attempts at eliminating potential sources of ion 
suppression. Following the extraction process, the DNA could be vacuum- or nitrogen 
gas-dried prior to reconstitution in LC-MS grade water to remove the traces of ethanol 
prior to digestion (Guo et al., 2017; Ambati et al., 2019). Similarly, the samples could 
be filtered following DNA degradation to remove the degradase enzyme and other 
protein contaminants, thus potentially improving the chromatographic separation and 
detection sensitivity (Thienpont et al., 2016). Further testing of different C18 columns 
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of varying lengths and pore sizes could also have a beneficial effect on the peak shape 
and width of the analytes of interest. The second major limitation of the in-house mass 
spectrometry method is the poor interday reproducibility for all three analytes of 
interest. This could potentially be addressed by assessing the effect of the length of 
exposure of the synthetic standard calibration curves to room temperature on the 
stability of cytosine and its derivatives. Similarly, large stocks of the three QC standard 
mixes could be prepared and stored to be used with every run, in order to minimise the 
error introduced by the diluting process. It is likely, however, that some of the interday 
variation observed is due to the differences in performance of both liquid 
chromatography and mass spectrometry and it is highly unlikely that one would be able 
to eliminate it completely. 
The reduction of global 5hmC levels in cancer cells compared to tumour tissue makes it 
an attractive potential diagnostic biomarker (Chen et al., 2013; Li et al., 2017; Tong et 
al., 2019). Mass spectrometry, given its quantitative nature, reliability and sensitivity 
could be the tool of choice for analysis of patient samples for diagnostic purposes. 
While the major limiting factor for the implementation of this method is the cost of the 
instrument itself (Chowdhury et al., 2017), there is a possibility of collaboration 
between hospitals and academic institutions that already own suitable mass 
spectrometers. Furthermore, it was recently shown that 5hmC levels were negatively 
correlated with the metastatic potential of papillary thyroid carcinomas (Tong et al., 
2019). This hints at the possibility of tools such as the method described in this chapter 
to be used for predicting the potential of tumours to become metastatic, although 
methods relying on assessment of 5hmC status at specific, previously validated genomic 
regions are more likely to be widely adopted in the clinical practice in the future (see 
Chapter 7 for more details). It is important to note, however, that such a use of this (and 
other previously established in the literature) mass spectrometry methods would have to 
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4.1 Chapter summary 
The aim of this study was to characterise the in vitro colorectal cancer metastasis model 
comprising of the primary SW480 and metastatic SW620 cell lines isolated from the 
same patient and to assess the impact of compound-based modulation of global 5hmC 
levels on the proliferation and migration of these cells. This work was undertaken based 
on the preliminary evidence showing the possible role of the TET enzymes and 5hmC 
in colorectal cancer metastasis. 
The primary SW480 cell line was found to have elevated 5mC and 5hmC levels as well 
as TET2 expression compared to its metastatic SW620 counterpart. TET1 levels have 
the opposite expression pattern, showing an increase in the SW620 cells while TET3 
expression is unchanged between the cell lines. The TET2 and TET3 protein levels were 
found to follow the same pattern as transcript expression data while the TET1 content 
was found to be the same in the two cell lines. The SW480 cell line displays an 
increased migration rate compared to SW620 cells while the metastatic cell line shows a 
higher proliferation rate and colony formation than the primary one. 
Vitamin C treatment of the SW480 and SW620 cells resulted in the expected increase in 
5hmC levels but had no effect on the expression of the TET enzymes. No changes in 
either were found with the dimethyl 2-oxoglutarate and nickel (II) chloride treatments, 
despite the use of previously published doses. Low dose (0.1 mM) vitamin C was found 
to have no effect on cellular migration in the two cell lines. The ascorbic acid-induced 
reduction in proliferation and colony formation was rescued with the addition of 
catalase, indicating that it was caused by hydrogen peroxide-induced cytotoxicity rather 
than 5hmC-mediated effects.  
Taken together, these results provide a detailed characterisation of the SW480 and 
SW620 cell lines as well as the in-depth description of the effects of ascorbic acid 






The development of cancer is a highly complex process that involves a cascade of 
events and interactions with the surrounding environment. Aside from the genetic, 
epigenetic and metabolic intracellular changes that drive cancer progression, there is a 
wide range of external factors that contribute to tumorigenesis. These include, but are 
not limited to, interaction with the immune system and the local stroma as well as 
nutrient and oxygen availability dictated by the presence and distribution of blood 
vessels. A hallmark of the cancer cells is their ability to migrate and invade the 
surrounding tissue, leading to the process of metastasis (Hanahan and Weinberg, 2000). 
The role of epigenetics, and more specifically 5hmC, in metastasis still remains poorly 
understood (see section 1.5.4 for a detailed description). The Murrell group has 
preliminary data obtained from CRC patients suggesting a possible role of 5hmC and 
the TET enzymes in the metastatic process (Figure 4.1). Global 5hmC levels were 
reduced in the primary adenocarcinomas compared to the normal colon tissue (Figure 
4.1 A). However, the global 5hmC levels were elevated in the liver metastasis biopsies 
as compared to the primary cancer. While it is possible that the metastatic niche in the 
liver itself causes the cancer cells to increase their 5hmC content, an alternative 
interpretation of this result is that the elevation in 5hmC levels could be a driver of the 
metastatic cascade, possibly by activating genes associated with motility and invasion. 
Additionally, data from independent expression databases shows that high expression of 
TET2 and TET3 transcripts leads to a shorter time to metastasis development while high 
expression of TET1, TET2 and TET3 transcripts results in shorter survival as compared 
to low expression of these enzymes in CRC patients (Figure 4.1 B). Taken together, this 
data suggests that the investigation of the role of TET enzymes and 5hmC in CRC 




Figure 4.1 Preliminary data supporting the potential role of 5hmC and the TET 
enzymes in colorectal cancer metastasis 
(A) The 5hmC levels measured in patient samples from a normal colon, 
adenocarcinoma of the colon and liver metastases by mass spectrometry. This 
unpublished result was obtained as a follow-up to the study on the role of 5hmC in 
colorectal cancer development (Uribe-Lewis et al., 2015). 
(B) Survival curves generated using the PROGgeneV2 or SurvExpress tool and colon 
cancer expression databases (GSE28814 and GSE28722) indicate that that ‘low-
TET2/3’ patients have a better metastasis-free survival. In a different study (GSE17536) 
with a similar number of patients (n>170), the overall 3-year survival rate for patients 
with high TET1/2/3 is lower than those with low TET1/2/3 (Murrell, unpublished data). 
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4.2.1 In vitro modelling of colorectal cancer metastasis - the SW480 and SW620 cell 
lines 
When studying the processes of tumour progression and metastasis, it is desirable to 
mimic these conditions as closely as possible via the use of in vivo models. Murine 
models remain the most widely used tool for studying tumour progression, metastasis 
and promising therapeutic interventions (Khanna and Hunter, 2009; Cekanova and 
Rathore, 2014). Murine models can be further subdivided into chemically induced, 
genetically engineered or transplantation ones. While all of these have their advantages, 
work with mice requires dedicated facilities, complex ethical approvals and trained 
staff. It is also more costly and less time efficient than the in vitro experimental 
techniques (Cekanova and Rathore, 2014). 
The in vitro cancer models, initially in the form of immortalised cell lines, have been 
utilised since the early second half of the 20th century (Mirabelli et al., 2019). The 
simplest form of these models is a cell line grown in two-dimensional culture. This was 
improved by introducing a co-culture system where the selected cell line is cultured in 
the presence of stromal cells, most notably fibroblasts (Mirabelli et al., 2019). This 
allows one to account for the effects of the interactions with cells in the tumour 
microenvironment on cancer cells’ response to various treatments or physical 
conditions. 
The model chosen to investigate the effect of altering TET enzymes expression and 
modulating the 5hmC levels included two CRC cell lines: SW480 ([SW-480] ATCC 
CCL-228) and SW620 ([SW-620] ATCC CCL-227), which were obtained from the 
same patient (Leibovitz et al., 1976). The SW480 cell line was isolated from a 50 year-
old Caucasian male’s adenocarcinoma of the colon. These cells are cuboidal in shape 
and form small colonies of cells with epithelial-like morphology. Leibovitz and 
colleagues also observed that the cells have small villi projections on their surface 
(Leibovitz et al., 1976). The cells were found to be capable of forming tumours in nude 
mice with low rate of metastasis to the lung also reported (Tomita et al., 1992; De Both 
et al., 1999; Ma et al., 2008). The number of chromosomes per cell was estimated at 55 
with the cells belonging to B type (the tumour has invaded the muscle surrounding the 
lining of the colon) on Duke’s tumour classification based on the original biopsy taken 
from the patient. 
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The SW620 cell line was isolated from a lymph node metastasis from the same patient 
as the SW480 line (Leibovitz et al., 1976). It was cultured from a lymph node biopsy a 
year after the SW480 cell line was isolated from the primary tumour site. This was due 
to the cancer recurrence in the patient with a widespread metastasis throughout the 
abdomen. These were classified as Dukes type C adenocarcinoma (indicating that the 
tumour has spread to the neighbouring lymph nodes). The cells have a mostly smooth 
cell surface under the electron microscope and a spherical morphology with a number of 
elongated cells also present in the culture (Leibovitz et al., 1976). The number of 
chromosomes was estimated at 54. The SW620 cells were found to be highly 
tumorigenic in mice, forming metastases in lymph nodes and liver (Céspedes et al., 
2007; Vuletic et al., 2017; Xu et al., 2020). 
These two cell lines hence form a limited and simplistic model of CRC metastasis, 
which nonetheless could be useful for preliminary in vitro studies of the process. These 
cells also exhibit changes in the transcript levels of the three TET enzymes. This was 
revealed through an initial assessment of TET enzymes mRNA levels via qRT-PCR in a 
panel of twelve CRC cell lines (Supplementary Figure 5) performed in collaboration 
with Professor Ann Williams at the University of Bristol. The results demonstrated an 
over three-fold upregulation of TET1 mRNA levels and a three-fold downregulation of 
TET2 in the SW620 cells compared to the SW480 cell line, while the levels of TET3 
were similar in the two cell lines. Based on the origin of the two cell lines and the 
changes in TET expression described above, these were selected for further assessment 
during this PhD project. 
 
 
4.2.2 Assessment of proliferation and migration in cell lines derived from primary 
and metastatic tumours 
The SW480 and SW620 cell lines have previously been studied as in vitro models of 
metastasis, especially in terms of their proliferation and migration. Zhang and 
colleagues reported that the SW620 cell line exhibits a higher proliferation rate in vitro 
that the SW480 cells (Zhang et al., 2017). These results were in contradiction to two 
other publications whose authors found no changes in the proliferation rate between the 
two cell lines (Dai et al., 2017; Chen et al., 2019). The in vitro migration of SW480 
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cells was found to be higher than that of SW620 cells (Dai et al., 2017; Zhang et al., 
2017). This was also true when in vitro invasion of the two cell lines was compared 
(Chen et al., 2019). A study of mouse xenografts found a significantly higher growth 
rate of the SW620 tumours in vivo, supporting the above mentioned in vitro results 
obtained by Zhang and colleagues (Hewitt et al., 2000; Zhang et al., 2017). The same 
study found that while the SW480 cells display a higher migration rate in vitro, the 
SW620 cell line showed an increased invasiveness in vivo as measured by a greater 
number of metastatic lesions formed in the animal (Hewitt et al., 2000). 
 
 
4.2.3 Compound-based modulation of TET activity 
The TET enzymes belong to a group of iron (II) and α-ketoglutarate dependent 
dioxygenase enzymes. Their activity depends not only on post-translational protein 
modifications such as acetylation (Zhang et al., 2017), phosphorylation (Bauer et al., 
2015; Zhang et al., 2019), PARylation (Ciccarone et al., 2015) and O-GlcNAcylation 
(Shi et al., 2013) but also on the availability of oxygen, iron (II) and α-ketoglutarate. 
The levels of 5hmC in the DNA of a cell should therefore be modulated by compounds 
or physiological conditions that affect the abundance of either of these three factors. The 
most extensively studied to date compound that is capable of that is ascorbic acid (AA), 
also known as vitamin C. The Nobel Prize winner Linus Pauling proposed that vitamin 
C has efficacy in cancer treatment (Cameron and Pauling, 1976). However, the clinical 
trials conducted at the Mayo Clinic in the United States in late 1970s disproved these 
claims (Creagan et al., 1979). More recently, evidence emerged indicating that vitamin 
C as an adjuvant to chemotherapy has beneficial effects on the immune system and 
potential protective effect against the toxicity of the treatment (Ohno et al., 2009; 
Klimant et al., 2018; Pawlowska et al., 2019). Additionally, cancer patients are known 
to suffer from vitamin C deficiency and hence the benefits of AA supplementation may 
stem from there as well (Carr and Cook, 2018; Cimmino et al., 2018).  
Vitamin C was also shown to act as a co-factor for the TET enzymes and enhance 
generation of 5hmC (Minor et al., 2013). Since then, it has been demonstrated to 
contribute to pluripotency maintenance and cell reprogramming of iPSCs (Stadtfeld et 
al., 2012; Blaschke et al., 2013; Gao et al., 2013; Schwarz et al., 2014). It was shown to 
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inhibit cancer hallmarks, including unchecked growth and migration, in numerous 
different cancer types in vitro (Gustafson et al., 2015; Ge et al., 2018; Peng et al., 2018; 
Sant et al., 2018; Shenoy et al., 2019). Interestingly, more recently it was demonstrated 
that vitamin C acts as a reducing agent in conversion of iron (III) to iron (II) rather than 
a co-factor for the TET enzymes as was previously thought (Hore et al., 2016). This 
provided a direct mechanism of action of AA to produce an upregulation in global 
5hmC levels and highlighted the importance of iron (II) level for epigenetic regulation 
of the DNA. This role of vitamin C is particularly important given that iron (III) is the 
predominant intracellular form of this element (Hore et al., 2016). 
The TET activity also depends on the levels of intracellular metabolite α-ketoglutarate, 
also known as 2-oxoglutarate. The Krebs cycle is responsible for α-ketoglutarate 
generation through the action of IDH1 and IDH2 enzymes (Chou et al., 2016). This 
molecule therefore acts as an intermediate between intracellular metabolic state and the 
epigenetic machinery. Higher intracellular levels of 2-oxoglutarate were shown to 
elevate the 5hmC content of the DNA by promoting 5mC oxidation by the TET 
enzymes (Letouzé et al., 2013). Despite that, it has not been used in research of cancer 
epigenetics to the same extent as AA. While cell-permeable dimethyl α-ketoglutarate 
has been utilised on numerous occasions in metabolic research (Zhang et al., 2014; 
Carey et al., 2015; Bott et al., 2019), it has not been extensively researched in terms of 
its effect on the cytosine methylation dynamics in cancer. In a model of pancreatic 
ductal adenocarcinoma, α-ketoglutarate was found to be a key mediator of p53 driven 
tumour suppression (Morris et al., 2019). At least a part of that effect was attributed to 
the resulting increase in 5hmC levels. It was additionally reported that 2-oxoglutarate 
may lead to an increased TET activity via a MYC-driven mechanism in B cell 
lymphoma (Qiu et al., 2020). Intriguingly, the authors also demonstrated that this 
pathway leads to an increased nuclear accumulation of the TET proteins and suggested 
that it could be contributing to tumorigenesis by demethylation of cancer-promoting 
promoters and enhancers. The influence of this metabolite on epigenetic profiles and 
properties of cancer cells warrants further investigation. 
The activity of TET enzymes can also be inhibited by a number of compounds. 
Accumulation of metabolites such as succinate and fumarate has previously been 
demonstrated to lead to a reduction in TET activity (Xiao et al., 2012; Laukka et al., 
2016). Similarly, 2-hydroxyglutarate produced by mutated IDH1 and IDH2 enzymes is 
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a competitive inhibitor of the TET enzymes, occupying the same site as α-ketoglutarate 
(Xu et al., 2011). Dimethyloxalylglycine, a synthetic inhibitor and a structural analogue 
of 2-oxoglutarate, was previously used to assess the effects of TET inhibition in 
multiple model systems (Zhao et al., 2014; Amouroux et al., 2016; Mahé et al., 2017). 
Lastly, nickel (II) ions were described as a potent inhibitor of 5hmC formation using a 
purified catalytic domain of TET1 as a model system (Yin et al., 2017). Due to 
structural similarities, nickel (II) was able to displace iron (II) from the enzyme’s active 
site. A year later, the same group demonstrated that nickel (II) ions administered in the 
form of nickel chloride hexahydrate reduced 5hmC levels in human somatic cell line as 
well as mESC line (Yin et al., 2018). 
There are numerous methods of compound-based modulation of global 5hmC levels in 
cells’ DNA. Each of these has a number of off-target effects and affects a different part 
of the cell physiology. This chapter assesses how vitamin C, dimethyl 2-oxoglutarate 
and nickel (II) chloride alter 5hmC levels and their phenotypic effect on proliferation 















4.3 Experimental objectives  
Aim: to characterise the in vitro properties of the two colorectal cancer cell lines, 
SW480 and SW620, selected as a simplistic metastasis model and the effects of 
compound-based 5hmC levels modulation on the in vitro migration and proliferation 
rates of these cells. 
Objectives: 
1. Establish the TET expression, TET protein content and 5hmC levels in SW480 
and SW620 cell lines 
2. Establish the baseline parameters of proliferation and migration in the SW480 
and SW620 cells 
3. Assess the impact of vitamin C, dimethyl 2-oxoglutarate and nickel (II) chloride 
on TET expression and abundance of 5hmC in SW480 and SW620 cell lines 
4. Assess the impact of vitamin C on proliferation, colony formation and migration 















4.4 Results  
4.4.1 Establishment of the TET expression, TET protein content and 5hmC levels 
in SW480 and SW620 cell lines 
The SW480 and SW620 CRC cell lines were chosen for this investigation because they 
originate from the same patient at two different stages of cancer progression. Since the 
Murrell group has preliminary data showing that 5hmC levels are increased in 
metastatic liver tissue relative to the primary tumour in a subset of CRC patients (Figure 
4.1 A), the levels of TET transcription were examined by qRT-PCR (Figure 4.2). TET1 
was significantly upregulated (4.6-fold) and TET2 significantly downregulated 
(approximately 9-fold) in the metastatic SW620 cell line as compared to the primary 
CRC SW480 cell line (Figure 4.2 A). The transcript levels of TET3 were unchanged. It 
should be noted that ACTB was selected as a reference gene using the GeNORM 
technique (see section 2.6.4 for details) which allows one to select the most stably 
expressed reference genes in a given system (Vandesompele et al., 2002).  
The same pattern of expression was observed when the absolute mRNA levels (Figure 
4.2 B) of each TET enzyme were determined through the use of standard curves as 
described in section 2.7. HCT116 CRC cell line, which was previously extensively 
studied by the Murrell research group and shown to have similar TET levels as CRC 
patient samples, was also included in an analysis as a control sample (Uribe-Lewis et 
al., 2015). The pattern of TET transcripts expression in SW480 and SW620 closely 
resembled that obtained through the relative expression measurements shown in Figure 
4.2 A. TET3 had the highest expression of all the TETs in both HCT116 and SW620 cell 
lines (0.5 and 0.9 pg of vector, respectively) while TET2 was the most abundant of the 
three transcripts in the SW480 cell line (1.4 pg). TET1 was found to have the lowest 
expression of all three TETs in both HCT116 and SW480 cell lines (0.1 pg), while in 
the SW620 cell line TET1 expression was found to be higher than that of TET2 (0.3 and 
0.2 pg, respectively), the lowest abundance TET transcript in that cell line. The total 
levels of all TET transcripts were lower in the HCT116 cell line (0.8 pg) than both in 
SW480 and SW620 cells (2.5 and 1.4 pg, respectively). This likely reflects the 




Figure 4.2 TET1 and TET2 transcripts display different expression patterns in 
SW480 and SW620 cell lines 
(A) The expression of the TET transcripts in SW620 cell line relative to SW480 cell 
line. The TET mRNA levels were normalised to ACTB reference gene. The error bars 
represent the standard deviation of three independent replicates. The significance was 
established using a one-way ANOVA followed by the Tukey’s single-step multiple 
comparison (** p<0.01). 
(B) The absolute expression levels of the TET transcripts in HCT116, SW480 and 
SW620 cell lines equivalent to the picograms of plasmid used for preparation of a serial 





The levels of the three TET proteins in the SW480 and SW620 cell lines were assessed 
using the Western blotting technique. The representative image of the antibody staining 
is shown in Figure 4.3 A. The full images of the blots for each of the TETs demonstrate 
the presence of multiple non-specific bands following staining with anti-TET1 and anti-
TET3 antibodies. The amount of TET2 protein was found to be significantly (3.9-fold) 
higher in the primary SW480 cell line compared to SW620 cells (Figure 4.3 B). 
Surprisingly, no significant difference in TET1 levels was found. In agreement with the 
qRT-PCR results, the TET3 content was observed to be the same in the two cell lines. 
Following the assessment of the mRNA and protein levels of the TET enzymes in the 
CRC cell lines, the abundance of 5mC and 5hmC in their DNA was measured (Figure 
4.4) using both dot blot and mass spectrometry techniques. Dot blot analysis detected no 
discernible differences between these cell lines in terms of their 5mC and 5hmC content 
(Figure 4.4 A) whereas mass spectrometry analysis showed that the levels of 5mC were 
significantly reduced in the metastatic SW620 cell line compared to the two cell lines 
isolated from primary colorectal carcinomas - SW480 and HCT116 (Figure 4.4 B). The 
global levels of 5hmC was also significantly lower in SW620 cells compared to SW480 
cells. The SW620 cell line had 1.6% 5mC and 0.03% 5hmC (out of all cytosines) levels, 
while 5mC values were 3.7% and 3.1% and 5hmC content 0.10% and 0.11% for 
HCT116 and SW480 cells, respectively. The dot blot technique is known to be only 
semi-quantitative, whereas mass spectrometry is more sensitive and quantitative over 
five orders of magnitude for 5hmC quantification as described in section 3.4.1. The 
reduction in 5hmC levels in the metastatic cell line is contrary to what was expected 
given the increase in TET1 expression and the unpublished observation of increased 




Figure 4.3 The TET2 protein is significantly more abundant in the SW480 cell line 
compared to the SW620 cells 
(A) A representative Western blot image of the assessment of TET1, TET2, TET3 and 
ß-Tubulin protein levels in SW480 and SW620 cell lines. The bands used for TET1, 
TET2 and TET3 levles quantification are highlighted by the solid, blue rectangles. The 
ß-Tubulin band is outlined by the dotted, red rectangles. 
(B) The TET protein levels in SW480 and SW620 cell lines. The staining results were 
normalised to the ß-Tubulin content in each cell line. The error bars represent the 
standard deviation of three independent replicates. The significance was established 










Figure 4.4 The metastatic SW620 cell line has a significantly lower 5mC and 5hmC 
content than the SW480 primary colorectal cancer cell line  
(A) The dot blots showing representative 5hmC, 5mC and methylene blue stains in 
HCT116, SW480 and SW620 colorectal cancer cell lines and the graphical 
representation of the results obtained. The error bars represent the standard deviation of 
three independent replicates. 
(B) The mass spectrometry results of 5mC and 5hmC quantification in the three cell 
lines. The signal obtained for each cytosine modification is displayed as a percentage of 
signal obtained for all cytosines. The error bars represent the standard deviation of three 
independent replicates. The significance was established using a one-way ANOVA 
followed by the Tukey’s single-step multiple comparison (* p<0.05; ** p<0.01). 
 
 
4.4.2 Establishment of the baseline parameters of proliferation and migration in 
the SW480 and SW620 cell lines 
Following the assessment of TET mRNA and protein levels as well as 5mC and 5hmC 
content in the two cell lines, their in vitro characteristics and properties were 
investigated. When observed under the light microscope, the two cell lines had similar 
morphology to the one originally described by Leibovitz and colleagues (Figure 4.5 A) 
(Leibovitz et al., 1976). The SW480 cells formed large colonies of epithelial-like cells, 
polygonal in shape with a few protrusions of the cell membrane. The SW620 cells on 
the other hand formed fewer colonies, with the individual cells either spherical or 
bipolar with elongated shape. The SW620 cell line was found to have a significantly 
smaller average diameter (15 µm) than the SW480 cell line (32 µm) (Figure 4.5 B). 
Uncontrolled cell proliferation is a hallmark of cancer cells. The rate of proliferation of 
the SW480 and SW620 cell lines was assessed over 96 hours using trypan blue and 
haemocytometer-based manual counting (Figure 4.6 A). During the first 24 hours of 
proliferation, the two cell lines do not show any significant difference in their division 
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rate. However, over the next 72 hours, SW620 cells were found to proliferate 
significantly quicker, reaching over double the cell number (1,503,000 cells per mL) at 
the 96 hours end point compared to the primary line (729,000 cells per mL).  
The colony formation assay measures not only the rate of cellular proliferation, but also 
the ability of single cells in a cell population to form independent colonies. The SW620 
cell line was found to have significantly higher clonogenic growth than the SW480 cells 
(Figure 4.6 B). The number of colonies formed by the SW620 cells was 2.5-fold higher 
(250 colonies per well) as compared to the SW480 cell line (100 colonies per well). 
Interestingly, an opposite trend was observed for the colony size. The primary SW480 
cells were found to form colonies of a larger size (32 square pixels) than the metastatic 
SW620 cells (26 square pixels). This difference, albeit small, was found to be 
significant. 
Next, the migration rate of the two cell lines was investigated using the scratch assay. 
The representative images of the initial (0 hour) and endpoint (48 hours) gap for both 
cell lines are shown in Figure 4.7 A. The SW480 cell line was found to have a 
significantly higher migration rate over 48 hours than the SW620 cell line (Figure 4.7 
B), closing 36% of the gap after 48 hours compared to 16% for the SW620 cells. This 
was also true at the 24 hour time point, where the SW480 cells migrated through 23% of 




Figure 4.5 The SW620 cell line has a significantly reduced cell size compared to 
SW480 cell line 
(A) The representative images of SW480 and SW620 cell lines taken 48 hours after 
seeding at 20X magnification, showing the respective cellular morphologies. Scale bar 
= 200 µm. 
(B) The comparison of cell diameter between the SW480 and SW620 cell lines. The 
error bars represent the standard deviation of one hundred cells measured for each cell 





Figure 4.6 The SW620 cell line exhibits a higher proliferation rate and colony 
formation ability that the SW480 cell line 
(A) The cell growth of SW480 and SW620 measured at 24 hour intervals for 96 hours. 
The error bars represent the standard deviation of three independent replicates. The 
significance was established using an unpaired t-test (** p<0.01; *** p<0.001). 
(B) The representative images taken of the fixed and stained SW480 and SW620 
colonies 12 days after seeding. The bar graphs depict the average colony size and area. 
The error bars represent the standard deviation of four independent replicates. The 




Figure 4.7 The SW480 cell line has a higher migration rate than the SW620 cell 
line 
(A) The representative images of migrating SW480 and SW620 cells taken at 0 hours 
and 48 hours after the scratch was made, at 10X magnification. Scale bar = 400 µm. 
(B) The percentage reduction in gap width over 48 hours for SW480 and SW620 cell 
lines. The error bars represent the standard deviation of eight independent replicates. 





4.4.3 Assessment of the impact of vitamin C, dimethyl 2-oxoglutarate and nickel 
(II) chloride on TET expression and abundance of 5hmC in SW480 and SW620 
cell lines 
The analysis of in vitro cancer properties of SW480 and SW620 cell lines was followed 
by the investigation of how the treatment with compounds known to enhance and inhibit 
the activity of TET enzymes affects the cancer characteristics assessed in the previous 
section. In order to achieve this, SW480 and SW620 cells were treated with AA (with 
and without the addition of catalase), DMαKG and NiCl2. The doses used for the initial 




4.4.3.1 The assessment of the effect of ascorbic acid treatment on the TET and 
5hmC levels in SW480 and SW620 cell lines 
Vitamin C is known to be an essential nutrient that is required for a multitude of 
physiological processes inside the body. It can, however, also cause cellular toxicity via 
excessive hydrogen peroxide production (Uetaki et al., 2015). Catalase is known for its 
ability to scavenge the hydrogen peroxide formed by AA treatment and has been used to 
differentiate the effects of vitamin C on cancer cells due to epigenetic changes or 
hydrogen peroxide-mediated cytotoxicity. Based on previous research, a concentration 
range between 0.1 and 1 mM of AA with and without supplementation of 100 µg/mL 
catalase solution was used (Blaschke et al., 2013; Shenoy et al., 2017; Shenoy et al., 
2019). These treatments were assessed for their cytotoxicity using their morphology and 
the MTT assay (Figure 4.8). The SW480 cells were found to retain their morphology 
after 48 hours of treatment with the lowest, 0.1 mM, dose of AA (Figure 4.8 A). The 0.5 
mM treatment resulted in more spherical cells being present and a lower cell 
confluency, while the 1 mM dose resulted in all cells losing their wild type morphology 
and a drastically reduced cell number.  
The same pattern was observed for the SW620 cells, except the effect of most doses 
appeared to be more pronounced. These morphological changes were prevented from 
occurring in both cell lines by the addition of the catalase enzyme (Figure 4.8 B). This 
was true even for the highest, 1 mM AA concentration. The morphological changes 
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observed were mirrored by the MTT assay results. The 0.5 mM and 1 mM 
concentrations of AA led to large reductions in cell viability of the SW480 (82 and 97% 
reduction, respectively) and SW620 (80 and 99% reductions, respectively) cell lines 
while the 0.1 mM treatment had no apparent effect in that regard (Figure 4.8 C). The 
reduction in cell viability was rescued by the addition of catalase (Figure 4.8 D). Due to 
the fact that catalase prevented cytotoxicity at 1 mM AA concertation, the 0.5 mM of 
vitamin C with catalase was not included in the further assays. 
While it is known that vitamin C affects the activity of TET enzymes, it is unclear 
whether it affects the levels of their transcripts. The levels of TET mRNAs were 
assessed following a 48 hour AA treatment with and without the presence of catalase. In 
the SW480 cell line, TET1 and TET2 levels were elevated, albeit not significantly, in the 
AA treated SW480 cells (Figure 4.9 A). There were no such changes seen in the 
samples supplemented with catalase. TET3 levels on the other hand appeared to be 
reduced in all treated samples, although none of these changes were found to be 
significant. In the SW620 cell line, none of the TET transcripts showed significant 











Figure 4.8 The cytotoxicity of ascorbic acid treatment is rescued by addition of 
catalase 
(A) The morphology of the two cell lines after a 48 hour treatment with the indicated 
doses of ascorbic acid (AA). The images were taken at 20X magnification. Scale bar = 
200 µm. 
(B) The morphology of the two cell lines after a 48 hour treatment with the indicated 
doses of AA supplemented with the catalase enzyme. The images were taken at 20X 
magnification. Scale bar = 200 µm. 
(C) and (D) The results of the MTT assay following a 48 treatment of the two cell lines 
with the indicated doses of AA alone or AA supplemented with catalase, respectively. 
The 560 nM absorbance indicates the degree of cell viability. The error bars represent 




Figure 4.9 The levels of TET mRNAs remain largely unaffected following a 48 
hour ascorbic acid treatment of SW480 and SW620 cells with and without catalase 
supplementation 
The expression of the TET transcripts in (A) SW480 and (B) SW620 cell lines treated 
with ascorbic acid (AA) and catalase. The TET mRNA levels were normalised to ACTB 
reference gene. The error bars represent the standard deviation of three independent 
replicates. The significance was established using a one-way ANOVA followed by the 
Tukey’s single-step multiple comparison. 
 
The ability of AA to increase the global 5hmC levels has been demonstrated in 
numerous cell line types. The abundance of both 5mC and 5hmC in the SW480 and 
SW620 cell lines following incubation with either vitamin C on its own or in 
conjunction with catalase was assessed using both the dot blot staining (Figure 4.10) 
and mass spectrometry (Figure 4.11). The 48 hour incubation of both cell lines with 0.1 
and 0.5 mM of vitamin C resulted in a mild upregulation of global 5hmC levels in both 
cell lines with a greater upregulation in the SW480 cells (1.50- and 1.54-fold, 
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respectively) (Figure 4.10 A) than SW620 cells (1.03 and 1.06, respectively) (Figure 
4.10 B) compared to the untreated samples. The global levels of 5mC were unchanged 
in both cell lines. Similarly, AA treatment of the cells in the presence of catalase 
resulted in an increase in 5hmC content in both SW480 (Figure 4.10 C) and SW620 
(Figure 4.10 D). The 0.1, 0.5 and 1 mM AA supplemented with catalase treatments 
resulted in 5.1-, 4.2- and 3.6-fold upregulation of 5hmC content in SW480 cells 
compared to untreated control and 4.2-, 3.5- and 3.6-fold increase in SW620 cells. 
Intriguingly, the increase in 5hmC levels compared to untreated and catalase only 
controls was much larger than was observed for the AA on its own, despite catalase 
treatment itself not having an effect on global 5hmC content. The abundance of 5mC 
was again found to be unchanged by the AA and catalase treatments.  
Mass spectrometry measurements of cytosine modifications following AA treatment 
contradicted the results outlined above (Figure 4.11 A). The 5hmC levels were mildly 
upregulated in both cell lines following the incubation with the two selected doses, 
although this did not reach significance in either of the cell lines. In line with the dot 
blot results, the 5mC levels were unchanged in both SW480 and SW620 cells. When the 
vitamin C was combined with catalase, an increase in 5hmC levels was observed with 
the 1 mm vitamin C dose in both cell lines, however this was determined to not be 
significant. On the other hand, little change in the abundance of 5hmC was seen with 
the 0.1 mM dose in either cell line. Just as in the earlier observations, the 5mC levels 
showed little change with a small increase in the samples treated with 1 mM AA and 
catalase. The mass spectrometry results therefore indicate that AA treatment does not 





















Figure 4.10 Ascorbic acid with and without the presence of catalase causes a small 
upregulation of global 5hmC, but not 5mC, levels in SW480 and SW620 cell lines 
following a 48 hour treatment 
(A) and (B) The representative staining results of dot blot assessment of 5hmC and 5mC 
levels in SW480 and SW620 cell lines, respectively, following a 48 hour incubation 
with indicated doses of ascorbic acid (AA). The errors bars represent the standard 
deviation of three independent replicates.  
(C) and (D) The representative staining results of dot blot assessment of 5hmC and 5mC 
levels in SW480 and SW620 cell lines, respectively, following a 48 hour incubation 
with catalase only and indicated doses of AA with catalase. The errors bars represent 




Figure 4.11 Mass spectrometry assessment of the global 5mC and 5hmC levels in 
SW480 and SW620 cell lines following a 48 hour ascorbic acid treatment 
(A) and (B) The results of mass spectrometry assessment of 5hmC and 5mC levels in 
SW480 and SW620 cell lines following a 48 hour incubation with indicated doses of 
ascorbic acid (AA) or AA supplemented with catalase, respectively. The errors bars 
represent the standard deviation of six (for AA) or three (for AA with catalase) 
independent replicates. The significance was established using a one-way ANOVA 





4.4.3.2 The assessment of the effect of nickel (II) chloride and dimethyl 2-
oxoglutarate treatment on the TET and 5hmC levels in SW480 and SW620 cell 
lines 
The experiments aiming at elucidating the possible role of AA-induced increase in 
5hmC levels on the in vitro cancer characteristics of SW480 and SW620 cell lines were 
followed by similar analysis with NiCl2 and DMαKG. This would allow for direct 
comparison of results obtained with vitamin C to those with another compound known 
to increase 5hmC levels, but through a different mechanism. Should the results obtained 
be similar, this will make it more likely that they are due to the increase of 5hmC levels 
rather than any off-target effects. On the other hand, one would then expect to see the 
opposite trend following the treatment of cells with NiCl2 given its inhibitory action on 
the TET enzymes. 
The doses of the two compounds previously used in the literature were tested for their 
cytotoxicity in the SW480 and SW620 cells through the MTT assay (Figure 4.12). The 
three concentrations of DMαKG tested did not result in increased cell death in either of 
the cell lines following 48 hours of treatment (Figure 4.12 A). On the other hand, the 
highest dose (200 µM) of NiCl2 lowered the cell viability by 46% and 50% in SW480 
and SW620 cell line, respectively, compared to untreated control (Figure 4.12 B). Given 
the high acidity of DMαKG, it was speculated that one might be able to use higher 
doses of it in culture if it is supplemented with a suitable buffer. In order to test that, 
two higher concentrations of DMαKG (10 mM and 25 mM) with and without 10 mM 
HEPES supplementation were assessed for their cytotoxic properties. It was found that 
the 10 mM DMαKG dose resulted in a small degree of cell death in both the SW480 
(14%) (Figure 4.12 C) and the SW620 (22%) (Figure 4.12 D) cell lines. When the 
concentration of the compound was increased to 25 mM, the cell viability was reduced 
by 69% in the primary cell line and 93% in the metastatic counterpart. The addition of 




Figure 4.12 High doses of dimethyl alpha-ketoglutarate and nickel (II) chloride are 
cytotoxic in SW480 and SW620 cell lines 
(A) and (B) The results of the MTT assay following a 48 hour treatment of the SW480 
and SW620 cell lines with dimethyl alpha-ketoglutarate (DMαKG) or nickel (II) 
chloride (NiCl2), respectively. The 560 nM absorbance indicates the degree of cell 
viability. The error bars represent the standard deviation of three independent replicates. 
(C) and (D) The results of the MTT assay following a 48 hour treatment of the SW480 
and SW620 cell lines, respectively, with higher doses of DMαKG with and without 
HEPES supplementation. The 560 nM absorbance indicates the degree of cell viability. 
The error bars represent the standard deviation of three independent replicates. 
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The results of the MTT assay described above led to the selection of following doses of 
the two compounds for subsequent experiments: 1 mM and 5 mM of DMαKG as well 
as 50 µM and 100 µM of NiCl2. These concentrations were used to assess the effect of 
these treatments on the levels of TET transcripts (Figure 4.13). The DMαKG resulted in 
mild upregulation of TET1 and TET2 transcripts in both cell lines (Figure 4.13 A). The 
expression of TET3 remained largely unchanged with its levels mildly reduced in 
treated SW480 cells. None of the above changes were found to be significant. The 
treatment of SW480 cells with NiCl2 did not result in significant changes in TET 
expression overall (Figure 4.13 B). The only significant changes observed in SW620 
cells following the treatments were the 2.2-fold and 1.9-fold upregulations of the TET1 





Figure 4.13 The levels of TET mRNAs remain largely unaffected following a 48 
hour dimethyl alpha-ketoglutarate and nickel chloride treatments of SW480 and 
SW620 cells 
The expression of the TET transcripts in (A) dimethyl alpha-ketoglutarate (DMαKG) 
and (B) nickel (II) chloride (NiCl2) treated SW480 and SW620 cells. The TET mRNA 
levels were normalised to ACTB reference gene. The error bars represent the standard 
deviation of three independent replicates. The significance was established using a one-
way ANOVA followed by the Tukey’s single-step multiple comparison (* p<0.05). 
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The 5hmC and 5mC content of the NiCl2- and DMαKG-treated SW480 and SW620 
cells was next assessed using the dot blot technique (Figure 4.14). The SW480 cell line 
DNA showed no changes in neither 5hmC nor 5mC content following the treatment 
with either of the NiCl2 doses (Figure 4.14 A). The same pattern was observed with the 
SW620 cell line DNA, albeit a mild reduction of both 5mC and 5hmC levels can be 
seen in the 50 µM NiCl2-treated sample (Figure 4.14 B). The SW480 cells treated with 
the selected doses of DMαKG showed no changes in global 5mC levels while the 
abundance of 5hmC was mildly lowered by the 1mM (9%) and 5mM (14%) treatments 
compared to the untreated control (Figure 4.14 C). Following the same treatment, the 
SW620 cells’ DNA showed no changes in global 5mC and 5hmC levels (Figure 4.14 
D). 
These results were subsequently confirmed using the in-house mass spectrometry 
technique (Figure 4.15). The NiCl2 treatment resulted in no changes in 5mC and 5hmC 
levels in either cell line (Figure 4.15 A). This is in stark contrast to the expected result 
given that NiCl2 is known to inhibit the TET enzymes’ function. There were no 
significant changes in 5mC and 5hmC levels following the DMαKG treatment in neither 
of the two cell lines (Figure 4.15 B).  
In order to test whether a higher dose of DMαKG might be required to produce an 
increase in 5hmC levels in the two CRC cell lines, the cells were incubated with 10 mM 
dimethyl alpha ketoglutarate with and without the presence of 10 mM HEPES solution. 
HEPES was used in an attempt to buffer the highly acidic DMαKG. Following a 48 
hour incubation period, the DNA from both cell lines was assessed for 5mC and 5hmC 
content using the dot blot technique (Figure 4.16). It was found that the increased dose 
of DMαKG did not result in the expected increase in 5hmC levels in neither the SW480 
(Figure 4.16 A) nor SW620 (Figure 4.16 B) cell line. The abundance of 5mC also 
remained unchanged. 
In light of the lack of expected changes in 5hmC levels despite assessing multiple 










Figure 4.14 Nickel (II) chloride and dimethyl alpha-ketoglutarate treatments do 
not change global 5hmC and 5mC levels in SW480 and SW620 cell lines following 
a 48 hour treatment 
(A) and (B) The representative images of 5hmC and 5mC staining in SW480 and 
SW620 cell line DNA samples, respectively, following a 48 hour incubation with 
indicated doses of nickel (II) chloride (NiCl2). The errors bars represent the standard 
deviation of three independent replicates. 
(C) and (D) The representative images of 5hmC and 5mC staining in SW480 and 
SW620 cell line DNA samples, respectively, following a 48 hour incubation with 
indicated doses of dimethyl alpha-ketoglutarate (DMαKG). The errors bars represent the 




Figure 4.15 Nickel (II) chloride and dimethyl alpha-ketoglutarate treatments do 
not change the global 5hmC and 5mC levels in SW480 and SW620 cell lines 
following a 48 hour treatment 
(A) The results of mass spectrometry assessment of 5hmC and 5mC levels in SW480 
and SW620 cell lines following a 48 hour incubation with indicated doses of nickel (II) 
chloride (NiCl2). The errors bars represent the standard deviation of three independent 
replicates. The significance was established using a one-way ANOVA followed by the 
Tukey’s single-step multiple comparison. 
(B) The results of mass spectrometry assessment of 5hmC and 5mC levels in SW480 
and SW620 cell lines following a 48 hour incubation with indicated doses of dimethyl 
alpha-ketoglutarate (DMαKG). The errors bars represent the standard deviation of three 
independent replicates. The significance was established using a one-way ANOVA 






Figure 4.16 A high dose of dimethyl alpha-ketoglutarate treatment does not change 
global 5hmC and 5mC levels in SW480 and SW620 cell lines following a 48 hour 
treatment 
(A) The representative images of 5hmC and 5mC staining of SW480 cell line DNA 
samples, following a 48 hour incubation with indicated dose of dimethyl alpha-
ketoglutarate (DMαKG) with and without HEPES supplementation. The errors bars 
represent the standard deviation of three independent replicates. 
(B) The representative images of 5hmC and 5mC staining of SW620 cell line DNA 
samples, following a 48 hour incubation with indicated dose of DMαKG with and 
without HEPES supplementation. The errors bars represent the standard deviation of 
three independent replicates. 
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4.4.4 Assessment of the impact of vitamin C on proliferation and migration rates of 
SW480 and SW620 cell lines 
The potential anti-tumour effects of AA warrant further investigation into the stages of 
tumour progression it affects and the mechanisms by which this is achieved. In 
particular, it is critical to determine whether the effects are due to the cytotoxic 
properties of AA or its role in regulating the epigenome. When the effects of vitamin C 
on cell proliferation were assessed, the 0.1 mM dose was found to reduce the cell 
number of both SW480 and SW620 cell lines, but to non-significant levels (Figure 4.17 
A). This AA concentration was chosen as it was found earlier to be non-toxic to the 
cells through the MTT assay while the higher doses greatly reduced cell viability. The 
introduction of the catalase enzyme allowed the use of a higher vitamin C concentration 
without the associated cytotoxic effect. The presence of catalase prevented any 
significant reduction in cell proliferation in the SW480 cell line, even at the 1 mM AA 
concentration (Figure 4.17 B). This suggests that the large reduction in cell viability 
observed through the MTT assay was a result of cytotoxicity due to the excessive 
hydrogen peroxide generation rather than epigenetic changes, given that addition of 
catalase rescued this effect. In the case of SW620 cell line, the presence of catalase did 
not prevent the 1 mM AA dose from significantly reducing the number of cells present 
in the cell culture dish well after 96 hours by 46% compared to the catalase-only 
control. This effect was not highly significant, however, and is in line with the general 
observation that the SW620 cell line appears to be more sensitive to the cytotoxic 
effects of vitamin C treatment. 
In order to confirm these results, as well as assess the effect of AA treatment on the 
ability of individual cells to form independent colonies, the CFA assay was utilised and 
both cell lines were treated with AA with and without catalase (Figure 4.18). The 
colony number was significantly reduced in the SW480 cells from 71 to 14 colonies per 
well (Figure 4.18 A), but not the SW620 cell line (Figure 4.18 B), following treatment 
with 0.1 mM of AA. Conversely, the colony area was significantly reduced in the 
SW620 cells (by 24%), but not the SW480 cell line, compared to the untreated control. 
The addition of catalase rescued the reduction in the number of colonies even with the 
higher AA dose for both the SW480 (Figure 4.18 C) and SW620 (Figure 4.18 D) cell 
lines. No significant changes in colony number were observed for the SW480 cells, 
while the colony size did in fact increase as with both doses studied compared to both 
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the control and catalase only treated samples (Figure 4.18 E). The treatment with 0.1 
mm dose supplemented with catalase resulted in 1.13- and 1.33-fold increase in colony 
area compared with untreated and catalase-only controls, respectively. The higher, 1 
mM, concentration of vitamin C increased the colony area 1.13- and 1.32-fold relative 
to untreated and catalase-only controls, respectively. The treatment of SW620 cells with 
AA and catalase resulted in no significant change in neither the colony size nor area 
(Figure 4.18 F). This provides further evidence for the AA’s effect on cell proliferation 
being due to hydrogen peroxide mediated cytotoxicity rather than its effect on 
epigenetics in SW480 and SW620 cell lines. 
Next, the effects of AA treatment on cell migration were assessed in the two cell lines 
(Figure 4.19). The 0.1 mM dose of AA resulted in a mild reduction in the scratch 
diameter over the 48 hours both in terms of percentage and absolute width in SW480 
cells (Figure 4.19 A). These changes were not significant. The SW620 cell line 
displayed an increase in the migration rate following vitamin C treatment (Figure 4.19 
B). These changes also did not reach significance.  
The migration rate was also unchanged by the catalase and AA treatment in both 
SW480 (Figure 4.19 C) and SW620 (Figure 4.19 D) cell lines. In SW480 cells, both 
doses of vitamin C with catalase led to a modest increase in migration rate both in terms 
of the absolute and percentage gap closure between the leading edge of migrating cells 
(Figure 4.18 E). This was also the case for the migrating SW620 cells (Figure 4.18 F), 
but none of these changes were found to be significant. In light of these results, it 
should be concluded that the epigenetic changes induced by AA treatment in the two 
CRC cell lines do not significantly affect proliferation, colony formation or cell 




Figure 4.17 Low dose of ascorbic acid does not reduce the proliferation rate of 
SW480 and SW620 cells 
(A) The cell counts of SW480 and SW620 treated with 0.1 mM ascorbic acid (AA) 
measured at 24 hour intervals for 96 hours. The error bars represent the standard 
deviation of six independent replicates. The significance was established using an 
unpaired t-test. 
(B) The cell counts of SW480 and SW620 treated with the indicated AA doses and 
catalase, measured at 24 hour intervals for 96 hours. The error bars represent the 
standard deviation of five independent replicates. The significance was established 









Figure 4.18 The addition of catalase rescues the ascorbic acid-induced reduction in 
colony formation ability of SW480 and SW620 cells 
(A) and (B) The representative images and graphical representation of colony formation 
of SW480 and SW620 cells, respectively, following treatment with 0.1 mM of ascorbic 
acid (AA). The error bars represent the standard deviation of three independent 
replicates. The significance was established using an unpaired t-test (* p<0.05; ** 
p<0.01). 
(C) and (D) The representative images of SW480 and SW620 cell lines’, respectively, 
colony formation following treatment with AA and catalase. 
(E) and (F) The impact of AA and catalase treatment on the colony formation ability of 
SW480 and SW620 cells, respectively. The error bars represent the standard deviation 
of three independent replicates. The significance was established using a one-way 
ANOVA followed by the Tukey’s single-step multiple comparison (* p<0.05; ** 













Figure 4.19 The migration of SW480 and SW620 cells in not affected by ascorbic 
acid treatment 
(A) and (B) The representative images and results of SW480 and SW620 cell line 
migration, respectively, following treatment with 0.1 mM of ascorbic acid (AA). The 
images were taken at 0 hours and 48 hours after the scratch was made, at 10X 
magnification. Scale bar = 400 µm. The error bars represent the standard deviation of 
ten and nine independent replicates, respectively. The significance was established 
using an unpaired t-test. 
(C) and (D) The representative images of SW480 and SW620 cell line migration, 
respectively, following treatment with catalase and indicated doses of AA. The images 
were taken at 0 hours and 48 hours after the scratch was made, at 10X magnification. 
Scale bar = 400 µm. 
(E) and (F) The graphical representation of SW480 and SW620 cell line migration, 
respectively, following treatment with catalase and indicated doses of AA. The error 
bars represent the standard deviation of four independent replicates. The significance 











This chapter describes the work performed with the aim of characterising the in vitro 
properties of the two CRC cell lines, SW480 and SW620, and the effects of compound-
based 5hmC levels modulation on the in vitro characteristics of these cells. The results 
described here therefore contribute to answering the main question of this thesis: 
whether the TET enzymes and 5hmC contribute to the process of CRC metastasis. It 
provides a detailed characterisation of the two-cell line model used during this PhD 
project to study the metastatic characteristics in vitro from the epigenetic standpoint. 
Following that, the effects of vitamin C-based 5hmC levels modulation on these in vitro 
properties were also investigated. 
The first two objectives of this chapter involved a comprehensive characterisation of the 
SW480 and SW620 cells lines both in terms of their TET expression and 5hmC levels as 
well as their in vitro proliferation, colony formation and migration. TET1 expression 
was shown to be elevated in the metastatic SW620 cells while the opposite trend was 
observed for TET2 levels, which were significantly higher in the primary SW480 cells. 
No changes were seen in TET3 expression. These changes were also confirmed by 
assessing the absolute expression of each TET gene in the two cell lines. TET2 and 
TET3 protein levels were found to closely follow the transcript expression analysis 
results: TET2 was found to be significantly elevated in the primary cell line while TET3 
remained unchanged. TET1 levels on the other hand were found to be the same in the 
two cell lines, which is in stark contrast to the qRT-PCR data. This discrepancy could 
be explained by poor specificity of the anti-TET1 antibody used given the numerous 
non-specific bands present in the blots as shown in Figure 4.3. Additionally, the TET1 
protein could be differently regulated by post-translational modifications in the two cell 
lines which would result in the same protein levels despite differences in TET1 
transcript content. 
The upregulation of TET1 in SW620 cells as compared to the SW480 cell line was also 
observed by two independent groups (Kai et al., 2016; Tian et al., 2017). On the other 
hand, Huang and colleagues reported little change in TET1 levels between the two cell 
lines, although they observed the same expression pattern for TET2 and TET3 as 
reported here (Huang et al., 2016). Wu and co-authors reported a higher expression of 
all three TET transcripts in the metastatic SW620 cells, with the most pronounced 
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difference observed in the TET3 levels (Wu et al., 2016). These discrepancies are likely 
due to different reference genes used and differences in the primer efficiencies and 
exons targeted by the TET primers. The geNORM technique was utilised in this project 
to find the most stable reference gene in the SW480 and SW620 cell lines, which was 
found to be ACTB. This further strengthens the results described in this chapter. 
Huang and colleagues reported undetectable TET1 protein levels in the SW620 cell line 
(Huang et al., 2016). Another publication found all three TET enzymes to be present at 
similar levels in the two CRC cell lines with TET1 slightly more abundant in SW620 
cells and TET3 more prevalent in SW480 cells (Wu et al., 2016). The two articles and 
the work presented in this chapter used different antibodies to detect the levels of the 
three TET proteins which could explain the differences in results observed (Huang et 
al., 2016; Wu et al., 2016). The direct comparison of the 5hmC levels could not be 
found in the literature. It is likely that the higher global abundance of this cytosine 
modification in SW480 cells is due to the higher overall levels of TET transcripts as 
determined by the absolute quantification qRT-PCR. 
The cell proliferation rate was higher in the metastatic SW620 cell line as compared to 
its primary counterpart, the SW480 cell line. The same result was previously published 
in the literature and could reflect the fact that the SW620 cells had to increase their 
proliferation rate in order to establish the secondary niche in the lymph node of the 
patient (Schønberg et al., 2006; Lei et al., 2011) . On the other hand, the proliferation of 
the SW480 cells might have been limited in the primary tumour by its size and the 
blood supply. The opposite pattern was seen for migration, where the primary SW480 
cell line had a significantly higher migration rate than the SW620 cells. This result is 
also in line with the previously published work (Kubens and Zänker, 1998; Lei et al., 
2011; Slater et al., 2018) and could indicate that the SW480 cells isolated from the 
primary tumour are progressing in the carcinogenesis process toward a metastatic 
phenotype. On the other hand, the SW620 cells having already metastasised in vivo are 
more likely to prioritise growth and survival over migration. 
It is important to note that the SW480 and SW620 represent a limited and very 
simplistic model of colorectal cancer metastasis. The two cell lines have been in culture 
for over four decades and likely lost numerous properties and characteristics they had 
before they were taken from the patient. The SW620 cell line was obtained from a 
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biopsy taken from a lymph node metastasis and thus does not represent a good tool for 
studying colorectal cancer metastasis to the liver, which is the main focus of this PhD 
project. Lastly, the two cell lines represent a two distinct time points in the 
tumorigenesis and metastatic cascade and cannot hence be used to investigate which 
steps of these processes could be influenced by the TET enzymes and pathological 
alterations in global 5hmC levels. Nevertheless, SW480 and SW620 cell lines form an 
easy to use, cheap and time-efficient in vitro model that can be used for an initial 
assessment of the likely roles of the TETs in CRC progression. The results obtained 
from this investigation, however, should be interpreted with the abovementioned 
limitations in mind. 
The second set of objectives for this part of the PhD project was to assess the impact of 
treatment with compounds modifying 5hmC levels on the in vitro proliferation, colony 
formation and migration of SW480 and SW620 cell lines. The best known and studied 
of the molecules chosen is AA. The potential anti-cancer properties of vitamin C have 
been studied for over half a century. Despite the initial scepticism, the evidence for its 
efficacy in cancer treatment has been accumulating, particularly as an adjuvant to 
chemotherapy. The in vitro and in vivo tumour growth suppression caused by AA has 
largely been attributed to generation of hydrogen peroxide and reactive oxygen species 
(Park et al., 2004; Chen et al., 2008). This observation is supported by the rescue of cell 
viability observed for both SW480 and SW620 cells when the physiological AA 
concentration (1 mM) (Lykkesfeldt and Tveden-Nyborg, 2019) was supplemented with 
catalase. Additionally, catalase was capable of preventing the reduction in proliferation 
observed for all doses of AA administered to the two cell lines. This further reinforced 
the hypothesis that the reduction in proliferative capacity of SW480 and SW620 cells 
following AA treatment was due to cytotoxicity associated with excessive hydrogen 
peroxide production rather than its effects on the activity of TET enzymes. 
The low dose (0.1 mM) of AA was not found to affect the migration of the SW480 and 
SW620 cell lines. Similarly, no changes were observed in the migration of either cell 
line when the 1 mM vitamin C and catalase were added to cell culture medium. It is 
tempting to speculate that the 1 mM dose of AA used on its own would have resulted in 
a significant reduction in migration of the two cell lines. Indeed, high doses of AA were 
found to reduce cell migration both in vitro and in vivo in different cancer types 
(Polireddy et al., 2017; Gan et al., 2019). However, high doses of AA on its own were 
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not tested in this project as they were found to result in death of the majority of cells in 
culture. Additionally, the focus of this study was on the epigenetic changes, and more 
specifically the increase in global 5hmC levels, induced by vitamin C rather than its 
cytotoxic effects in cancer cells. 
The AA treatment, with and without catalase, resulted in no changes in the expression 
of the TET enzymes, which is in line with the evidence that vitamin C affects TET 
enzyme activity rather than the expression of the genes. Indeed, the same dose of AA as 
the one used in this study (1 mM) was recently shown to have no effect on the 
expression of the TET enzymes in the CRC HCT116 cell line (Gerecke et al., 2020). 
Perhaps the most unexpected result obtained during this study was a small, non-
significant upregulation of global 5hmC levels following the AA treatment. The vitamin 
C on its own led to a modest increase in 5hmC levels while the global 5mC abundance 
was unchanged despite studies suggesting that AA treatment of cancer cell lines reduces 
their 5mC content (Cimmino et al., 2018; Ge et al., 2018). This could reflect the 
comparatively modest increase in 5hmC levels observed in this study. Similarly, the 
higher doses of AA supplemented with catalase led to a modest, non-significant 
increase in 5hmC levels as measured by mass spectrometry. This is in contrast to results 
of multiple previously published studies where similar doses of vitamin C resulted in a 
few-fold elevation of global 5hmC content in numerous cancer cell line types (Ge et al., 
2018; Peng et al., 2018; Gerecke et al., 2020). This discrepancy could be explained by 
different methodologies used to measure the 5hmC levels. Out of the studies referenced 
above, only Gerecke and colleagues utilised the gold standard measurement of 5hmC 
levels which is liquid chromatography coupled to mass spectrometry. The other two 
studies only used the dot blot staining, which is semi quantitative and prone to 
measurement error due to unequal DNA loading and potential for antibody cross-
reactivity. The potential for discrepancy between the two methods is best illustrated by 
the results shown in Figures 4.10 C and D and Figure 11 B. While the dot blots results 
indicated a between 3.5- and 5.1-fold upregulation of 5hmC levels in the AA and 
catalase treated samples, the mass spectrometry data showed a more modest, 
approximately 1.5 to 1.8-fold increase in global 5hmC abundance which was not found 
to be significant. When such contradictions arise, the mass spectrometry results should 
be accepted as more accurate given the superior sensitivity and fully quantitative nature 
of this technique. Additionally, the different formulations of AA used by the different 
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research groups and in this project may exhibit varying stability in the cell culture 
media and thus lead to different outcomes in terms of increasing the activity of the TET 
enzymes (Ge et al., 2018; Peng et al., 2018). Lastly, the high proliferation rate of the 
SW480 and SW620 cell lines may limit the potential for an increase in 5hmC levels 
following AA treatment due to insufficient time available within the cell cycle to re-
establish the new patterns of 5hmC distribution caused by vitamin C. 
An intriguing concept was recently proposed by Cho and colleagues regarding a 
differential effect of low and high AA doses on CRC cells (Cho et al., 2018). The low 
doses, such as those achieved with oral administration, were proposed to generate 
insufficient hydrogen peroxide and reactive oxygen species to kill cancer cells and 
hence to induce a hormetic response which leads to an increased tumour growth. On the 
other hand, high doses, such as the ones obtained with intravenous infusions, were 
proposed to create sufficient oxidative damage to kill cancer cells. The authors were 
indeed able to show the hormetic response taking place in CRC cell lines expressing 
low levels of the SVCT-2 vitamin C transporter. This theory could provide an 
explanation for the different results obtained by Linus Pauling and collaborators who 
administered a high IV dose to the patients and the studies subsequently released by the 
Mayo clinic which relied on oral route of administration and consequently achieved a 
lower concentration in the study subjects. 
In addition to the findings described above, previously published research does support 
5hmC and TET enzymes-dependent effects of AA treatment of cancer cells. Indeed, it 
was found to reduce cell proliferation and tumour invasiveness in lymphoma and 
melanoma cell lines, respectively, in a hydrogen peroxide-independent manner while 
raising the global 5hmC levels (Gustafson et al., 2015; Shenoy et al., 2017). This 
mechanism may help to explain the anti-metastatic effects observed in the PANC-1 
pancreatic cell line in vitro as well as the 4T1 breast and B16FO melanoma cell lines in 
vivo (Cha et al., 2013; Polireddy et al., 2017). In summary, both the cytotoxic effects of 
vitamin C as well as its effects on cancer cells through epigenetic pathways clearly 
warrant further investigation based on the data outlined above. Given that AA is an 
essential nutrient in humans and many cancer patients suffer from vitamin C deficiency 
(scurvy) (Fain et al., 1998; Klimant et al., 2018) combined with the established safety of 
the high intravenous doses in patients and the cytotoxic effects that appear to be specific 
to cancer cells, the use of AA is an exciting prospect in cancer therapy once again. 
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The incubation of SW480 and SW620 cells with NiCl2 and DMαKG resulted in little 
changes in transcript levels of the three TET enzymes, with TET1 elevated slightly 
under most of the treatment conditions. While the literature on the subject is scarce, this 
result was expected given that these compounds are proposed to only modulate the TET 
activity rather than expression of these enzymes (Yang et al., 2016). In particular, no 
data is available on the effect on NiCl2 treatment on the expression of TET1, TET2 and 
TET3 genes in culture and hence this represents a novel contribution to our 
understanding of the effect of this compound on the epigenetic machinery in cancer cell 
lines. 
The treatments with the two compounds did not result in the expected changes in global 
5hmC levels in SW480 and SW620 cell lines. The results of both the dot blot and mass 
spectrometry analyses indicate that the abundance of 5mC and 5hmC in both cell lines 
remained constant under all concentrations used. In fact, even the trial of a much higher 
dose of DMαKG (10 mM) did not lead to the expected upregulation of 5hmC levels. In 
light of this fact, further work was not conducted with these compounds. It is not clear 
why these treatment did not produce the expected outcome in terms of changing the 
global 5hmC content, despite their previous successful use in the literature (Yang et al., 
2016; Yin et al., 2018). The SW480 and SW620 cells might already contain sufficiently 
high concentration of alpha-ketoglutarate and iron (II) to ensure the optimal function of 
the TET enzymes. Additionally, shorter or longer incubation times with the two 
compounds might be required in order to see the expected changes in 5hmC levels due 
to their stability and turnover in culture. 
This study represents a solid starting point for further investigation of how compounds 
modulating 5hmC levels affect in vitro cancer properties. The main limitation of the 
study is the use of the three compounds for only one, 48 hour, time period (aside from 
the proliferation and colony formation assays). A time course experiment assessing the 
TET activity with multiple time points ranging from hours up to a week could provide 
the insight into what treatment period is optimal for achieving the greatest effect on 
function of the TET enzymes. This would then better inform the time period for which 
the functional assays should be conducted and how often should the cells be re-
supplemented with the compounds. An interesting example of the importance of 
treatment period was reported by Shenoy and colleagues where lymphoma cells showed 
a gradual reduction in cell viability following a 72 hour treatment period with a high 
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dose (5 mM) vitamin C treatment supplemented with catalase (Shenoy et al., 2017). 
This indicates tumour suppression via hydrogen peroxide-independent, possibly 5hmC-
depenendent, mechanism. Lastly, as this project is focused on the possible epigenetic 
contribution to CRC metastasis, the use of the three compounds described in this 
chapter in conjunction with a cell invasion assay, such as a Boyden chamber containing 
extracellular matrix-like mesh, would be the next experiment that should be conducted 
as a follow up to this study. This would allow one to more closely recapitulate the 
tumour microenvironment and the effect of varying doses of the 5hmC-modifying 





















Genetic manipulation of TET 
enzymes in an in vitro 





5.1 Chapter summary 
The aim of this investigation was to elucidate the effects of genetic modulation of TET 
expression on the proliferation and migration of SW480 and SW620 colorectal cancer 
cell lines. This work was undertaken in order to complement the results obtained with 
compound-mediated modifications of 5hmC levels as described in Chapter 4. 
CRISPR/Cas9 TET knockouts of SW480 and SW620 cell lines generated by Horizon 
Discovery were characterised and found to have reduced transcription of the TET genes. 
This reduction was confirmed through protein levels analysis, in particular in the 
primary cell line. Unexpectedly, global 5hmC content persisted in the DNA albeit at 
reduced levels. Following these findings, the cells were considered as TET knockdowns 
(KDs) rather than complete knockouts as initially thought. 
Reduction in TET expression was found to result in a lower proliferation rate of the 
TET KD cell lines. The TET knockdowns had different effects in the two colorectal 
cancer cell lines: they resulted in higher migration rate of the primary SW480 cell line 
and they reduced the migration of metastatic SW620 cells. The overexpression of TET1 
and TET3 enzymes in the two TKD SW480 cell lines resulted in a partial rescue of the 
migratory phenotype while little effect of individual TET overexpression on migration 
rate was observed in the TKD SW620 cell line. 
Taken together, these results provide an in-depth description of the effects of genetic 
modulation of TET enzymes levels on the in vitro proliferation and migration of the 
SW480 and SW620 cell lines and provide evidence for opposite effects of these 










The reduction in global 5hmC levels, a hallmark of multiple tumour types, was found in 
CRC biopsies (Uribe-Lewis et al., 2015; Gilat et al., 2017; Tian et al., 2017). 
Intriguingly, there are conflicting reports regarding the expression of the TET genes in 
CRC tumour biopsies. Uribe-Lewis and colleagues found that the mRNA levels of all 
three TET genes were unchanged in adenomas and adenocarcinomas of the colon 
compared to normal tissue (Uribe-Lewis et al., 2015). A different study reported that 
TET1 levels were reduced in half of the analysed CRC samples (Kudo et al., 2012). 
Rawłuszko-Wieczorek and colleagues found that the expression of TET1, TET2 and 
TET3 were all reduced in CRC patient biopsies compared to surrounding colonic tissue 
(Rawłuszko-Wieczorek et al., 2015). They also found a positive correlation between 
high TET2 expression and overall survival in CRC sufferers.  
Two independent groups reported the reduction in TET1 levels in CRC patient samples 
and confirmed that a TET1 knockdown leads to increased in vitro proliferation (Neri et 
al., 2015; Tian et al., 2017). The preliminary data indicating a potential role of the TETs 
in CRC metastasis (section 4.2, Figure 4.1) is supported by the findings of Puig and 
collaborators (Puig et al., 2018). They demonstrated an increase in proportion of high-
5hmC levels biopsies in the liver metastases compared to matched primary CRC patient 
samples. High TET2 and 5hmC levels were also negatively correlated with disease-free 
survival of CRC sufferers following chemotherapy treatment. In light of the evidence 
described above, the role of the TET enzymes and 5hmC in CRC progression warrants 
further investigation.  
In order to investigate the role of the TET enzymes in the SW480 and SW620 cell line 
model of CRC metastasis, knockout cell lines were generated using the clustered 
regularly interspaced palindromic repeats/CRISPR-associated 9 (CRISPR/Cas9) 
technology by Horizon Discovery (see Supplementary Figure 6 for details). The cell 
lines created include a TET2 single knockout (SKO), TET2 and TET3 double knockout 
(DKO) and TET1, TET2 and TET3 triple knockout (TKO) in each of the SW480 and 
SW620 cell lines. Two different TKO clones were generated in SW480 cells, termed 
TKO 1 and TKO 2. This chapter presents the characterisation of all the above-
mentioned cell lines and the effect of TET knockouts on in vitro cell proliferation, 
colony formation and migration. 
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5.3 Experimental objectives  
Aim: to examine the effects of CRISPR/Cas9-induced mutations in genes encoding all 
three TET enzymes on in vitro proliferation, colony formation and migration of the 
SW480 and SW620 colorectal cancer cell lines. 
Objectives: 
1. Confirm the CRISPR/Cas9 -induced knockouts at mRNA and protein levels and 
assess their effect on the global 5hmC content in SW480 and SW620 cell lines 
2. Establish the impact of the single, double and triple TET knockouts on cell 
proliferation, colony formation and migration in the SW480 and SW620 cells 
3. Examine the effect of the TET rescue through exogenous overexpression in the 

















5.4 Results  
5.4.1 Confirmation of the CRISPR/Cas9 -induced knockouts at mRNA and protein 
levels and assessment of their effect on the global 5hmC content in SW480 and 
SW620 cell lines 
The Supplementary Figure 6 shows the TET knockout strategy devised together with 
Horizon Discovery to generate single, double and triple TET knockouts using the 
CRISPR/Cas9 system. The internal validation of the data provided by Horizon 
Discovery was conducted by performing sequencing of all the knockout cell lines and 
confirming the presence of required deletions (Supplementary Figure 7). Based on the 
literature search on cell survival following TET deletions, it was decided to sequentially 
target TET2, then TET3 and finally TET1 in both cell lines. Since the insertions and 
deletions made by the CRISPR/Cas9 method can affect the stability of mRNA and lead 
to nonsense mediated decay (Tuladhar et al., 2019), the mRNA levels of the three TETs 
in each of the congenic cell lines were assessed by qRT-PCR (Figure 5.1). In the 
SW480 cells, the levels of TET1, TET2 and TET3 were significantly reduced in all the 
knockout cell lines, including the SKO and DKO cells (Figure 5.1 A). This unexpected 
result showing reduced TET3 and TET1 levels in a single TET2-targeted cell line could 
possibly be explained by the TET enzymes regulating each other’s expression in the 
SW480 cells. The levels of TET1 were reduced to between 0.34 and 0.41 relative to the 
abundance in the wild type cell line, with the values for TET2 ranging from 0.15 to 0.20 
and for TET3 between 0.29 and 0.32. TET2 was the most abundantly expressed 
transcript of the three TETs in this cell line prior to the knockout (section 4.4.1, Figure 
4.2 B). The reduction observed in the knockout cell lines, while substantial, resulted in a 
large amount of the TET2 transcript persisting at a level of approximately equivalent to 
0.3 picograms of the standard curve vector used. This amount of transcript is 
approximately twice as high as the original absolute amount of TET1 mRNA in this cell 
line. The total absolute TET levels were reduced to amount equivalent to approximately 
0.6 picograms of vector used in the two TKO cell lines compared to the original value 
of 2.5 picograms in the wild type cells. 
In the SW620 cell line, the mRNA level of TET2 was no different in the SKO cells and 
appeared to be increased following the double knockout, when TET3 was subsequently 
targeted. Given the low initial abundance of TET2 mRNA in this cell line (section 4.4.1, 
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Figure 4.2 B), it appears that the CRISPR/Cas9-induced mutation did not affect the 
stability of the TET2 transcript in any of the three knockout cell lines. The upregulation 
of the TET2 mRNA levels in the DKO cells is in line with the unpublished observations 
made by the Murrell group that TET2 is upregulated by targeting TET3 with siRNA in 
HCT116 cells (data not shown). This may suggest that the TET enzymes may 
transcriptionally regulate one another. However, no published reports of similar results 
could be found and the changes in TET2 abundance may simply be an effect of low 
transcription levels and background noise. In the TKO cells, the TET1 transcript were 
significantly reduced (lowered to 0.39 and 0.30, respectively, of the SKO and DKO 
levels) (Figure 5.1 B). Based on the absolute TET levels in the SW620 cell line (section 
4.4.1, Figure 4.2 B), the total residual TET transcript levels in the TKO cell line are 
calculated at equivalent to approximately 0.7 picograms of vector used compared to 1.4 
picograms in the wild type cells. 
The levels of the three TET proteins in the knockout SW480 and SW620 cell lines were 
assessed by Western blotting (Figure 5.2). The representative image of the antibody 
staining is shown in Figure 5.2 A. In the SW480 knockout cell lines, TET1 content was 
found to be reduced by 78% in TKO 1 cells compared to the wild type cells (Figure 5.2 
B). The reduction in TET3 content was the highest out of all the TETs, reaching 86% in 
the TKO 1 cell line and 92% in the TKO 2 cells compared to the abundance observed in 
the SW480 wild type line. 
The TET protein levels in the three SW620 knockout cell lines were not reduced as 
efficiently as in the primary cell line (Figure 5.2 C). None of the changes in the protein 
levels of the three TET enzymes were found to be significant. It should be noted that the 
variation in TET3 signal obtained for the three independent samples analysed was 
higher than the other TETs. It is hence likely that this counterintuitive result is due to 
experimental error or variation in antibody staining as the anti-TET3 antibody produced 





Figure 5.1 The CRISPR/Cas9 genetic knockout strategy failed to ablate the 
expression of the TET genes in the SW480 and SW620 cell lines 
The expression of the TET transcripts in (A) SW480 and (B) SW620 wild type (WT) 
and single (SKO), double (DKO) and triple (TKO) TET knockout cell lines. The TET 
mRNA levels were normalised to ACTB reference gene. The error bars represent the 
standard deviation of three independent replicates. The significance was established 
using a one-way ANOVA followed by the Tukey’s single-step multiple comparison (* 







Figure 5.2 The CRISPR/Cas9 genetic knockout strategy failed to ablate the TET 
protein levels in the SW480 and SW620 cell lines 
(A) A representative Western blot image of the assessment of TET1, TET2, TET3 and 
ß-Tubulin protein levels in wild type (WT), single (SKO), double (DKO) and triple 
(TKO) TET knockout SW480 and SW620 cell lines. 
The TET protein levels in WT, SKO, DKO and TKO (B) SW480 and (C) SW620 cell 
lines. The staining results were normalised to the ß-Tubulin content in each cell line. 
The error bars represent the standard deviation of three independent replicates. The 
significance was established using a one-way ANOVA followed by the Tukey’s single-
step multiple comparison (* p<0.05). 
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The TET knockout SW480 and SW620 cell lines were also assessed for their global 
5mC and 5hmC content using the dot blot technique (Figure 5.3). The single and double 
knockout SW480 cell lines both have a modest reduction in 5mC levels and a similar 
approximately 40% reduction in 5hmC content compared to the wild type cells (Figure 
5.3 A). The single and double knockout SW620 cells on the other hand display no 
changes in 5mC levels with global 5hmC levels lower by approximately 15% relative to 
the unmodified SW620 cell line (Figure 5.3 B). The triple TET knockout in SW480 
cells resulted in no change in 5mC levels and a 65% reduction in 5hmC content for both 
knockout cell lines (Figure 5.3 C). The triple TET knockout SW620 cell line showed 
slightly higher levels of 5mC and approximately 25% lower 5hmC levels compared to 
the wild type SW620 cells (Figure 5.3 D). Taken together, this data points to a more 
efficient knockdown of TET transcript and protein levels, as well as the activity of these 
enzymes, in the primary SW480 cell line compared to its metastatic SW620 counterpart. 
This is further supported by the TET activity assay results shown in Supplementary 
Figure 8. 
The mass spectrometry data for the triple TET knockout cell lines is not shown due to 
the 5hmC signal having a signal to noise ratio below 10 and hence being non-
quantifiable (data not shown). The levels of 5mC were found to be significantly 
increased in the TKO SW620 cells, but not in TKO1 and TKO 2 SW480 cell lines, 
compared to the wild type cells as measured by mass spectrometry (Supplementary 
Figure 9). This could be due to the aforementioned reduced global 5hmC content in this 
cell line. 
Based on the results shown in Figure 5.1, Figure 5.2 and Figure 5.3 the cell lines will be 
referred to in subsequent text as knockdowns (KD) rather than knockouts (KO) to 










Figure 5.3 The CRISPR/Cas9 genetic knockout strategy failed to ablate the global 
5hmC content in the SW480 and SW620 cell lines 
(A) and (B) The representative staining and graphical representation of the results of dot 
blot assessment of 5hmC and 5mC levels in wild type (WT), single (SKO) and double 
(DKO) TET knockout SW480 and SW620 cell lines, respectively. The errors bars 
represent the standard deviation of three independent replicates.  
(C) and (D) The representative staining and graphical representation of the results of dot 
blot assessment of 5hmC and 5mC levels in WT and triple (TKO) TET knockout 
SW480 and SW620 cell lines, respectively. The errors bars represent the standard 
deviation of four independent replicates. 
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5.4.2 The impact of the TET knockdowns on cell proliferation, colony formation 
and migration in the SW480 and SW620 cells 
Based on the results described above, the TKD SW480 and SW620 cell lines are not a 
complete functional knockout of the TET enzymes. Nevertheless, the reduction in the 
TET levels and their catalytic activity puts these cell lines on par with multiple 
knockdowns of the TET enzymes described in the literature (Wu et al., 2015; Cui et al., 
2016; Pei et al., 2016; Zhou et al., 2018). Based on the previously reported phenotypic 
changes due to the said knockdowns, it is likely that there will be pronounced 
phenotypic differences between the TKOD and wild type SW480 and SW620 cell lines. 
The SW480 and SW620 cell lines were next assessed for the effect of the TET enzymes 
knockdown on cell morphology and size (Figure 5.4). The SKD, DKD and TKD cell 
lines did not exhibit any obvious morphological differences compared to the wild type 
cells (Figure 5.4 A). The SW480 knockdown cell lines were also found to have no 
difference in cell size compared to the wild type cells (Figure 5.4 B). On the other hand, 
the SKD and DKD SW620 cell lines have significantly reduced cell diameter, 15.1 and 
15.6 µm, compared to the wild type cells (17.3 µm) while the TKD SW620 cells were 
found to have a significantly higher cell diameter of 21 µm (Figure 5.4 B). 
The rate of cell proliferation was compared between the wild type and knockdown 
SW480 and SW620 cell lines (Figure 5.5). Only one of the TET knockdown SW480 cell 
lines (TKD 2) displayed a significantly reduced proliferation rate compared to the wild 
type cells at 72-hour (615,000 and 900,000 cells, respectively) and compared to the 
TKD1 cell line at 96-hour (933,000 and 1,294,000 cells, respectively) time points 
(Figure 5.5 A). None of the TET knockdowns resulted in a significantly altered rate of 






Figure 5.4 The cell size comparison between wild type and TET knockdown SW480 
and SW620 cells 
(A) The representative images of SW480 and SW620 wild type (WT), single (SKD), 
double (DKD) and triple (TKD) TET knockdown cell lines taken 48 hours after seeding 
at 20X magnification. Scale bar = 200 µm. 
(B) The comparison of cell diameter between the wild type and TET knockdown 
SW480 and SW620 cell lines. The error bars represent the standard deviation of two 
hundred wild type one hundred knockdown cells measured for each cell line in a single 
culture dish. The significance was established using a one-way ANOVA followed by 
the Tukey’s single-step multiple comparison (* p<0.05; ** p<0.01). The results of the 




Figure 5.5 The comparison of proliferation rates of wild type and TET knockdown 
SW480 and SW620 cell lines 
The cell counts of (A) SW480 and (B) SW620 wild type (WT), single (SKD), double 
(DKD) and triple (TKD) TET knockdown cell lines measured at 24 hour intervals for 96 
hours. The error bars represent the standard deviation of eight independent replicates for 
the WT cells, three independent replicates for the SKD and DKD cells and five 
independent replicates for the TKD cells. The significance was established using a one-
way ANOVA followed by the Tukey’s single-step multiple comparison (* p<0.05). 
 
The colony formation assay with the abovementioned cell lines provided a different 
insight into their rate of in vitro growth (Figure 5.6). The colony formation appeared to 
be reduced for almost all TET knockdowns in both SW480 (Figure 5.6 A) and SW620 
(Figure 5.6 B) cell lines. The number of colonies formed was significantly reduced in 
both the SKD and DKD SW480 cell lines (reduction in the average colony count of 56 
and 53%, respectively) compared to the wild type cells (Figure 5.6 C). Additionally, 
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SKD SW480 cells showed a significantly smaller average colony area (reduced by 30%) 
than the unmodified cells. TKD 2 SW480 cells displayed a reduced colony formation 
ability when compared to the wild type cell line (reduction in the average colony count 
of 65). The TKD 1 SW480 cell line formed 25% larger colonies than the wild type cells 
with no significant changes observed in the TKD 2 cells. 
The SKD, DKD and TKD SW620 cells were all found to have a significantly reduced 
number of the colonies formed compared to the unmodified cell line (by 32, 42 and 
47%, respectively) (Figure 5.6 D). The DKD and TKD SW620 cell lines were also 
found to have a significantly reduced colony size (by 12 and 23%, respectively) 
compared the wild type colonies. 
The migration of the wild type and TET knockdown SW480 and SW620 was assessed 
by the scratch assay (Figure 5.7). The migration rate appeared higher in the knockout 
SW480 cell lines compared to unmodified cells (Figure 5.7 A). The opposite pattern 
was observed in the SW620 cell line, with the knockdown cells migrating less than the 
wild type cells (Figure 5.7 B). All the SW480 TET knockdown cell lines were found 
have migrated the same distance as the wild type cells inside the scratched gap with no 
significant changes observed (Figure 5.7 C). The SW620 TET knockdown cell lines, on 
the other hand, showed reduced migration ability compared to the parent cell line 
(Figure 5.7 D). The percentage gap closure was found to be significantly lower for the 






Figure 5.6 The knockdowns of the TET enzymes lead to a reduction in colony 
formation ability of SW480 and SW620 cells 
(A) and (B) The representative images of colony formation of wild type (WT), single 
(SKD), double (DKD) and triple (TKD) TET knockdown SW480 and SW620 cell lines, 
respectively, taken between 10 and 14 days after seeding.  
(C) and (D) The depiction of the average colony size and area in WT, SKD, DKD and 
TKD SW480 and SW620 cell lines, respectively. The error bars represent the standard 
deviation of four independent replicates. The significance was established using a one-
way ANOVA followed by the Tukey’s single-step multiple comparison (* p<0.05; ** 








Figure 5.7 The triple knockdown of the TET enzymes lead to a reduction in 
migration of the SW620 cell line  
(A) and (B) The representative images of migration of wild type (WT), single (SKD), 
double (DKD) and triple (TKD) TET knockdown SW480 and SW620 cell lines, 
respectively. The images were taken at 0 hours and 48 hours after the scratch was made, 
at 10X magnification. Scale bar = 400 µm.  
(C) and (D) The depiction of the percentage gap closure between the 0 hour and 48 hour 
time points in WT, SKD, DKD and TKD SW480 and SW620 cell lines, respectively. 
The error bars represent the standard deviation of eight independent replicates for the 
WT cells, three independent replicates for the SKD and DKD cells and five independent 
replicates for the TKD cells. The significance was established using a one-way ANOVA 












5.4.3 Assessment of the effect of the TET enzymes levels rescue through acute 
overexpression on the migration of the triple knockdown SW480 and SW620 cell 
lines 
The results showing pronounced effects of TET triple knockdown on migration of 
SW620 cells were followed up by a rescue experiment using transient overexpression of 
each of the TET enzymes in the three TKD cell lines. While the changes in migration 
observed with TET knockdown SW480 cell lines were found to not be significant, they 
all appeared to have an elevated migration rate compared to the wild type cells. The 
TKD 1 and TKD 2 cell lines were hence also included in this investigation. This 
experiment would allow one to understand better which of the TET enzymes had the 
biggest effect on migration of the two CRC cell lines. The overexpression constructs 
used contain human TET1 and TET3 genes and mouse Tet2 gene (Tahiliani et al., 2009; 
Ko et al., 2010; Ko et al., 2013).  
The overexpression of the three TET enzymes in all the transfected samples was 
validated by qRT-PCR (Figure 5.8). The expression of TET1 was on average 19-fold 
higher compared in the TET1 overexpression sample to the control TKD 1 SW480 cells 
(Figure 5.8 A). The levels of TET2 did not change in any of the samples, indicating no 
positive or negative feedback on its expression due to the acute overexpression of the 
other TETs. The successful expression of the mouse Tet2 transcript was confirmed in 
the transfected cells (see Supplementary Figure 10 for Tet2 expression relative to the 
ACTB levels), and TET3 levels were found to be approximately10-fold higher in the 
TET3 overexpression sample compared to controls.  
In the TKD 2 SW480 cell line, the TET1 levels were on average 23-fold higher in the 
TET1 overexpressing cells compared to the control samples (Figure 5.8 B). In a similar 
fashion to the results obtained in the TKD 1 SW480 cells (Figure 5.8A), the TET2 
expression remained largely unchanged in all samples. The successful expression of 
mouse Tet2 transcript was confirmed in the transfected cells (see Supplementary Figure 
10 for Tet2 expression relative to the ACTB levels), and TET3 levels were over 7-fold 
higher in the TET3 overexpression sample compared to controls.  
The TET1 levels were on average over 6-fold higher in the TKD SW620 TET1 
overexpressing cells compared to the control samples (Figure 5.8 C). The levels of 
TET2 were unchanged by the overexpression of the three TET enzymes and the 
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successful expression of mouse Tet2 transcript was also confirmed (see Supplementary 
Figure 10 for Tet2 expression relative to the ACTB levels). Lastly, TET3 levels were 
found to be approximately 6-fold higher in the TET3 overexpressing cells compared to 
the untransfected control. 
The overexpression of each of the three TET enzymes led to a modest decrease in the 
migration of the TKD 1 SW480 cell line with no obvious increase in the cell death due 
to the transfection process (Figure 5.9 A). Overexpression of the TET3 enzyme was 
found to have the greatest effect on migration and resulted in significantly reduced gap 
closure compared to all the other samples (Figure 5.9 B). The overexpression of TET1 
and TET3 resulted in 22  and 48% reduction in gap closure compared to the 
untransfected cells. Additionally, TET3 overexpression led to a 44% lower reduction in 
gap width compared to cells treated with transfection reagent-only. 
The individual TET overexpression in TKD 2 SW480 cells, in a similar fashion to the 
TKD 1 cell line, resulted in a small reduction in their migration ability compared to the 
control cell lines (Figure 5.10 A). However, in contrast to the TKD 1 cells, acute 
overexpression of the three TET enzymes resulted no change in the migration ability of 
the TKO 2 SW480 cells (Figure 5.10 B).  
The TKO SW620 cells similarly appeared to have a lower migration rate when the three 
TET enzymes were individually overexpressed exogenously (Figure 5.11 A). All 
overexpression samples exhibited a reduced percentage gap closure compared to the 
untransfected control and TET3 overexpression also significantly lowered the 
percentage gap closure compared to transfection only control (Figure 5.11 B). TET3 
overexpressing cells were determined to close the scratch gap the least of the three 
overexpression samples (4%), followed by the TET2 (9%) and TET1 (10%) 










Figure 5.8 The acute TET enzymes overexpression leads to an upregulation in the 
corresponding mRNA levels in the three TKD cell lines 
The expression of the human TET1/2/3 and mouse Tet2 transcripts in untransfected 
control, transfection reagent-only control (Fugene) and TET1/2/3 overexpressing 
(TET1/2/3 o-e) (A) TKD 1 SW480, (B) TKD 2 SW480 and (C) TKD SW620 cell lines. 
The TET mRNA levels were normalised to ACTB reference gene. The error bars 
represent the standard deviation of three independent replicates. 
 
The TET3 overexpression also resulted in significantly lower migration compared to the 
transfection reagent-only control cells which on average migrated 11% of the original 
scratch width into the gap. Interestingly the absolute and percentage gap reduction was 
also significantly lowered by the addition of transfection reagent on its own. This is in 
line with the observation that the transfection process itself resulted in considerably 
more cell death in the TKD SW620 cell line compared to the TKD 1 and TKD 2 SW480 
cells (data not shown). 
It should be noted that the increased mRNA levels of the TETs following their 
overexpression were not reflected in the protein levels of any of the conditions in the 
three cell lines (Supplementary Figure 11). This was an unexpected observation which 
cannot be easily explained and is possibly a major limitation of these experiments. It is 
tempting to speculate that the antibodies used in this project did not bind to the 
overexpressed proteins. Due to the time constraints of the project and limited sample 







Figure 5.9 The results of TET enzymes overexpression on migration of the TKD 1 
SW480 cell line 
(A) The representative images of migration of untransfected control, transfection 
reagent-only control (Fugene) and TET1/2/3 overexpressing TKD 1 SW480 cells. The 
images were taken at 0 hours and 48 hours after the scratch was made, at 10X 
magnification. Scale bar = 400 µm.  
(B) The depiction of the percentage gap closure between the 0 hour and 48 hour time 
points assessed using the ImageJ software in untransfected control, Fugene and 
TET1/2/3 overexpressing TKD 1 SW480 cells. The error bars represent the standard 
deviation of three independent replicates. The significance was established using a one-
way ANOVA followed by the Tukey’s single-step multiple comparison (** p<0.01). 







Figure 5.10 The results of TET enzymes overexpression on migration of the TKD 2 
SW480 cell line 
(A) The representative images of migration of untransfected control, transfection 
reagent-only control (Fugene) and TET1/2/3 overexpressing TKD 2 SW480 cells. The 
images were taken at 0 hours and 48 hours after the scratch was made, at 10X 
magnification. Scale bar = 400 µm.  
(B) The depiction of the percentage gap closure between the 0 hour and 48 hour time 
points assessed using the ImageJ software in untransfected control, Fugene and 
TET1/2/3 overexpressing TKD 2 SW480 cells. The error bars represent the standard 
deviation of three independent replicates. The significance was established using a one-







Figure 5.11 The results of TET enzymes overexpression on migration of the TKD 
SW620 cell line 
(A) The representative images of migration of untransfected control, transfection 
reagent-only control (Fugene) and TET1/2/3 overexpressing TKD SW620 cells. The 
images were taken at 0 hours and 48 hours after the scratch was made, at 10X 
magnification. Scale bar = 400 µm.  
(B) The depiction of the percentage and absolute gap closure between the 0 hour and 48 
hour time points assessed using the ImageJ software in untransfected control, Fugene 
and TET1/2/3 overexpressing TKD SW620 cells. The error bars represent the standard 
deviation of three independent replicates. The significance was established using a one-
way ANOVA followed by the Tukey’s single-step multiple comparison (** p<0.01). 














This chapter provides a summary of the investigation into the effect of the manipulation 
of TET enzymes levels on the in vitro properties of two CRC cell lines - SW480 and 
SW620. However, these results come with the caveats of experimental limitations. The 
first limitation is that the cell lines obtained from Horizon Discovery had varying 
success with regard to the efficiency of the TET knockdown and still retained some 
evidence of enzymatic activity as indicated by the detectable persistence of low 5hmC 
levels in both SW480 and SW620 knockdown cell lines despite all three TET genes 
being successfully targeted at the genomic level. To date, there is no evidence for a 
fourth TET enzyme or a mechanism whereby 5hmC is maintained during replication in 
the absence of functional TET enzymes. Moreover, TET TKO mouse embryonic stem 
cells lack detectable levels of 5hmC in their genome (Dawlaty et al., 2014). In light of 
this evidence, we hence regard these cell lines as catalytic knockdowns rather than 
knockouts. 
At the transcript level, the qRT-PCR results obtained indicated a greater degree of 
knockdown in SW480 compared to SW620 cells. None of the cell lines, however, 
appeared to be knockouts of the TET enzymes on mRNA level. The CRISPR/Cas9 
strategy to introduce insertion/deletion mutations still allows a gene to be transcribed 
despite a disrupted DNA sequence and a premature STOP codon which terminates 
translation prematurely leading to a shortened, often non-functional protein. However, it 
is known that in most cases the mRNA produced is degraded via nonsense mediated 
decay in the nucleus before being exported out (Shi et al., 2015; Tuladhar et al., 2019). 
Additionally, while one of the alleles may be a functional knockout, the other can 
compensate for it in terms of the gene expression (Hildebrandt et al., 2015). Lastly, it is 
also known that a large proportion of CRISPR/Cas9 induced mutations results in a 
variable level of residual protein expression (Smits et al., 2019). The similar pattern of 
knockdown of the TET enzymes in all four SW480 knockdown cell lines may be due to 
TET2, which is the highest abundance TET enzyme in these cells (see section 4.4.1, 
Figure 4.2 B), being involved in control of the expression of TET1 and TET3 genes by, 
for example, demethylating their promoters. It should be noted that this is purely a 
speculation as no evidence of such regulatory mechanism has been published to date. If 
that is the case, the knockdown of TET3 and TET1 in DKD and TKD cell lines, 
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respectively would have little effect on their mRNA expression. In SW620 cells, the 
supposed TET2 knockout had no effect on the expression of the three TET enzymes. 
TET3 knockdown in the DKD cell line reduced its expression while elevating levels of 
TET1 and TET2. None of these changes were found to be significant. The TET1 
knockdown in the TKD cells led to a significant reduction in only the TET1 transcript 
relative to SKD and DKD cell lines. 
The protein and 5hmC levels in the TET knockdown SW480 cell lines do not support 
qRT-PCR data showing an equal knockdown of all three TET transcripts in SKD, DKD, 
TKD 1 and TKD 2 cell lines. This could potentially be due the levels of TET proteins 
remaining relatively stable despite fluctuations in mRNA content. Given that TET2 is 
the most abundant of the TET proteins in SW480 cells, the changes in TET1 and TET3 
transcription observed in SKD cell line might not affect the protein levels to the same 
extent as TET2. A non-significant reduction in TET protein content was observed in the 
SKD and DKD cell lines together with 40% lower global 5hmC levels compared to the 
wild type cells. The reduction in both 5hmC and TET protein levels was greater in the 
two TKO cell lines compared to SKD and DKD cells, which further strengthens the 
results of functional assays where the greatest changes were observed in the two TKD 
cell lines. 
In SW620 cells, the different results of TET expression and TET protein levels analysis 
were also observed. The significant reduction in TET1 content observed in TKD SW620 
cells did not translate into a reduction of its protein levels. Despite this, the reduction in 
5hmC levels indicates that the activity of the TET proteins is lower in the TKD cell line 
than the wild type counterpart. This could be due to the levels of TET1 and TET2 
sufficiently reduced to elicit changes in global 5hmC levels despite the unexpected 
increase in TET3 content. The reduction in both TET transcripts and 5hmC levels was 
greater in the TKD SW620 cell line compared to the SKD and DKD cell lines. 
 The TET TKD thus appears to be more efficient in SW480 cells than the metastatic 
counterpart as seen by the greater reduction in both TET expression and 5hmC content. 
A partial limitation of this study is the absence of the mass spectrometry 5hmC content 
data due to its levels being below the quantification limit. This could be overcome in the 
future by attempting to analyse a larger quantity of the TKD DNA on the mass 
spectrometer to increase the 5hmC amount above that limit. 
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Taken together, these results indicate that the SW480 and SW620 knockdown cell lines 
are not complete knockouts on functional level. However, the knockdown cell lines 
described here represent a viable, albeit limited, model to study the effects of TET and 
5hmC levels reduction in the in vitro CRC model. This is because of the opposite roles 
of the TET enzymes in cancer development reported in the literature and the scarcity of 
data regarding their function in CRC progression and metastasis. 
It is important to note the limitations of use of the CRISPR/Cas9 gene editing system to 
produce clonal knockout cell lines. The process of obtaining a single clone harbouring 
the desired deletion from a population of transfected cells represents a massive selection 
bottleneck. The resulting cell line is a homogenous population of cells arising from a 
single cell which previously was a tiny part of a heterogenous cell line. As such, this 
particular cell might not be representative of the whole original population and have 
properties that made it successful during the selection process. This highlights the need 
to analyse multiple clones harbouring the same deletion before any conclusions can be 
made about the observed phenotype. The practice of analysing multiple clones isolated 
from the original transfected population will also minimise the chances that off-target 
effects of the CRISPR/Cas9 system play a role in any phenotypes observed with a 
particular clone and thus strengthens any subsequent findings. It is also important to 
include a non-targeting control guide RNA in the CRISPR experiment. The sequence of 
this guide is often a scrambled sequence of the guide targeting the genomic region of 
interest. This approach thus provides a further control for any off-target effects 
potentially arising following the CRISPR/Cas9 vector transfection into cells. 
The proliferation and colony formation assay results indicate that reduced TET levels 
result in lower rates of proliferation, although the effects appear to be more pronounced 
with regards to the colony formation ability. In SW480 cells, the different rates of 
proliferation in the two TKD cell lines are certainly puzzling given their similar levels 
of TET knockdowns and 5hmC levels. It may reflect differences in off-target effects or 
properties of the single parent cell between these two cell lines, highlighting the need to 
analyse multiple CRISPR/Cas9 clones alluded to above, and ultimately to do full 
sequence analysis. TET1 was previously shown to play a role in regulating proliferation 
and migration in CRC cell lines in vitro (Tian et al., 2017) and may hence help to 
explain the disparity in the results if there is a difference in the degree of functional 
TET1 knockdown in the two TKD SW480 cell lines which was to an extent observed on 
 201 
protein level. The colony formation assay results further support this with TKD 1 cells 
showing no change in the number of colonies formed and an increased colony size, 
while TKD 2 cell line displayed a reduction in colony count compared to the wild type 
cells. Contrary to the proliferation assay, SKD and DKD SW480 also showed a 
reduction in proliferative capabilities. This is possibly due to the colony formation assay 
highlighting the ability of a single cell in a population to proliferate independently and 
establish a new colony. When the colony sizes are compared, little difference is seen 
between these cell lines and wild type cells. While the TET knockdown SW620 cells 
show no change in growth rate measured by the proliferation assay, the SKD, DKD and 
TKD cell lines have a significantly lower rate of colony formation compared to the wild 
type cells. In a similar fashion to the SW480 knockdown cell lines, it is hence likely that 
the ability of individual cells to form independent colonies is affected while there is 
little effect on the rate of growth of the whole cell population. Together, these results 
demonstrate that cells with lower TET and 5hmC levels have a modest growth reduction 
as would be expected given the pro-oncogenic role of TETs previously described in the 
literature (Tian et al., 2017; Good et al., 2018). These results are, however, counter-
intuitive given the abundance of data supporting the tumour suppressive functions of the 
TET enzymes (see section 5.2 for details). In general, the findings described in this 
chapter do support the notion that TETs may play opposite roles in different cancer 
types. 
The increased motility and ability to migrate of cancer cells is a crucial step in the 
metastatic cascade. The in vitro migration of the TET knockdown SW480 and SW620 
cell lines was therefore directly compared using the scratch assay. In the primary 
SW480 cells, all the TET knockouts resulted in no change in migration rate compared to 
the wild type cell line. Interestingly, the TET TKD in the metastatic SW620 cell line 
showed little effect on proliferation but had a suppressive effect on migration of these 
cells (Figures 5.5 and 5.7, respectively), with the TKD cell lines showing a marked 
reduction in migration. This result is similar to that of Tian and colleagues who also 
found that TET1 knockdown in SW620 cells decreased their invasiveness (Tian et al., 
2017). These findings highlight the intriguing potential switch in the effects of the TET 
enzymes on cancer hallmarks depending on the stage of cancer progression (Tian et al., 
2017).  
This differential response of the two CRC cell lines, SW480 and SW620, to the TET 
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knockdowns in terms of their migration warranted further investigation. The initial 
question asked was whether a rescue in expression in any individual TET enzyme will 
be sufficient to reverse the phenotype in case of SW620 cells and whether TET 
overexpression will lead to a migratory phenotype in the SW480 cell line. In the TKD 1 
and 2 SW480 cell lines, overexpression of TET1 and TET3 resulted in the greatest 
reduction of the migration rate. The degree of this effect was positively correlated to the 
degree of overexpression achieved in the TKD SW480 cells. Greater overexpression of 
TET3 lead to more significant reduction of the migratory phenotype in TKD 1 SW480 
cells. The overexpression of TET2, meanwhile, did not result in significant changes in 
migration rate of neither of the TKD SW480 cell lines. This could possibly be due to the 
TET2 overexpression vector containing a mouse gene rather than a human one which 
could lead to differences in the genomic regions that gain 5hmC following its 
overexpression. 
In the TKD SW620 cell line, the overexpression of the TET enzymes unexpectedly 
resulted in a further reduction of the migration rate. However, it should be noted that 
unlike in TKD SW480 cells, the transfection process itself significantly reduced the 
migration of this cell line. This is likely due to the observed high quantity of cells dying 
following transfection (data not shown). It is therefore possible that transfection with 
the overexpression plasmids resulted in an even higher death rate and hence a reduction 
in the distance migrated by the cells. Additionally, the overexpression of the three TET 
enzymes achieved was lower in the TKD SW620 cells compared to the TKD 1 and 
TKD 2 SW480 cell lines. Given the caveat that the overexpression rescue experiment 
resulted in a higher than physiologically normal transcription, further rescue 
experiments with catalytically inactive mutant TET enzymes are required. 
Time constraints of this project did not allow experiments to be performed that would 
further elucidate the role of the TET proteins in this in vitro CRC metastasis model. 
Assessment of the invasion of TET knockdown SW480 and SW620 cell lines through 
the use of transwell assays, previously utilised to assess the effect of TET levels 
manipulation on cancer cell invasion (Tian et al., 2017; Yu et al., 2020), would 
complement the migration data and provide further insight into the role of these 
enzymes in the metastatic process. A generation of SW480 and SW620 cell lines stably 
overexpressing each individual TET enzyme as well as all three TET proteins at once 
would allow to assess the effect of increased TET and 5hmC levels on in vitro 
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proliferation and migration. Lastly, tagging the aforementioned cell lines with 
fluorescent protein and luciferase reporters and introducing them into an animal model 
such as nude mice would provide information about how the in vitro findings described 

























The changes in 5hmC and 





6.1 Chapter summary 
The aim of this study was to investigate the changes in TET expression and 5hmC 
content during the process of cellular differentiation and whether this knowledge can be 
used to improve the in vitro differentiation process. 
The data describing the link between dynamic changes in 5hmC distribution and gene 
expression in mouse small intestine was further validated following controversy 
regarding the role of TET1 in mouse intestinal differentiation. A differentiation protocol 
of hESCs to hepatocyte-like cells (HLCs) was then used to provide a novel insight into 
fluctuation in TET and 5hmC levels during in vitro generation of liver cells. The TET1 
transcript was found to be the most abundant of the TETs in H9 ESCs and its levels 
gradually decreased during differentiation while the opposite pattern was seen for TET2 
and TET3. The global 5hmC content displayed a “U” pattern, initially dropping as the 
cells differentiated towards definitive endoderm (DE) and increased again in HLCs to 
levels higher than those observed in ESCs. A transient shRNA-mediated knockdown of 
TET1 levels in ESCs was utilised in an unsuccessful attempt to improve differentiation 
to the DE stage. 
Taken together these results provide a novel insight into the changes in 5hmC and TET 
levels during mouse intestinal differentiation and in vitro generation on HLCs from 
hESCs. They also highlight a potential strategy for improving the differentiation of 
HLCs from pluripotent sources by altering the levels of TET proteins and 5hmC 











The process of cellular differentiation involves a complex myriad of chromatin 
remodelling and gene expression changes that allow cells containing the same genome 
to change their identity from a pluripotent progenitor to the differentiated progeny. 
Tumorigenesis and metastasis occur when the processes of cellular differentiation go 
awry. Mouse embryonic stem cells (mESCs) have been extensively used to study the 
role of the TET enzymes in pluripotency and differentiation (comprehensively reviewed 
by Ross and Bogdanovic, 2019). Tet3 is known to be the most abundantly expressed Tet 
transcript in the mouse oocyte and zygote with Tet1 and Tet2 mRNA detected at very 
low levels (Iqbal et al., 2011; Wossidlo et al., 2011). However, as the cells differentiate 
towards the blastocyst stage, from which ESCs are derived, the pattern of Tet expression 
changes starkly. Tet1 is the most highly expressed Tet transcript in the mESC while 
Tet2 levels are few-fold lower but still easily detected and Tet3 is barely detectable in 
these cells (Koh et al., 2011). Similarly, the levels of Tet1 and Tet2 are elevated 
following generation of iPCSs from mouse embryonic fibroblasts, while the abundance 
of the Tet3 transcript is reduced in the process (Koh et al., 2011). Both mESCs and 
iPSCs are also known to have high 5hmC levels compared to more differentiated, 
multipotent cells (Szwagierczak et al., 2010; Koh et al., 2011). While the Tet triple 
knockout mESCs are able to maintain their pluripotency and normal morphology (Lu et 
al., 2014), their differentiation to embryonic bodies (Dawlaty et al., 2014) and neural 
lineages (Li et al., 2016) is severely impaired. Additionally, Tet1/Tet3 double and Tet 
triple knockout embryos show numerous developmental defects and embryonic lethality 
(Kang et al., 2015; Dai et al., 2016; Li et al., 2016). 
The changes in TET and 5hmC levels have also been studied during hESC 
differentiation. TET TKO hESCs, similarly to mESCs, do not show any defects in 
proliferation, morphology or pluripotency maintenance but display differentiation 
impairments (Verma et al., 2018). Differentiation of H9 hESCs towards the 
haematopoietic lineage was found to be associated with a large reduction of TET1 and 
gradual upregulation of TET2, with a small increase in TET3 transcript levels also noted 
(Langlois et al., 2014). TET2 was additionally described to be critical for 
haematopoietic differentiation with a TET2 knockdown skewing H9 ESCs 
differentiation from mesoderm to neuroectoderm (Langlois et al., 2014). Li and 
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colleagues provided an insight into changes in TET and global 5hmC levels during a 
multi-stage H1 hESCs differentiation protocol towards the pancreatic lineage (Li et al., 
2018). During the differentiation protocol, global 5hmC content was observed to dip 
initially during the first two stages by approximately 70% followed by a recovery to 
approximately 80% of the levels seen in hESCs in the last differentiation stage, the 
pancreatic endoderm (Li et al., 2018). Similarly to the observations made by Langlois 
and colleagues, TET1 levels were found to decrease during the differentiation process, 
while TET2 and TET3 transcripts increased their abundance as the cells differentiated 
towards the pancreatic endoderm (Langlois et al., 2014; Li et al., 2018). 
 
 
6.2.1 The role of the TET enzymes and 5hmC in mouse intestinal differentiation 
The mammalian intestine and colon are an easily accessible model system in which to 
study the epigenetics of multipotent stem cells and their differentiated progeny 
(Sheaffer et al., 2014; Van Der Heijden and Vermeulen, 2019). The epithelium of 
mammalian intestine is a series of villi projections that grow from crypts at their base 
and protrude into the intestinal lumen (see section 1.2.4, Figure 1.2). The crypts contain 
the intestinal stem cells (ISCs) and Paneth cells while the villi are formed of fully 
differentiated cells responsible for nutrient absorption (Beumer and Clevers, 2016). It 
was shown in both mouse and human that while global 5mC levels remain relatively 
constant across the intestinal crypt and villus, the global 5hmC content is high in the 
nonproliferating, differentiated villus progeny and low in the rapidly proliferating stem 
cell compartment (Uribe-Lewis et al., 2015; Kim et al., 2016; Uribe-Lewis et al., 2020). 
The role and abundance of the TET enzymes during the intestinal differentiation, 
however, remains controversial. Kim and colleagues demonstrated a higher expression 
of Tet1 in the mouse ISCs compared to the other two Tets and highlighted its essential 
role in maintenance and function of the ISCs population in the mouse small intestine 
(Kim et al., 2016). Additionally, they showed that the expression of Tet1 was 
significantly downregulated, and the levels of Tet2 and Tet3 were significantly 
upregulated, in the differentiated villus cells compared to the ISCs (Kim et al., 2016). 
On the other hand, a recently published study from the Murrell group (Uribe-Lewis et 
al., 2020) found that the levels of Tet1 are low in the ISCs population and decrease 
further during intestinal differentiation. This is consistent with the previous report by 
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the same group showing low TET1 levels compared to TET2 and TET3 expression in 
the human colon (Uribe-Lewis et al., 2015). Additionally, the expression of Tet2 and 
Tet3 displayed a very modest upregulation in the differentiated progeny and thus cannot 
account for the increase in global 5hmC levels (Uribe-Lewis et al., 2020). Lastly, 
Chapman and colleagues demonstrated an increase in TET1 expression during in vitro 
differentiation of colonocytes, which is in direct contrast to the two studies described 
above (Chapman et al., 2015). Given this discrepancy in results, the expression and role 




















6.3 Experimental objectives  
Aim: to examine the changes in 5hmC and TET levels during adult and embryonic stem 
cell differentiation of the small intestine and the liver to further our understanding of 
their role in untransformed tissue. 
Objectives: 
1. Confirm the changes in TET expression during mouse small intestine 
differentiation 
2. Establish the changes in TET and global 5hmC levels during the differentiation 
of human embryonic stem cells to hepatocyte-like cells 
3. Attempt to improve the differentiation efficiency of human embryonic stem cells 

















6.4 Results  
6.4.1 The confirmation of changes in TET expression during mouse small intestine 
differentiation 
The Murrell group previously generated RNA-seq and hmeDIP-seq data for two cell 
types in the mouse small intestine: the stem cell crypt progenitors (CD24a_Mid cells) 
and the differentiated villus progeny (CD24_Neg cells) (Uribe-Lewis et al., 2020). The 
aforementioned discrepancy in Tet levels observed by the Murrell group and Kim and 
colleagues meant that further confirmation of changes in Tet expression during mouse 
intestinal differentiation was required (Kim et al., 2016). Thus, more mouse ISCs and 
differentiated intestinal progeny cells were obtained and the Tet transcription levels was 
independently assessed by qRT-PCR (Figure 6.1). This independent qRT-PCR 
validation of the Tet expression showed a similar pattern in changes of Tet abundance 
during the differentiation of mouse small intestine as observed by RNA-seq (Figure 6.1 
A). The levels of Tet1 were reduced by 81% (compared to a 90% reduction observed by 
RNA-seq) while the levels of Tet2 and Tet3 were increased by 39% and 30%, 
respectively (compared to an increase of 54% and 17%, respectively, observed by RNA-
seq) in the differentiated villus cells compared to crypt progenitor cells. In order to 
assess the levels of expression of individual Tets in both cell lines, their levels were 
normalized to the Polr2a reference gene, revealing that Tet3 is the most abundant Tet in 
both cell types (Figure 6.1 B). Importantly, the expression of the three Tets and the 
Polr2a reference gene were adjusted to account for the primer efficiencies (see 
Supplementary Figure 12 for details). 
The discrepancy in the expression of Tet1 reported by Kim and co-authors and Uribe-
Lewis and colleagues could be due to alternative exon usage (Kim et al., 2016; Uribe-
Lewis et al., 2020). The exon targeting by the Tet1 qRT-PCR primer pairs used by both 
groups was hence directly compared. The mouse Tet1 gene contains thirteen exons 
(Towers et al., 2018). The Tet1 primer pair used by Kim and colleagues (Kim et al., 
2016) targets the exon-exon junction between exons 12 and 13 while the primer pair 
used to generate the results presented in Figure 6.1 A and B binds to a sequence within 
exon 4 (data not shown). Two isoforms of Tet1 were previously described in embryonic 
and adult mouse tissues (Zhang et al., 2016). The full-length isoform was found to be 
expressed in mESCs and PGCs and absent in adult tissues, while the expression of the 
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shorter isoform lacking the first two exons was progressively increased during neuronal 
differentiation of mESCs. There is no evidence, however, of the alternative use of the 
exons targeted by the two primer pairs mentioned above. It is therefore unlikely that 














Figure 6.1 The validation of gene expression changes occurring during 
differentiation of mouse stem cell colonic crypt progenitors to differentiated villus 
progeny  
(A) and (B) The comparison of fold change in expression and gene expression relative 
to the reference gene, respectively, of the Tet transcripts between the mouse colonic 
crypt progenitors (CD24a_Mid cells) and differentiated villus progeny (CD24a_Neg 
cells) obtained by RNA-seq (Uribe-Lewis et al., 2020) and qRT-PCR. The Tet mRNA 
levels were normalised to Polr2a reference gene. Both graphs represent the results of 
analysis of three independent biological replicates and the error bars display the 
standard deviation of three independent replicates. 
(C) The comparison of fold change in expression of the genes selected for validation 
between CD24a_Mid and CD24a_Neg cells obtained by RNA-seq and qRT-PCR. The 
mRNA levels of the chosen genes were normalised to Polr2a reference gene. Both 
graphs represent the results of analysis of three independent biological replicates and the 
error bars display the standard deviation of three independent replicates. 
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6.4.2 Assessment of the changes in TET and global 5hmC levels during the 
differentiation of human embryonic stem cells to hepatocyte-like cells 
The analysis of the changes in Tet and 5hmC levels during adult stem cell 
differentiation in the mouse small intestine was followed by the assessment of TET 
abundance and global 5mC and 5hmC content in hESC differentiation. The specific 
protocol utilised in this chapter allows the stage-wise differentiation of hESCs to DE 
stage, a bipotent hepatic progenitor cell termed hepatoblast (HB stage) and finally to the 
HLC stage. This differentiation path was chosen in an attempt to model the influence of 
the TET proteins and 5hmC on normal liver development. This is important to 
understand in the light of the preliminary results (section 4.2) from the Murrell lab 
suggesting that liver metastasis may require increased TET activity and upregulation of 
global 5hmC. 
The H9 ESCs display a number of morphological changes during differentiation to 
HLCs (Figure 6.2). The elongated, spiky morphology of the H9 ESCs disappeared at the 
DE stage giving way to a more compact, triangular and polygonal cell shape. This step 
was also accompanied by a large amount of cell death as visualised by the smaller and 
brighter dead cells floating above the DE monolayer in Figure 6.2. HBs were defined by 
a further transition to a fully polygonal cell shape, forming a mosaic-like monolayer 
with defined boundaries between cells. They progressed to HLCs, which were 
characterised by a high cytoplasmic to nuclear ratio with smaller, well defined nuclei 
and occasional binucleated cells as well as the presence of multiple vacuoles which is in 
line with previous observations of hESC-derived and human liver-derived hepatocytes 
(Hay et al., 2008; Yu et al., 2012; Bartlett et al., 2014). 
The successful differentiation of the H9 ESCs was confirmed by qRT-PCR (Figure 6.3). 
The levels of OCT4 and ALB transcripts which are known to decrease (Hay et al., 2008) 
and increase (Yu et al., 2012) during the hepatic differentiation process, respectively, 
were measured at each stage of the protocol. The ALB content did not change at the DE 
stage and remained at low levels of expression (Figure 6.3 A). Upon reaching the 
bipotent HB stage, the ALB levels increased by almost 200-fold compared to the H9 




Figure 6.2 The morphological changes during human embryonic stem cell 
differentiation to hepatocyte-like cells 
The representative images of human H9 embryonic stem cells (H9 ESCs), definitive 
endoderm cells (DE stage), hepatoblast cells (HB stage) and hepatocyte-like cells (HLC 




Figure 6.3 Confirmation of successful H9 human embryonic stem cell 
differentiation to hepatocyte-like cells 
The confirmation of (A) ALB and (B) OCT4 expression changes during embryonic stem 
cell differentiation to hepatocyte-like cells. H9 ESCs = human H9 embryonic stem cells, 
DE = definitive endoderm, HB = hepatoblast, HLC = hepatocyte-like cell. The ALB and 
OCT4 mRNA levels were normalised to the average expression of RPL13A, GAPDH 
and ACTB reference genes as previously described (Baxter et al., 2015). The error bars 
represent the standard deviation of three independent replicates. 
 
The TET enzymes have previously been described to play critical roles in the 
differentiation of ESCs (Langlois et al., 2014; Li et al., 2018; Verma et al., 2018) and 
the formation of iPSCs through a dedifferentiation process (Gao et al., 2013; Zhu et al., 
2014; Secardin et al., 2020). Based on this research, it was hypothesised that the 
abundance of the individual TETs as well as 5hmC will fluctuate at different stages of 
the H9 ESC differentiation protocol to HLCs. The levels of the three TET transcripts 
were hence assessed by qRT-PCR in the same RNA samples from the four cell types as 
analysed above (Figure 6.4). The expression of TET1 was found to be gradually and 
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significantly reduced at all stages of the differentiation protocol: the DE cells had a fold 
change of 0.5 compared to the TET1 H9 ESCs levels, and this value decreased further to 
0.28 and 0.23 relative to the stem cell expression in HBs and HLCs, respectively 
(Figure 6.4 A). Conversely, the expression of TET2 and TET3 gradually increased 
during the differentiation process. TET2 levels increased 2.76-fold at the DE stage, 
followed by an incremental 3.94- and 4.36-fold elevation in HBs and HLCs, 
respectively, relative to TET2 expression in H9 ESCs. The increase in TET2 levels in 
the latter two stages was found to be highly significant. TET3 transcript content was 
elevated 1.86-fold in the DE cells, followed by 2.94-fold and 2.64-fold increase in HBs 
and HLCs compared to TET3 levels in H9 ESCs. However, none of these changes were 
found to be significant. 
The expression of the individual TETs was assessed in the H9 ESCs to better understand 
which of the three enzymes is contributing to the maintenance of 5hmC in these cells 
and to establish a baseline for the changes in TET expression shown in Figure 6.4 A 
(Figure 6.4 B). TET1 was found to have the highest expression out of the three 
enzymes, approximately 122-fold and 20-fold higher than TET2 and TET3, respectively 
Intriguingly, the higher absolute values of TET1 expression in in the H9 ESCs suggest 
that despite the changes in TET expression levels during the differentiation process 
depicted in Figure 6.4 A, TET1 is still the most predominant TET transcript. It should be 
noted that the large standard deviation observed in the qRT-PCR experiments likely 
stems from varying efficiency of differentiation in the three independent experiments. 
The qRT-PCR analysis was followed by the corresponding assessment of global 5mC 
and 5hmC levels in the same samples as analysed in Figure 6.3 and Figure 6.4 by the 
dot blot technique (Figure 6.5 A). The 5mC content was observed to progressively drop 
to roughly 74% in the HLCs compared to the initial amount observed in H9 ESCs. 
Global 5hmC levels were observed to reduce to 91% of the H9 ESCs content at the DE 
stage, followed by an increase to 120% and 116% of the stem cell levels in HBs and 
HLCs, respectively. The mass spectrometry analysis revealed a small drop in global 
5mC levels in the DE and HLC stages of differentiation, with no difference observed at 
the HB stage compared to the content observed in H9 ESCs (Figure 6.5 B). None of 




Figure 6.4 The TET enzymes significantly change their transcript levels during 
human embryonic stem cell differentiation to hepatocyte-like cells 
(A) The changes in levels of the TET transcripts during embryonic stem cell 
differentiation to hepatocyte-like cells. H9 ESCs = human H9 embryonic stem cells, DE 
= definitive endoderm, HB = hepatoblast, HLC = hepatocyte-like cell. The TET mRNA 
levels were normalised to the average expression of RPL13A, GAPDH and ACTB 
reference genes as previously described (Baxter et al., 2015). The error bars represent 
the standard deviation of three independent differentiation experiments. The 
significance was established using a one-way ANOVA followed by the Tukey’s single-
step multiple comparison (* p<0.05; ** p<0.01; ns = not significant). The results of the 
statistical test are shown in the table below the graph. 
(B) The expression levels of the three TET transcripts in H9 ESCs relative to the 
average expression of RPL13A, GAPDH and ACTB reference genes. The error bars 








Figure 6.5 The global 5hmC content shows significant changes during human 
embryonic stem cell differentiation to hepatocyte-like cells 
(A) The representative staining results of dot blot assessment of 5hmC and 5mC levels 
in human H9 embryonic stem cells (H9 ESCs), definitive endoderm cells (DE stage), 
hepatoblast cells (HB stage) and hepatocyte-like cells (HLC stage). The results have 
been normalised to the H9 ESCs sample as the replicates were analysed at different 
points in time. The error bars represent the standard deviation of three independent 
differentiation experiments.  
(B) The mass spectrometry results of 5mC and 5hmC quantification in human H9 
embryonic stem cells (H9 ESCs), definitive endoderm cells (DE stage), hepatoblast 
cells (HB stage) and hepatocyte-like cells (HLC stage). The signal obtained for each 
cytosine modification is displayed as a percentage of signal obtained for all cytosines. 
The error bars represent the standard deviation of three independent differentiation 
experiments. The significance was established using a one-way ANOVA followed by 
the Tukey’s single-step multiple comparison. 
 
The 5hmC levels displayed a similar pattern of changes to the one observed in the dot 
blot experiments. There was an initial drop in 5hmC content from 0.18% of all 
cytosines in the stem cells to 0.13% at the DE stage. This was followed by an increase 
in 5hmC levels to 0.44% of all cytosines in the HB cells. The HLC were characterised 
by 0.30% 5hmC content. None of the above changes which were found to be 
significantly different to the levels found in any of the other stages. 
Given the large variation observed in 5hmC and ALB levels in the HLCs, it was 
hypothesised that varying degrees is differentiation efficiency at the last stage of the 
protocol could be impacting the global 5hmC levels. In order to test this proposition, 
ALB levels relative to the three reference genes were compared to the 5hmC content for 
each of the three independent differentiation experiments (Supplementary Figure 13). 
No correlation between these two variables was found thus indicating that the variation 
in the 5hmC levels observed in HLCs is unlikely due to differences in the hepatic 
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phenotype achieved as measured by ALB expression.  
These results provide a detailed description of changes in 5hmC and TET transcript 
levels during hepatic differentiation of hESCs. They also highlight the distinct roles that 




6.4.3 Assessment of the effect of transient TET1 knockdown on the differentiation 
efficiency of human embryonic stem cells to hepatocyte-like cells 
The generation of HLCs from pluripotent stem cell cultures has significant promise in, 
among others, liver transplantation in liver failure sufferers and drug toxicity screening 
in pre-clinical treatment development (Hay et al., 2008; Yu et al., 2012). This is due to 
shortage of primary hepatocyte sources, their rapid dedifferentiation in cell culture 
conditions and heterogenous genetic backgrounds (Corbett and Duncan, 2019). 
However, HLCs are known to resemble more closely the human foetal hepatocytes 
rather than adult ones, in part in terms of the expression of the CYP enzymes 
responsible for liver metabolism which poses issues in terms of their utility in drug 
screening (Baxter et al., 2015). Development of strategies allowing for more efficient 
differentiation to hepatic cells and achieving an overall phenotype that resembles the 
adult hepatocyte characteristics more closely is hence urgently needed. 
The high levels of TET1 observed in the H9 ESCs compared to the other two TET 
transcripts and the large reduction in its expression upon differentiation to the DE stage 
led to the hypothesis that a knockdown of the TET1 levels in the H9 ESCs prior to the 
start of the differentiation protocol could improve the differentiation efficiency to the 
DE cells. This step was also targeted with the knockdown strategy as it is only three 
days long and hence ideal for this proof-of-principle experiment. TET1 was hence 
targeted with two different shRNA constructs in a transient transfection experiment. 
The degree of knockdown of the TET1 levels following the completion of 
differentiation to the DE stage was subsequently assessed by qRT-PCR (Figure 6.6 A). 
The TET1 shRNA 1 construct significantly reduced the TET1 expression relative to the 
relative to the non-targeting shRNA against firefly luciferase mRNA (0.75-fold). The 
TET1 shRNA 2 vector on the other hand did not produce a significant reduction in TET1 
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expression. The process of transfection itself led to a significant, 2.07-fold upregulation 
of TET2. The transfection with the TET1 shRNA 1 construct led to a statistically 
significant reduction in TET2 expression relative to the non-targeting control (0.38-
fold). Similarly, the levels of TET3 were also reduced in TET1 shRNA 1 transfected 
samples relative to the luciferase shRNA control (0.75-fold). There was no significant 
change observed in TET3 expression following the TET1 shRNA 2 transfection, 
however, TET2 levels exhibited a 0.64-fold change relative to the non-targeting 
luciferase shRNA control. Intriguingly, OCT4 levels were significantly reduced to 
between 24 and 30% of the control expression in all transfected samples thus indicating 
that it is caused by the process of transfection itself. 
The percentage of cells differentiated to the DE stage 72 hours after the start of the 
differentiation protocol was assessed by fluorescence-activated cell sorting (FACS) 
(Figure 6.6 B). The DE cell population was defined as positive for both CD117 (c-KIT) 
and CD184 (CXCR4) cell surface markers, which have been previously extensively 
used and validated in the literature (Holtzinger et al., 2015; Jiang et al., 2015; 
Mahaddalkar et al., 2020). In the untransfected control sample, only approximately 38% 
of cells reached the DE differentiation stage thus highlighting the inefficiency of this 
step (see Supplementary Figure 14 for representative FACS results). All three 
transfected samples showed a lower proportion of the DE cells than the untransfected 
control, but none of these changes were found to be significant. The TET1 shRNA 2 
transfection resulted in a higher percentage of DE cells than the non-targeting control 
although the difference was small, approximately 6%, and not highly statistically 
significant. Additionally, given that this construct did not alter the TET1 levels (Figure 
6.6 A), this is likely due to inherent variation in DE induction efficiency between 
independent experiments. 
Taken together, these results indicate that a small, transient knockdown of TET1 levels 




Figure 6.6 The knockdown of the TET1 levels in human embryonic stem cells does 
not improve the differentiation to the definitive endoderm stage 
(A) The validation of TET1 transcript knockdown in H9 human embryonic stem cells. 
The TET1, TET2, TET3 and OCT4 mRNA levels were normalised to the average 
expression of RPL13A, GAPDH and ACTB reference genes as previously described 
(Baxter et al., 2015). The results were normalised to the untransfected control sample. 
The error bars represent the standard deviation of three independent replicates. The 
significance was established using a one-way ANOVA followed by the Tukey’s single-
step multiple comparison (* p<0.05; **p<0.01).  
(B) The graphical representation of the percentage of cells that stained positive for 
definitive endoderm markers: CD184 and CD117, as measured by fluorescence-
activated cell sorting. The error bars represent the standard deviation of three 
independent differentiation experiments. The significance was established using a one-







This chapter describes the investigation into the role of the TET enzymes and 5hmC 
during cellular differentiation of both adult and embryonic stem cells. The data 
previously generated, and recently published, by the Murrell lab regarding the changes 
in levels and distribution of 5hmC and its link to gene expression alterations during the 
maturation of mouse small intestine is thoroughly validated (Uribe-Lewis et al., 2020). 
The changes in global 5hmC levels and TET expression during differentiation of H9 
hESCs to HLCs are also described, representing a novel contribution to the 
understanding of the role of these three enzymes and their product in the process of 
cellular differentiation. Lastly, an attempt to improve the differentiation efficiency of 
H9 cells to DE through a knockdown of TET1 levels is described. 
The differentiation of mouse small intestine represents a well-defined and easily 
accessible model for studying adult stem cell differentiation. The maturation of the 
colonic stem cells residing in the intestinal crypts to differentiated villus cells is 
accompanied by a plethora of gene expression changes facilitating the transition from 
self-renewal and maintenance to phenotype conducive with nutrient absorption and 
metabolism (Mariadason et al., 2005; Chang et al., 2008; Hiramatsu et al., 2019). 
Previous studies have described the changes in 5mC levels and distribution during 
mouse intestinal differentiation (Kaaij et al., 2013; Sheaffer et al., 2014; Kazakevych et 
al., 2017), thus providing insight into epigenetic regulation of this process. Given that 
5hmC is thought to be broadly associated with activation of gene expression, it is 
unsurprising that it was also found to be largely positively correlated with changes in 
transcript levels during mouse intestinal differentiation (Kim et al., 2016). Kim and 
colleagues described Tet1 as the most abundant Tet transcript in the crypt stem cells and 
severely disturbed crypt-villus axis morphology in Tet1 knockout mice (Kim et al., 
2016). They thus concluded that TET1 is critical for the function of mouse intestinal 
crypt stem cells. The data presented in Figures 6.1 A and B, however, directly 
contradicts this result, showing that both Tet2 and Tet3 are expressed at higher levels 
than Tet1 in both the stem cells and differentiated progeny and that Tet3 is the highest 
expressed Tet in both cell types. This discrepancy in results could be due to different 
approach to isolating the ISCs population from the mouse small intestine. Kim and 
colleagues utilised the high expression of Lgr5 as a marker for ICSs while Uribe-Lewis 
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and co-authors isolated these cells based on their CD24a levels (Kim et al., 2016; Uribe-
Lewis et al., 2020). While the Tet1 primer pairs used by both groups target different 
exons, there is no evidence of alternative usage of the targeted Tet1 exons as discussed 
in section 6.4.1. Alternative splicing is therefore unlikely to account for the differences 
reported by the two publications. Kim et al., however, did not specify whether their 
primers have been assessed for their amplification efficiency and utilised a different 
reference gene (Tbp), which could also contribute to the difference in Tet expression 
reported (Kim et al., 2016). Additionally, the changes in Tet2 and Tet3 expression 
observed here are small, while the already low expression of Tet1 in the ISCs is lowered 
further in the differentiated progeny. This result further highlights that the changes in 
the expression of the three Tet genes are unlikely to underlie the global increase in 
5hmC observed during mouse intestinal differentiation process. A future analysis of the 
protein content of the three TET enzymes and metabolite changes (in particular α-
ketoglutarate) in the two cell types could help to explain what drives the 5hmC 
accumulation in the differentiated villi cells. 
Further validation of the RNA-seq data described in Figure 6.1 C yielded mixed results. 
The discrepancy observed between the RNA-seq and qRT-PCR methods can likely be 
explained by the differences in measuring the transcript levels utilised by the two 
experimental techniques. Additionally, the biological variability between the animals 
from which the cells were taken and technical variation involved in the isolation of the 
two cell populations could also account for some of the differences observed. Lastly, the 
limited reliability of qRT-PCR in detecting changes in gene expression that are under 
two-fold could also be a contributing factor (Karlen et al., 2007).  
This chapter also describes the changes in TET transcripts and 5hmC levels during in 
vitro differentiation of hESCs to HLCs, which is a novel contribution to the 
understanding of the role of epigenetics during cellular differentiation. This research 
area has not yet been studied extensively and represents an exciting avenue to explore in 
terms of improving differentiation efficiency of the hESCs. It is particularly important 
in the process of generation of HLCs from the renewable resource of hESCs. As alluded 
to before, these cells hold significant promise for both liver transplantation procedures, 
which are the only treatment option for patients with liver failure, and toxicity 
assessment during drug development (Hay et al., 2008; Yu et al., 2012). As their name 
suggests, however, these cells are only “like” human hepatocytes and exhibit numerus 
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differences compared to them, most notably in the expression of the CYP enzymes. In 
fact, they were described to resemble the foetal hepatocytes more closely than adult 
ones (Baxter et al., 2015). Given that 5mC and 5hmC are known to play critical roles in 
regulating gene expression during differentiation, they represent not only a possible 
target for improving the differentiation efficiency, but also for making the HLCs 
resemble human adult hepatocytes more closely than they currently do. 
The H9 ESCs were characterised by high TET1 expression, with TET2 and TET3 genes 
being transcribed at much lower level and TET3 being more abundant than TET2. This 
is in line with observations made by Li and colleagues, who differentiated H1 ESCs to 
pancreatic progenitor cells (pancreatic endoderm) and assessed the changes in global 
5mC and 5hmC levels as well as the levels of TET transcripts (Li et al., 2018). They 
also described a progressive reduction in TET1 expression combined with a 
corresponding increase in the levels of TET2 and TET3, which is largely in line with the 
results shown in Figure 6.4, although no significant change in TET3 expression was 
observed during the differentiation protocol described here. In a similar fashion, they 
reported little changes in global 5mC levels which supports the observations made in 
Figure 6.5. Lastly, Li and colleagues also described a “U-shape” distribution in 5hmC 
levels during the differentiation process (Li et al., 2018). In a similar fashion to the 
findings of this chapter, a drop in 5hmC content occurred in the initial stages of the 
differentiation which was followed by a gradual recovery to levels approaching those 
seen in the ESCs. This was the main difference in findings between their data and the 
results described in this chapter as 5hmC content in HBs and HLCs surpassed that of the 
H9 ESCs. This discrepancy in results could be due to the high levels of 5hmC observed 
in the adult liver (Li and Liu, 2011; Nestor et al., 2012), and the fact that Li and co-
authors did not produce a terminally differentiated pancreatic cell in their protocol. A 
study of in vitro differentiation of a bipotent progenitor to hepatocytes further 
highlighted the importance of global 5hmC changes in the process (Rodríguez-Aguilera 
et al., 2020). The enrichment of 5hmC was found to be closely associated with genes 
involved in the hepatocyte-specific transcriptional landscape. 
Following on from the findings of TET levels and 5hmC content fluctuations during the 
maturation of HLCs from H9 ESCs, it was hypothesised that one can utilise these novel 
results in an attempt at improving the efficiency of the differentiation protocol and 
match the cellular identity of the resulting HLCs more closely to the human adult 
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hepatocytes. This is supported by the evidence that modulating Tet levels, both in vitro 
and in vivo, affects the endodermal lineage differentiation (Koh et al., 2011; Dai et al., 
2016). While the initial experiment detailed in Figure 6.6 was unsuccessful, further 
improvements could be made to better understand if this strategy could work and thus 
provide a proof-of-principle for further investigation. These were not completed due to 
the time constraints of the project. The first major limitation of the experiment was that 
the differentiation was terminated at the DE stage. This was chosen on purpose as it 
represents the shortest stage (taking only three days) of the protocol, thus making it 
ideal for an initial experiment. However, it is feasible that more noticeable 
improvements in differentiation efficiency would have been seen when the 
differentiating cells matured into HBs or HLCs. Additionally, only a small degree of 
TET1 knockdown (a 22% reduction) was achieved at the endpoint of the assay. This 
could be improved in future experiments by transfection followed by antibiotic 
selection, which produces stably transfected clones that would likely exhibit 
significantly lower TET1 levels. Lastly, combining the TET1 knockdown with TET2 
and TET3 overexpression could yield a better outcome by exacerbating the changes 
seen in TET transcript abundance in both directions. 
In summary, the work described in this chapter furthers the understanding of the 
dynamics of the TET enzymes and 5hmC during the mouse intestinal differentiation and 
provides a novel contribution in the field of stem cell research by highlighting the 
previously unknown changes in TET transcripts and global hydroxymethylation levels 


















The work described in this thesis furthers the understanding of the role of the TET 
proteins and 5hmC in cancer progression and cellular differentiation. The successful 
optimisation of the in-house mass spectrometry method of global 5mC and 5hmC 
detection in DNA samples provides a logical stepwise framework to follow by others 
aiming to study the changes in levels of these epigenetic modifications. In particular, the 
setup of this technique on a mass spectrometer less sensitive than ones previously used 
in the literature for similar applications means that this type of analysis should be 
available to a wider range of research groups in the future, especially ones with limited 
funding opportunities. This is further supported by a higher sensitivity of the in-house 
protocol compared to previously published external one used at King’s College London. 
This experimental technique will also be critical for future experiments performed by 
the Murrell group, which will build on the findings described in this thesis. Importantly, 
a similar approach to the one described here can be used to establish a protocol for 
detection of global 5fC and 5caC levels in the future. 
The detailed in vitro characterisation of the SW480 (primary) and SW620 (metastatic) 
CRC cell lines resulted in creation of a detailed baseline for the behaviour of these cells 
in culture. This provides a critical context for understanding the results described in this 
thesis and for future experiments performed using this in vitro CRC metastasis model. 
In particular, it will be critical to understand their behaviour in transwell invasion assays 
to complement the migration data reported here. This should be further followed by 
assessment of the in vivo metastatic properties of the two cell lines, either in zebrafish or 
mouse models. Both cell lines have already been transfected with, and are stably 
expressing, a red fluorescent protein and luciferase reporters by the author and are hence 
ready to be used for such an experiment (data not shown). The future characterisation of 
SW480 and SW620 cells should also focus on assessing their metabolic profiles, and in 
particular 2-oxoglutarate, to better understand the effects they have on the global 5hmC 
levels. This could be complemented by determining the post-translational modifications 
affecting the activity of the three TET proteins in the two cell lines. 
The anti-cancer properties of vitamin C were confirmed in the SW480 and SW620 cell 
lines. While the ascorbic acid treatment elevated 5hmC levels in the two cell lines, its 
suppressive effects on proliferation and colony formation were found to be 5hmC-
independent through the use of peroxide ions scavenger catalase. It was also discovered 
that the vitamin C treatment did not affect the expression of the three TET genes in the 
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two CRC cell lines; a novel finding which further supports its role in increasing the 
5hmC levels by affecting the activity of the TET proteins. In the future, it would be 
particularly interesting to extend the treatment period of the two cell lines with the low 
vitamin C dose, possibly to multiple weeks, to study its long-term effects. Additionally, 
a higher concentration of ascorbic acid supplemented with catalase should be 
investigated as it could lead to a greater upregulation in global 5hmC levels which could 
potentially provide a phenotypic effect not seen with the lower doses. Lastly, the most 
intriguing follow-up to this study would be to expose CRC patients to similar doses of 
intravenous vitamin C as previously used by Linus Pauling and measure the global 
5hmC changes in tumour samples following the treatment compared to biopsies taken 
prior to the treatment. It is tempting to speculate that a number of epigenetic changes 
would be observed following such treatment that have a suppressive effect on the 
primary tumour but could inadvertently promote CRC metastasis in the patients. All the 
experiments listed above should be combined with whole genome bisulfite and ox-
bisulfite sequencing to complement the global 5mC and 5hmC changes with an 
understanding of the regions that gain hydroxymethylation. This in turn should allow 
one to make more accurate predictions regarding the functional significance of these 
local changes. Should the results of the abovementioned investigations be promising, 
one can envision wide adoption of vitamin C as an adjuvant to cancer therapy given its 
low cost and toxicity as well as widespread availability. 
The results obtained with the TET knockdown SW480 and SW620 cells are limited by 
the fact that the TET and 5hmC ablation was incomplete even in the triple TET 
knockdown cell lines. Future work should determine exactly why that is the case despite 
the confirmation of the presence of CRISPR/Cas9- induced mutations in all knockdown 
cell lines by two independent experiments. Intriguingly, the reduced TET and 5hmC 
levels had a different effect on the migration of the primary and metastatic CRC cell 
lines. The TET TKDs in the SW480 cells resulted in no change of the in vitro migration 
rate than the one observed in the wild type cell line, while a reduction in migration was 
observed for the SW620 TKD cells. It will be critical to confirm this effect both in the 
in vitro transwell invasion assay and in animal experiments comparing the in vivo 
metastatic behaviour of the TKD cell lines and the wild type counterpart. If the results 
of these support the findings reported here, once could speculate that there is a switch in 
the role of the TET enzymes and 5hmC in the tumorigenesis process. In the early stages 
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of tumour development, the TETs could be playing a tumour suppressive role by 
restricting the growth of the tumour. During the metastatic cascade, however, they could 
be responsible for activating the expression of genes involved in cellular motility and 
epithelial to mesenchymal transition cycles. In that setting, they could have an 
oncogenic function in CRC and potentially other cancer types. These experiments 
should also be supplemented by studying the effects of TET overexpression in these two 
cell lines. Observing the opposite effects on migration due to TET overexpression in 
SW480 and SW620 cells would strengthen the findings described here and reduce the 
likelihood of them arising due to off-target effects of the CRISPR/Cas9 system. The use 
of overexpression vectors encoding both the full length and catalytically inactive TET 
enzymes will shed a light on whether the phenotypic effects observed in the two CRC 
cell lines are 5hmC-dependent. It is tempting to speculate that, at least in part, these will 
be mediated by catalytically independent function of the TET enzymes, in particular the 
repressive complex of TET1 and SIN3A. Lastly, based on the current findings, it is 
likely that the body of knowledge regarding the functions of the TET proteins that are 
independent of 5mC oxidation will substantially grow in the future years. 
The use of loci-specific 5hmC changes as a diagnostic tool for early cancer detection 
will likely be widely adopted in the future. This is a cutting-edge field that is early in its 
development, but the preliminary evidence is certainly promising. In particular, the use 
of cell-free DNA offers a non-invasive way of obtaining material for 5hmC-based 
diagnostic purposes. It will also allow the clinicians to detect the disease early which is 
critical in, for example, pancreatic cancer sufferers. The vast majority of them present 
with late-stage disease which is no longer operable and often has already metastasised 
to other organs. The main challenge for this technology is the thorough validation of 
tumour type-specific differentially hydroxymethylated loci in cell-free DNA that will 
ensure high sensitivity and specificity of the test. 
The findings validating the expression of the Tet genes in mouse small intestine add to 
the body of evidence supporting the role of 5hmC in the intestinal differentiation and 
shed light on the controversy regarding the importance of TET1 in that process. Future 
research should aim to resolve how 5hmC is accumulating in the differentiated villus 
cells compared to the stem cell crypt progenitors despite little change seen in the 
expression of the three Tet genes between these two cell types. In particular, the 
assessment of the TET protein levels will either validate the Tet transcript expression 
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profile in the differentiated and stem cells or provide an explanation for the 5hmC 
changes observed during intestinal differentiation. It is certainly possible for the TET 
transcript and protein levels to show pronounced differences; this was indeed observed 
in some of the TET knockdown SW480 and SW620 cell lines described here. The 
assessment of intracellular metabolite and iron levels in the two cell types, as well as the 
oxygen gradients across a section of the mouse small intestine, will provide a clear 
answer to the role of the three cofactors (oxygen, iron (II) and 2-oxoglutarate) in 
establishing the global 5hmC patterns across the crypt-villus axis. 
The assessment of TET expression and global 5mC and 5hmC changes during 
differentiation of hESCs to HLCs represents a novel finding that expands the growing 
understanding of the function of the TETs in acquisition of cellular identity. While the 
initial experiment aiming at utilising these results to improve hESC differentiation 
efficiency to definitive endoderm failed, likely due to insufficient TET1 knockdown 
levels and excessive cell death associated with the transfection process, a different 
approach will likely yield considerably better results. The creation of a stable TET1 
knockdown hESC cell line prior to its differentiation will avoid the large amount of cell 
death occurring prior to the start of the differentiation process while having little effect 
on hESC pluripotency based on the phenotype of TET1 knockout mESCs. This could be 
combined with overexpression of either TET2 or TET3 to further exacerbate the 
changes reported here. However, while such a crude approach could yield positive 
results, it is tempting to speculate that a more targeted, locus-specific induction of 
methylation and hydroxymethylation content changes will be used in the future to 
generate HLCs resembling more closely the adult hepatocytes and iPSCs that are more 
similar to ESCs than currently possible. This will likely be achieved through approaches 
such as fusion of the catalytic domain of a TET enzyme with an inactive Cas9 enzyme, 
which were previously successfully utilised in the literature (Choudhury et al., 2016; Xu 
et al., 2016; Xu et al., 2018). One can envision creating a library of guide RNA 
sequences that target the fusion enzyme to key loci that need to be activated in the target 
cell type, such as HLCs or iPSCs. If this strategy proves successful and scalable, it will 
significantly contribute to the fields of regenerative and personalised medicine as well 
as drug toxicity screening.  
Almost five decades ago, the “war on cancer” was declared, and although many battles 
have been won, the patients still remain on the losing side. Given the focus of this thesis 
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on the role of epigenetic mechanisms in CRC metastasis to the liver, it is the hope of the 
author that the findings described here will contribute to the field of cancer prevention. 
That hope reflects the simple truth that preventative measures are superior to the cure in 
numerous aspects, and in particular when it comes to chronic diseases such as cancer. 
With an increasing number of tests and treatments available to patients every year, as 
well as the increasing awareness regarding risk factors for tumour development, the 








































Supplementary Figure 1 The representative chromatograms of all the compounds 
analysed on the Xevo TqD triple quadrupole mass spectrometer 
(A) The representative chromatograms for 2′-deoxycytidine (top graph) and 2’-
deoxycytidine (15N3) (isotopically-labelled internal standard, bottom graph). 
(B) The representative chromatograms for 5-methyl-2′-deoxycytidine (top graph) and 5-
methyl-2’-deoxycytidine-d3 (isotopically-labelled internal standard, bottom graph). 
(C) The top two graphs show representative chromatograms for 5-hydroxymethyl-2′-
deoxycytidine quantifier (top graph) and qualifier (bottom graph) ions. The bottom two 
graphs show representative chromatograms for the 5-hydroxymethyl-2’-deoxycytidine-
d3 (isotopically-labelled internal standard) quantifier (top graph) and qualifier (bottom 
graph) ions. 
The y-axis represents the signal obtained on the mass spectrometer and the x-axis 

































Supplementary Figure 2 The representative chromatographic results of liquid 
chromatography columns and conditions testing 
The representative chromatograms for 2′-deoxycytidine (top graph), 5-methyl-2′-
deoxycytidine (middle graph) and 5-hydroxymethyl-2′-deoxycytidine quantifier and 
qualifier ions (bottom two graphs) for synthetic standard samples ran on: (A) the C18 
column, (B) the C18 column with the addition of 10 mM ammonium acetate to the 
mobile phase and (C) the HILIC column. 
The y-axis represents the signal obtained on the mass spectrometer and the x-axis 











































Supplementary Figure 3 The representative chromatographic results of liquid 
chromatography flow rate testing 
The representative chromatograms for 2′-deoxycytidine (top graph), 5-methyl-2′-
deoxycytidine (middle graph) and 5-hydroxymethyl-2′-deoxycytidine quantifier and 
qualifier ions (bottom two graphs) for synthetic standard samples ran through the liquid 
chromatography column with the following flow rates: (A) 150 µL/min, (B) 200 
µL/min, (C) 250 µL/min and (D) 300 µL/min. 
The y-axis represents the signal obtained on the mass spectrometer and the x-axis 







Supplementary Figure 4 The result summary of the external analysis of global 5-
methylcytosine and 5-hydroxymethylcytosine levels in HCT116, SW480 and 
SW620 cell lines obtained from King’s College London 
The filenames 42314 - 42317 represent the synthetic standard calibration curve for the 
three compounds. C = cytosine, 5-mC = 5-methylcytosine, 5-Ohm-C = 5-
hydroxymenthylcytosine. 
The filename 42318 represents the solvent-only control containing the digestion enzyme 
matrix. 
The filenames 42319 - 42327 describe the results of global 5mC and 5hmC levels 
analysis in three independently isolated DNA samples of the three colorectal cancer cell 









Supplementary Figure 5 The expression levels of the three TET genes in a panel of 
twelve colorectal cancer cell lines 
The TET expression was normalized to the TBP reference gene. The graph represents 
the results of the analysis of one biological replicate for each cell line. The error bars 







































Supplementary Figure 6 The details of the strategy used by Horizon Discovery to 
generate the TET knockdown SW480 and SW620 cell lines 




Supplementary Figure 7 The sequencing results of the TET knockdown SW480 
and SW620 cell lines 
The results of sequencing of PCR products containing the regions targeted for 
CRISPR/Cas9-mediated deletions of (A) TET1, (B) TET2 and (C) TET3 in wild type 
(WT), single (SKD), double (DKD) and triple (TKD) TET knockdown SW480 and 
SW620 cell lines. The PAM and guide RNA sequences are highlighted in blue and 
yellow, respectively. The muted regions are denoted by the hyphens highlighted in red. 
* = the samples showing extensive scarring around the deletion site. ** = the sample 
does not show any deletions despite harbouring the TET2 mutation as shown by the 
sequencing of SW620 DKD and TKD samples; this is likely an experimental error or 




Supplementary Figure 8 The TET knockdown SW480 cell lines show a greater 
reduction in TET activity that the SW620 cell lines compared to the wild type 
counterparts 
The results of the TET activity assay in wild type (WT), single (SKD), double (DKD) 
and triple (TKD) TET knockdown (A) SW480 and (B) SW620 cell lines. The error bars 
represent the standard deviation of two independent replicates. Only one WT sample for 
each cell line was included in the results due to an abnormally low reading of the second 







Supplementary Figure 9 The triple TET knockdown SW620 cell line has elevated 
5mC levels compared to the wild type counterpart  
The mass spectrometry results of global 5mC levels quantification in wild type (WT) 
and triple (TKD) TET knockdown (A) SW480 and (B) SW620 cell lines. The signal 
obtained for 5mC is displayed as a percentage of signal obtained for all cytosines. The 
error bars represent the standard deviation of (A) four and (B) three independent 
replicates. The significance was established using (A) a one-way ANOVA followed by 








Supplementary Figure 10 The confirmation of mouse Tet2 overexpression relative 
to ACTB reference gene levels in the three triple TET knockdown cell lines  
(A) Mouse Tet2 expression relative to ACTB levels in untransfected control, 
transfection reagent-only control (Fugene) and TET1/2/3 overexpressing (TET1/2/3 o-e) 
TKD 1 SW480, TKD 2 SW480 and TKD SW620 cell lines. The results were generated 
using the ΔCt instead of ΔΔCt values (Livak and Schmittgen, 2001). 



















Supplementary Figure 11 The TET protein levels are unchanged by the acute 
overexpression of the individual TET enzymes  
The representative images of Western blots and the graphical representation of the 
results of the assessment of TET1, TET2, TET3 and ß-Tubulin protein levels in 
untransfected control, transfection reagent-only control (Fugene) and TET1/2/3 
overexpressing (A) TKD 1 SW480, (B) TKD 2 SW480 and (C) TKD SW620 cells. In 
each blot, two independent replicates of samples are shown, denoted as “1” and “2”. 
The staining results were normalised to the ß-Tubulin content in each cell line. The 




Supplementary Figure 12 The experimentally determined primer efficiencies of the 
Tet1/2/3 and Polr2a primers 
(A) The standard curves for the Tet1/2/3 and Polr2a primer pairs depicting the linearity 
(R2 values) of amplification efficiency in a 10-fold cDNA dilution series. The dotted 
lines represent the lines of the best fit. 






















Supplementary Figure 13 The ALB expression in hepatocyte-like cells does not 
show a correlation with their global 5hmC levels 
The ALB expression relative to the three reference genes used was plotted against the 
global 5hmC levels for each of the three independent replicates. For each of the three 
















































































































Supplementary Figure 14 The representative examples of FACS analysis results of 
staining for CD117 and CD184 definitive endoderm markers the in the TET1 
knockdown human embryonic stem cell samples 
The details of the FACS sorting for APC (CD117) and PE (CD184) staining in (A-D) 
unstained and (E-H) stained with both antibodies (A and E) untransfected control, (B 
and F) luciferase shRNA control, (C and G) TET1 shRNA 1 and (D and H) TET1 
shRNA 2 samples. The unstained samples were used to set the background signal for 
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